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Abstract 
The primary etiologic factor of periodontitis is bacterial plaque biofilm. 
Nevertheless, the factors that determine the progression of periodontitis are complex 
and poorly understood.
 
Hence, the potential involvement of autoimmunity in the 
pathogenesis of periodontitis has been considered intermittently for years. 
The basic hypothesis for this PhD was that autoimmunity to native and/or post-
translationally modified periodontal extracellular matrix proteins is involved in the 
progression of periodontitis. 
 
Objectives 
The main objective of the study was to extend the understanding of periodontal 
disease pathogenesis beyond the common bacterial etiology and to address the 
hypothesis that periodontal disease is an auto-immune disease. This research will try to 
identify the exact neoepitope. 
 
Specific aims 
(i).  To investigate the involvement of autoimmune reactivity towards native 
collagen type I (CI) and collagen type III (CIII), as well as CI and CIII post-
translationally modified by reactive oxygen specious (ROS) known to present in 
the inflamed tissue, ROS-CI and ROS-CIII, respectively.  
(ii). Develop human antibody fragment(s) specific to CI, ROS-CI, CIII and ROS-
CIII for diagnostic application. 
 
Methods 
Modification of CI or CIII was confirmed by SGS-PAGE, Capillary 
Electrophoresis and 3D-fluorescence. The presence of autoantibodies to ROS-CI and 
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ROS-CIII in sera and saliva were then studied by ELISA and Western blotting using 
sera and saliva from individuals with Aggressive Periodontitis (AgP), Chronic 
Periodontitis (CP) and Gingivitis (G).  
Antibodies specific to ROS-CI and ROS-CIII were developed using phage 
display semi-synthetic human single chain fragment variable (scFv) libraries. 
 
Results 
Autoantibodies to native CI, native CIII, ROS-CI and ROS-CIII were observed 
exclusively in patients with AgP. Human antibody fragments specific to native and 
ROS-CI were developed and evaluated.   
 
Conclusions 
A.  Autoimmune reactions to native and post-translationally modified self antigens 
may play a role specifically in the pathogenesis of AgP.  
B.  Anti-ROS scFv specific to ROS-CI and ROS-CIII may have diagnostic future 
applications.
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Chapter 1: General Introduction 
1.1 Background 
1.1.1 Clinical Background 
 Periodontitis and gingivitis are the two major forms of inflammatory diseases 
affecting the periodontium. Periodontitis is the most common oral disease. It is a 
chronic inflammatory disease of the gingiva and the adjacent tooth attachment apparatus 
that results in progressive loss of the periodontal ligament and the supporting alveolar 
bone.
8,88 
Gingivitis (G) is an inflammatory process limited to the soft tissue, the gingiva, 
and characterized clinically by gingival redness, oedema, bleeding and does not result in 
clinical attachment loss.
48
 Despite the similarities in histopathology between gingivitis 
and periodontitis, there is no evidence indicating that periodontitis is an inevitable 
consequence of gingivitis.
 
The proportion of gingival lesions converting to periodontitis, 
and the factor causing this conversion has not been well understood.
 137
 
 There are many forms of periodontitis. The definition of the two main forms of 
periodontitis is based on a combination of clinical signs and symptoms.
8,9
 Aggressive 
periodontitis (AgP) is a form of periodontitis that occurs in patients who are otherwise 
clinically healthy. Common features include rapid attachment loss and bone destruction 
and familial aggregation. Chronic periodontitis (CP), a form of periodontal disease 
resulting in a chronic inflammation within the supporting tissues of the teeth, 
progressive attachment and bone loss. It is prevalent in adults, but can occur at any age. 
Progression of attachment loss usually occurs slowly, but periods of rapid progression 
can occur.
81,137  
 Many risk factors are considered to be involved in the initiation and progression 
of periodontitis, among them tobacco use,
14,53 
diabetes,
51,112
 age,
51,52
 and male gender.
52
 
However, the primary etiologic factor in periodontal diseases is the formation of 
bacterial plaque biofilm.
51,52
 More than 300 species of bacteria have been identified 
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within periodontal pockets, but it is likely that only a limited number of gram negative 
bacteria within the gingival tissues
 
are associated with periodontal diseases and alveolar 
bone loss.
101,117
 Among those for which the epidemiological evidence is strongest are 
Porphyromonas gingivalis, Bacteroides forsythus and Aggregatibacter 
actinomycetemcomitans.
29,51,52 
 Numbers of host mediated destructive processes are initiated by bacterial 
virulence mechanisms. Neutrophils, which normally provide protection by phagocytosis 
and killing of the infecting agent, can themselves contribute to tissue damage. During 
the process of phagocytosis, these cells typically “spill” some of their enzymes 
extracellularely during a process known as degranulation. Some of these enzymes are 
capable of degrading the surrounding host tissues including collagen and constituents of 
the basement membrane, contributing to tissue damage. An important part of the tissue 
damage in periodontitis is a result of the mobilization of activated monocytes, 
lymphocytes, fibroblasts and other host cells. The interaction between these cells and 
bacterial factors, especially lipopolysaccharide (LPS), is thought to stimulate production 
of both catabolic cytokines and inflammatory mediators. Such cytokines and 
inflammatory mediators promote the release of matrix metalloproteinases, which are 
destructive to the extracellular matrix and bone.
29,111
 
 Subgingival infection generates various host immune responses, resulting in 
secretion of cytokines by T lymphocytes, which can act on bone and connective tissue 
cells. Antigen activated T cells may directly trigger osteoclastogenesis, or secrete 
proinflammatory mediators which induce bone resorption and suppress bone formation. 
In addition they also stimulate matrix metalloproteases leading to tissue 
degradation.
29,111
  
The potential involvement of autoimmunity in the pathogenesis of periodontitis 
has been considered intermittently for many years. Autoantibodies against a wide range 
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of self antigens, such as collagen type I (CI), host DNA, laminin, fibronectin and 
desmosine have been described in a number of previous studies.
5,6,7,32,47,83
 However 
these reports have provided inconsistent results.  For example some groups have 
described high levels of autoantibodies to CI
40,139
 whilst others report low levels of anti-
CI.
61
 More recently it has been suggested that autoimmune responses may be increased 
particularly in patients with AgP.  De-Gennaro and co–workers32 showed increased 
autoantibodies to fibronectin and laminin, but not to CI, in patients with AgP. In 
addition Koutouzis and co workers
83
 in a small pilot study, have shown increased tissue 
autoreactivity and anti-CI antibody titres specifically in patients with localized AgP. 
 The exact aetiology of autoimmune reactivity in periodontitis is not known, but 
may be linked to the inflammatory process resulting from Porphyromonas gingivalis 
infection.  
 The question is whether the autoimmune response is a primary pathogenic event, 
or whether the production of autoantibodies is secondary to the inflammation. The 
continued presence of bacteria in the gingival sulcus results in continuous inflammation, 
associated with influx of immune cells. Infiltrating lymphocytes and macrophage 
produce high levels of pro-inflammatory cytokines and chemokines as well as matrix 
metalloproteinases (MMP).
36,85,111,115
 Known cytokines released are interleukin-1 (IL-1) 
and tumour necrotic factor α (TNFα), both induce bone resorption.67,115  
 
1.1.2 Matrix metalloproteinases (MMP) 
 MMP belong to the family of more than 20 zinc endopeptidases. They are 
capable of degrading a large number of extracellular matrix proteins among them 
collagens, laminin, fibronectin, aggrecan, elastin, and proteoglycans. They are involved 
in the cleavage of cell surface receptors, in the release of apoptotic ligands, chemokine 
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and cytokine. MMPs play a role in cell proliferation, migration, differentiation, 
angiogenesis, apoptosis and host defence.
104 
 The MMPs share a common domain structure. The different groups of MMPs 
are collagenases, gelatinases, stromelysins and membrane type MMPs. The 
collagenases are capable of degrading triple-helical fibrillar collagens into distinctive 
3/4 and 1/4 fragments. These collagens are the major components of bone and cartilage, 
and MMPs are the only known mammalian enzymes capable of degrading them. The 
main collagenases are MMP-1, MMP-8, MMP-13 and MMP-18. 
 MMPs have long been implicated in periodontal disease. An example of MMP 
which is being released by bacterial plaque in the periodontal disease is MMP-8. It is a 
collagen cleaving enzyme (collagenase) and it cleaves CI at a specific peptide bond 
between Gly
775
 and the residue in position 776 (which can be either Leu or Ile).
89
 
 
1.1.3 Chemistry of Reactive oxygen species 
 Free radicals have one or more unpaired electrons in their outer orbital, indicated 
in their chemical formulas by (
.
). As a consequence they have increased reactivity 
towards other molecules. This reactivity is determined by the ease with which a species 
can accept or donate electrons. 
 Reactive oxygen species (ROS) are small molecules that are highly reactive due 
to the presence of unpaired valence shell electrons. ROSs form as natural by-products of 
the normal metabolism of oxygen and have important roles in cell signalling. However, 
during times of environmental stress ROS levels can increase dramatically, which can 
result in significant damage to cell structures. This cumulates into a situation known as 
oxidative stress.
146
 Mammalian cells have developed a battery of defences to prevent 
and repair the injuries caused by oxidative stress.
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 A key ROS formed during metabolic processes is superoxide. When cells 
metabolize they consume oxygen and utilize it in forming ATP. The mitochondria, 
which are found in most eukaryotic cells in large numbers, are in charge of this 
production of ATP through respiration. The respiration reactions are catabolic reactions 
that involve the oxidation of one molecule and the reduction of another (redox reaction). 
A common electron acceptor (oxidizing agent) is molecular oxygen. During glycolysis, 
pyruvate enters the mitochondria in order to be fully oxidized by the Krebs cycle. O2 
acts as a terminal electron acceptor, being reduced to water. Transfer of electron to 
oxygen yields the reactive intermediates. 
24,119
 
 Occasionally, during glycolysis electrons leak from their transporters and reduce 
oxygen, creating superoxide anions (O2∙−). These are released into the phagosomal 
space and into the extracellular environment.
11,74
 In addition, during inflammation, 
functional production of superoxide involves activation of the NADPH-oxidase, which 
shunts glucose-6-phosphate from the glycolysis pathway and utilizes molecular oxygen 
and NADPH to form the superoxide radical anion (O2∙−) on the outer surface of the 
polymorphonuclear (PMN) plasma membrane.
146
  
 The high concentration of superoxide radicals is rapidly converted to peroxide 
(H2O2), either by spontaneous dismutation of two superoxide radical anion (2O2∙− + 
2H
+
 => H2O2 + O2) or through a reaction catalyzed by superoxide dismutase (SOD).
24
 
Hydrogen peroxide (H2O2) can then take part in an iron-catalyzed interaction called the 
Fenton reaction forming the highly reactive and toxic radical, hydroxyl radical (OH
.
)
55
 
The average half-life of OH
.
 is 10
-9
 sec, this radical reacts instantaneously, with any 
biological molecule in its immediate environment by abstracting a hydrogen atom. 
 The non-radical species, hypochlorite (HOCl) is also a potent antimicrobial 
agent generated from hydrogen peroxide (H2O2) and chloride ions present in plasma by 
the enzyme myeloperoxidase (MPO) which is released from the PMN primary granules 
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during phagocytic degranulation. It is a stable molecule that can exist for hours or 
days.
30,58,97
 
 In addition an excess of nitric oxide radical (NO∙), another pro-inflammatory 
mediator with a half-life of 1
–10
 sec, is produced by macrophages via nitric oxide 
synthase (NOS) during acute inflammation in the vascular endothelium. This reacts 
with superoxide to form the unstable peroxynitrite (ONOO
-
) with a half-life of 0.05–1.0 
sec.
82
  
 
Figure 1.1: Generation of Reactive oxygen species (ROS) in mammalian organism 
(Nissim lectures figures) 
Superoxide dismutates shifts O2- to hydrogen peroxide (H2O2). H2O2 is converted by 
myeloperoxidase (MPO) in neutrophils to hypochlorous acid (HOC1). H2O2 is 
converted in a spontaneous reaction catalyzed by Fe
2+
 (Fenton reaction) to hydroxyl 
radical (OH•). Nitric oxide radical (NO∙) can shift O2- to peroxynitrite. 
 
 Another product associated with oxidative stress is advance glycation end 
products (AGE). These are a heterogeneous group of compounds formed by an 
irreversible non-enzymatic reaction between sugars and proteins.
4 
 ROS as a family can modify a number of structurally and metabolically 
functional macromolecules in an effort to balance their unpaired electronic state. 
Imbalance between production and elimination of ROS develops during inflammation, 
ischemia/reperfusion, altered metabolism, action of drugs, pollutants, etc. These 
changes can result in cellular damage, modulation of cell signalling, effects on gene 
regulation and expression, induction of apoptosis and necrosis and autoimmune 
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response.
12,112,131
 The damage leads to the loss of functional activity  of the proteins and 
includes cleavage, aggregation or structural modifications of proteins. AGE products 
have also been shown to contribute to this damage by mainly cross linking of 
proteins.
119
  
Within the inflamed lesion there is a high influx of immune cells, mainly 
polymorphonuclear leukocytes (PMN) which consume increased amounts of oxygen 
thus leading to overproduction of ROSs,
146   
including O2∙−, OH∙, NO∙ and ONOO∙, and 
non-radical derivatives e.g. H2O2 and HOCl (Figure 1.1).
24
  Additional oxidants present 
in inflammation are the advanced glycation end-products (AGE) produced by sequential 
oxidative reactions.
12,26 
 
1.1.4 Structural proteins of the periodontal tissue 
 In man, collagen comprises 1/3 of the total protein, accounts for three-quarters 
of the dry weight of skin. Collagen is the most prevalent component of the extracellular 
matrix (ECM). So far, 29 types of collagen, composed of at least 46 distinct polypeptide 
chains, have been identified and described.
19 
 
 Collagen structure consist of three parallel polypeptide strands in a left-handed, 
polyproline helical conformation coil, each with a one-residue stagger to form a right-
handed triple helix (Figure 1.2). The tight packing of the polypeptides in the triple helix 
determines that, in all types of collagen, every third residue is Glycine (Gly). It results 
in a repeating X-Y-Gly sequence, where X and Y may be any of various other amino 
acid residues. The amino acids in the X and Y positions of collagen are often proline 
(Pro, 28%) and hydroxyproline (Hyp, 38%).
122  
 Individual collagen triple helices, known as tropocollagen (TC), assemble in a 
complex manner that leads to the macroscopic fibres and networks observed in tissue, 
bone, and basement membranes (Figure 1.2). Collagen fibrillogenesis in situ occurs via 
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assembly of intermediate-sized fibril segments, called microfibrils.
92 
In that structure, 
three polypeptide strands are hold together in a helical conformation by a single 
hydrogen bond per triplet. The crosslinks can be both within and between 
microfibers.
113
 Collagen fibrillogenesis has a stabilizing effect on triple helices. 
Moreover, the assembly of strong macromolecular structures is essential to enable 
collagen to support stress in one, two, and three dimensions.
20
  
 
 
Figure 1.2: Biosynthetic route to collagen fibers 
Size and complexity is increased by posttranslational modifications and self-assembly. 
Oxidation of lysine side chains leads to the spontaneous formation of hydroxylysyl 
pyridinoline and lysyl pyridinoline cross-links. 
 
 Size and complexity is increased by posttranslational modifications and self-
assembly. Collagen fibres are formed through oxidation of lysine side chains leads to 
the spontaneous formation of hydroxylysyl pyridinoline and lysyl pyridinoline cross-
links. 
 There are many classes of collagenous structures in the ECM, including fibrils, 
networks, and transmembrane collagenous domains. Collagen fibrils formed mainly 
from type I collagen (all fibrous tissues except cartilage) and fibrils formed largely from 
type II collagen (cartilage) have slightly different structures. Over 90% of the collagen 
in the body consists of just four types I, II, III, and IV.
21,120 
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 In the periodontal tissue, the major structural protein, and hence the most 
prominent target for ROS is CI,
21 
which is susceptible to damage by ROS, as described 
below. The primary consequence of oxidative damage is the introduction of carbonyl 
groups into the protein.
24,87 
 
1.1.5 Mechanism of collagen modification by ROS and enzymes 
 The extracellular matrix molecules are good target for ROS, collagen is an 
especially good target since it is degraded during the first stages of inflammation by the 
action of both ROS and proteinases.
99
 Superoxide anions and hydroxyl radicals can 
aggregate collagen or cleave it into small fragments at Proline and Hydroxyproline 
residues, liberating hydroxyproline-containing fragments (figure 1.3). 
Figure 1.3: Peptide bond hydrolysis by OH∙ 
 
 Hydroxyl radicals are also able to cross-link collagen at Tyrosine residues by 
connecting two Tyrosine residues to form Dityrosine (figure 1.4).
49,76,81,99  
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Figure 1.4: Cross-link of collagen by OH∙ as formation of Di-tyrosine 
Tyrosine residues at the presence of hydroxyl radicals are changing to Tyrosyl 
intermediate radical. Two molecules are able to cross-link peptides by connecting and 
forming dityrosine. 
 
 Hypochlorous acid usually affects the side groups of Cysteine, Methionine, 
Tyrosine, Tryptophan, Lysine and Histidine and causing conformational changes in the 
collagen molecule (figure 1.5). Collagen exposure to hypochlorous acid can result in 
cross-linking of the molecules through hydrolysis and aldehydes forming.
99
 
 
 
 
 
 
Figure 1.5: Modification of amino acids side chain by HOCl 
When exposing Tyrosine side chain to HOCl, 3,5-dichlorotyrosine is evolving. Further 
conformational changes may occur. 
 
 Peroxynitrite usually affects the side chains of Cysteine, Tryptophan or 
Tyrosine. Cysteine is converted to disulfides and Methionine is converted to sulfoxide. 
In both the consequence of these reactions is primarily protein aggregation.
59,145
 
Another example is AGEs which are stable and include chemical structures such as 
pentosidine (figure 1.6), which links a lysine to an arginine on a separate protein, 
causing them to cross-link. This is done when a sugar such as Ribose reacts with Lysine 
to form a Schiff base (a double bond between the carbon atom of the sugar and the 
nitrogen atom of the lysine). Then an Amadori product is re-arrange from the Schiff 
OH
- 
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base, wherein the hydrogen atom from the hydroxyl group adjacent to the carbon-
nitrogen double bond moves to bond to the nitrogen, leaving a ketone. The Amadori 
product is oxidized and the irreversible AGE product is produced.
134
 
 
 
 
 
 
Figure 1.6: Non enzymatic glycation leading to advanced glycation end products 
(AGE) 
Mechanism of formation of pentosidine from peptide bound lysine and arginine side 
chains reacting with a Ribose to form a Schiff base. An Amadori product is re-arrange 
from the Schiff base, it oxidized and the irreversible AGE product, Pentosidine, is 
produced. 
 
Such post-translational modification of CI and collagen type III (CIII) by ROS 
results in the formation of altered self-protein that may initiate an autoimmune response. 
Furthermore, breach of tolerance may also be initiated by enzymatic post-translational 
modification. For example, cleavage of extracellular proteins by matrix 
metalloproteases (MMP) is well known to be associated with inflammatory diseases.
103
  
Another enzymatic modification is by post-translational modification with the help of 
peptidylarginine deiminase (PAD).
143
 These enzymatic post-translational modifications 
are of particular interest in periodontitis as Porphyromonas gingivalis produces both 
RgP-argingipain
72
 and PAD.
94
 RgP-Argingipain is a cysteine proteases and PAD is able 
to remove the amino group of carboxyl-terminal Arginine residues on a variety of 
peptides to yield ammonia and a Citrulline residue.
72,94,143
 Porphyromonas gingivalis is 
the only bacterium known to express a PAD enzyme.
148
  
 The PAD expressed by Porphyromonas gingivalis is not entirely homologue to 
human PAD but leads to an irreversible, post-translational conversion of Arginine to 
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Citrulline.
126,129
 In RA, citrullination is part of the patho-physiologic and an increased 
accumulation of citrullinated proteins is seen.
149
 The reduced immunotolerance of these 
patients to citrullinated proteins, especially for patients with severe RA, result in an 
increased formation of autoantibodies.
149
 The Porphyromonas gingivalis titer in patients 
with RA correlated significantly with the concentration of anti-citrullinated 
protein/peptide antibody (ACPA).
54,126
 Periodontal infections with pathogens such as 
Porphyromonas gingivalis, in association with a genetic predisposition, support 
inflammatory diseases like RA.
54,126
 It is thus possible that in a genetically susceptible 
individual, such citrullinated peptides may interrupt tolerance to endogenous 
citrullinated antigens, resulting in the generation of an immune response to citrullinated 
self-antigens.
62
 
 Patients with periodontitis have a higher prevalence of RA than patients without 
periodontitis.
44
 The claim that oral infections play a role in RA pathogenesis may be 
supported by the detection of bacterial DNA of anaerobes and high antibody titers 
against these bacteria in both the serum and the synovial fluid of RA patients in the 
early and later stages of the disease.
98 
 
1.1.6 Antibodies 
 An antibody or immunoglobulin (Ig) is a large, heavy (~150 kDa), Y-shaped 
protein. Antibody consists of four polypeptide chains, two identical heavy chain (HC) 
and two identical light chain (LC) polypeptides which are linked by disulphide bonds at 
HC-HC and HC-LC.
151
 Each of the heavy chains is consist of variable (VH), diversity 
(D), joining (JH), and constant (CH) genetic segments, and each of the light chains is 
consist of VL, JL, and CL segments. The constant regions are relatively conserved within 
a given species while those of the variable region are antigen-dependent. Combining of 
the heavy chain V-D-J regions and light chain V-J regions creates an antigen binding 
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Disulphide bridges 
Fab 
Fc 
site which recognizes a single antigenic called epitope.
73
 The variable region gives the 
antibody its specificity for binding antigen. Each V region consists of an alternating 
framework (FW), which is more conserved and three complementary-determining 
regions (CDRs) with vast sequence diversity. The CDRs interact with the antigen to 
form the core of an antigen-binding site. 
 Antibody fragments can be generated either by proteolytic digestion or by 
genetic engineering.  For example, Papain digestion results in cleavage of the HC at the 
N-terminal of the hinge disulphides, causing separation of the two Fab (fragment 
antibody) regions from each other and from the Fc (Figure 1.7). The larger, Fab weight 
~50 kDa and consists of VH-CH and VL-CL segments linked by disulfide bonds and 
contains one binding site. The smaller, Fv weight ~25kDa and consists only of the VL 
and VH regions. Recombinant gene technology allows generation of a smaller antigen-
binding fragments, such as the single-chain fragment variable (scFv) (~25-30 kDa), 
which consists of VH and VL connected by a short flexible polypeptide linker. Usually a 
15 amino acid linker is used. The linker allows the association of the VH and VL to form 
the antigen binding site.  
 
 
 
 
 
 
 
Figure 1.7: Structure of antibody and antigen-binding (Azzazya 2002) 
 
Structure of immunoglobulin G (IgG), Fab (antibody fragment), Fv (variable fragment) 
and scFv (single chain variable fragment). Variable domains of heavy (VH) chains, 
black ovals and light (VL) chains, white ovals. Constant regions of heavy (CH1-3) and 
light (CL) chains are represented by shaded and dotted ovals, respectively. ABD = 
antigen-binding domain (paratope). 
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 A lot of progress has been made in recent years with antibodies engineering, 
much of it based on human antibodies.
63,152
 Antibody fragments such as scFv can be 
expressed in E. coli and can readily be produced in high quantities for any application. 
The small size and single-gene qualities of scFv make them suitable for molecular 
biology-dependent techniques, such as construction of large, artificial libraries 
displayed on bacteriophage.
1,150 
Those technologies enable the generation of antigen-
specific antibody fragments in vitro, which can then be reverse-engineered into a full 
immunoglobulin if required. In vitro display technologies allow generation of antibodies 
against toxic or self-antigens.
50,144
 
 
1.1.7 Phage Display 
 Phage display antibody technology is a means for the generation of specific 
antibodies through antibody selection.  Small antibody fragments such as scFv
93
 are 
expressed as fusion proteins on the surface of bacteriophage and physical selection 
(“biopanning”) used to isolate, from huge, diverse libraries, phage bearing antibodies of 
the desired specificity.
131,136,150
 It has been proven for the routine isolation of antibodies 
for diagnostic and therapeutic applications.
136
 
 Bacteriophages or phages are viruses that infect a variety of Gram-negative 
bacteria. The filamentous phage particles (strains KM13, f1 and fd), that infect E. coli, 
consist of a single-stranded (ss) DNA that is enclosed in a protein coat. The major 
membrane protein of a viable phage consists of about 2700 copies of gene 8 protein 
(g8p or pVIII), and 3 to 5 copies of the gene III (g3)-encoded adsorption protein (g3p or 
pIII) that  is one of three minor coat proteins of the filamentous phage on its tip (Figure 
1.8).
127
  
 Filamentous phage does not produce a lytic infection in E. coli, the infected 
bacteria produce and secrete phage particles in the periplasmic space without 
Chapter 1: General Introduction
 
28 
undergoing lysis.
15,135
 Infection is initiated by the attachment of the phage g3p to the f 
pilus of a male E. coli (e.g., E. coli TG1).
124
 Only the circular phage ssDNA enters the 
bacteria where it is converted by the host DNA replication machinery into the double-
stranded (ds) plasmid like replicative form (RF). The RF undergoes rolling circle 
replication to make ssDNA and also serves as a template for expression of the phage 
proteins g3p and g8p. Phage progeny are assembled by packaging of ssDNA into 
protein coats and extruded through the bacterial membrane into the medium.
15,135
 
 Phage display technology enables the insertion of DNA sequences of interest 
into a location in the genome of filamentous bacteriophage during the library creation. 
The foreign DNA inserted into filamentous phage g3 is expressed and displayed on the 
surface of the phage as a fusion product to g3p coat proteins (Figure 1.8).
136,150
 The 
fusion is to the N-terminus
93
 or to the C-terminal domain of the phage,
13
  and displayed 
as Fab fragments
65
 or scFv fragments
93
 in which the VH and VL domains are linked by a 
flexible polypeptide.
16,69 
 
 
 
 
 
Figure 1.8: Schematic diagram of a filamentous 
phage displaying single chain variable fragment 
(scFv) molecules (Azzazya 2002) 
The phage consists of circular ssDNA surrounded by 
a coat protein. g8p (pVIII) is the major coat protein 
whereas g3p (pIII), at the tip of the phage, is one of 
the minor coat proteins. The genes encoding the 
variable domains of the scFv and a linker are fused 
to gene III (g3) in the genome of the filamentous 
phage. The scFv is displayed as a fusion to g3p 
protein at the tip of the phage. 
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A variety of vectors have been used for the presentation of antibodies on the 
phage surface. These include phage vectors, which encode the g3-fusion and all 
functions required for replication, packaging and infection of bacteria, and phagemid 
vectors which require "rescue" with a helper phage (figure 1.9).  
 
 
 
 
 
 
 
 
Figure 1.9: Schematic diagram of a phagemid vector 
Transcription is under control of the lacZ promoter. The ampicillin resistant gene 
(AMP) is for the selection and maintenance of the phagemid. The phagemid carries 
ColEi origin of replication for amplification in phage and E. coli. The secretion of the 
scFv fragment is directed by gene III signal peptide. The scFv genes are cloned for 
display on the phage coat protein, pIII. An amber stop codon in frame with and 
immediately following hexahistidine-tag and Myc-tag permit the expression of scFv as 
a fusion with gene III in an amber suppressor host (TG1) or as a fusion with only the 6 
× His-tag and Myc-tag in a non-suppressor host strain (HB2151). The scFv fragment is 
fused with hexahistidine tag and Myc tag for affinity purification and immuno-
detection, respectively. 
 
 The M13 origin (ori) allowing the genome to be packaged into the phage 
particles, the E. coli origin (colE1ori) of replication enables the phagemid to replicate in 
the E. coli host cells. An ampicillin (amp) resistance for selection of phagemid-
containing colonies, a peptide leader for secretion of phage gene III protein (g3p) fused 
with the antibody fragment (scFv) to the periplasm of the bacteria. The scFv consist of 
variable domain of the heavy chain (VH) and a variable domain of the light chain (VL), 
both of a human antibody, between them a peptide linker of 15 amino acids. 
Furthermore, an amber stop codon provides the opportunity to either produce the 
lacZ promotor 
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antibody fused to the coat protein of the phage, using a E. coli suppressor strain (e.g. 
TG1), or to produce soluble antibodies by expressing the vector in a non-suppressor 
strain (e.g. HB 2152). Tag sequence for detecting the antibody with the anti-tag 
antibody. 
 There are several approaches to building phage antibodies libraries. Naïve 
libraries are made from the genomic information derived from B cells of either non–
immunised (naïve) or immunised donors.
27
 An antibody repertoire from immunisation is 
generally restricted to generating antibodies against the antigen of the original 
immunogenic response, whereas naïve libraries have the advantage that they can 
theoretically be used for an unlimited range of antigens. The synthetic libraries, 
however, are based on in vitro rearrangements of V gene segments. The concept is 
based on mimicking the in vivo Ig gene rearrangement artificially in vitro. The 
advantage of the synthetic libraries is the ability to control the type and number of 
germline gene segments as well as the sequence of the synthetic CDRs.
35,107,133
 Hence, 
the semi-synthetic repertoires are not intrinsically biased and therefore can be used for 
selection of antibodies against a wide range of targets,
66,144
 including self-antigens.
107 
 
The Tomlinson library used in this study was created from single human heavy chain 
genes V3-23/DP-47 and JH4b and the light chain genes O12/O2/DPK9 and Jκ1 that 
were cloned into PIT2 phagmid vector.
35
 DP-47 is highly expressed in human 
antibodies.
34
 Variation was encoded into 18 residues selected from the CDR2 and 
CDR3 regions of both VH and VL, at positions chosen for their high diversity in the 
natural repertoire and their roles in known antibody-antigen contacts. Diversity was 
generated at these points using DVT (Tomlinson I library) or NNK (Tomlinson J 
library) codons.  Tomlinson I and J scFv-phage have been pre-selected for binding to 
protein A and protein L, and contain 1.47 x 10
8
 and 1.37 x 10
8
 clones respectively.   
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 Phage libraries are screened and enriched for antigen-specific clones by bio-
panning in which a phage displaying scFv is incubated with an immobilized antigen of 
interest (Figure 1.10).
27,107
 Unbound phage are removed by washing whereas phage 
displaying scFv that specifically bind the antigen are eluted, by changing the binding 
conditions (acidic or high basic) or by enzymatic cleavage of a protease site constructed 
between the antibody and g3p.
147
 
 
Figure 1.10: Bio-panning of phage-display library (Nissim lectures figures) 
The library is screened in four steps: binding of phage to the target immobilized antigen 
on a solid support, washing to remove unbound phage, dissociation to recover antigen-
specific phage, and amplification of the antigen-specific phage by infection of E. coli. 
Several rounds of selection are necessary (average 3-4 cycles). 
 
 The library is selected using immunotubes in several steps: (i) antigen 
immobilized on a solid support, (ii) binding of phages to the target antigen, (iii) washing 
to remove unbound phage, (iv) eluting of binders to recover antigen-specific phage, (v) 
amplification of the antigen-specific phage by infection of E. coli. 3-4 rounds of 
selection are usually needed. (vi) at the end panning of E. coli TG-1. 
 To reduce the background, the KM13 helper phage has been modified to contain 
a trypsin-cleavable site between the domain of pIII and the domain that anchors pIII to 
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the phage, which upon cleavage renders the phage non-infective (figure 1.11).
45,84
 In 
turns, the trypsin can cleave the scFv-gIII fusion protein at the myc site. This result in 
elution of phage that bound to the immobilized protein via the scFv only while leaving 
behind phage bound non specifically to the immunotube.  
 
Figure 1.11: Proteolytic selection (Goletz 2002) 
During packaging and rescue of a phagemid scFv library, the pIII from the helper phage 
(II) competes with the scFv-pIII fusion protein (I) for incorporation into the phage 
particles. The helper phage KM1315 encodes a modified pIII with an additional trypsin-
sensitive site between domains D2 and D3 (II). All three domains of pIII are essential 
for phage infectivity, while it is possible to attach or insert peptides between domain 
boundaries without abolishing infectivity. The pIII(wt) of the scFv-pIII fusion protein 
(I) cannot be cleaved by trypsin and hence retains the infectivity of the phage after 
trypsin treatment. The trypsin cleavage site in the myc tag of the scFv-pIII(wt) fusion 
protein allows the proteolytic elution of an infective phage from its antigen. 
 
 The figure presents a scFv-phage from a phagemid library using KM13 as 
helper-phage. During packaging and “rescue” of a phagemid scFv library, the pIII from 
the helper-phage (II) competes with the scFv-pIII fusion protein (I) for incorporation 
into the phage particles. The helper-phage encodes a modified pIII with an additional 
trypsin-sensitive site between domains D2 and D3 (II). All three domains of pIII are 
essential for phage infectivity. It is possible to attach or insert peptides between domain 
boundaries without abolishing infectivity. The pIII(wt) of the scFv-pIII fusion protein 
(I) cannot be cleaved by trypsin and hence retains the infectivity of the phage after 
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trypsin treatment. Most of rescued phages carry no scFv and become non-infective after 
trypsin treatment. The trypsin cleavage site in the myc tag of the scFv-pIII(wt) fusion 
protein allows the proteolytic elution of an infective phage from its antigen.  
 Eluted phage are amplified in E. coli TG-1.
78,90 
Since each phage packages the 
DNA encoding the coat protein-antibody fusion, there is a physical linkage between 
phenotype (specific antigen binding) and genotype (antibody gene sequence). In that 
way, it is possible to isolate phage purely on their binding properties, then amplify and 
characterise them.
66
 Ideally, only one cycle of selection should be required, however the 
binding of nonspecific phage limits the enrichment that can be achieved per cycle. In 
practice, several rounds of selection are necessary (on average 3-4 cycles). To produce 
soluble scFv, antigen-positive phage is used to infect a specific strain of E. coli (e.g., E. 
coli HB2151) that will direct production of soluble scFv.  
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1.2 Hypothesis 
 The basic hypothesis for this PhD is that autoimmunity to native and/or post-
translationally modified of CI and CIII is involved in the progression and severity of 
periodontitis. 
 
1.3 Aims of the Thesis 
 The main objective of the study was to extend the understanding of periodontal 
disease pathogenesis beyond the common bacterial aetiology and to address the 
hypothesis that periodontal disease is an auto-immune disease. Since the exact aetiology 
of autoimmune reactivity in periodontitis is not known, this study addresses the question 
whether the autoimmune response, to native and/or post-translationally modified 
extracellular matrix proteins, is a primary pathogenic event, or whether the production 
of autoantibodies is secondary to the inflammation. Moreover, this research will try to 
identify the exact neoepitope of the autoimmune response and to developed human 
antibody fragment specific to native and ROS modified CI and CIII for future 
diagnostic and therapeutic application. 
 Specific aims: 
1. To optimize the in vitro post-translational modification of CI, CIII and bovine 
serum albumin (BSA) by different ROS, such as HOCl, OH∙, ONOO∙ and 
glycation, known to be present in the inflamed periodontium. Confirmation of 
the modification will use sodium dodecyl sulfate–polyacrylamide (SDS-PAGE) 
gel electrophoresis, 3-dimensional (3D) fluorescence analysis and Capillary 
Electrophoresis (CE). 
2. To determine whether autoantibodies against native and post-translational 
modified CI and CIII are present during inflammation in sera and saliva from 
individuals with AgP, CP and G by ELISA and WB. 
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3. To identify the exact neoepitope of the immune response by Mass spectrometry.  
4. To develop antibodies specific to native and ROS CI and CIII by employing 
phage display technology using semi-synthetic human single chain fragment 
variable (scFv) libraries, as a tool to identify post-translational modification by 
ROS in the inflamed periodontal tissue.  
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Chapter 2: Materials & Methods 
2.1 Materials 
2.1.1 Instrumentation and computer programs 
- ChemStation B.02.01 (Agilent Technologies, USA). 
- Curix 60 Film processor (Agfa, Belgium). 
- Hitachi Fluorescence Spectrophotometer F-4500 (Hitachi, Japan). 
- Hypercassette RPN11643 (Amersham, UK). 
- GENion plate reader (TECAN, UK).  
- Magellan 4 software (TECAN, UK). 
- MJ Mini-Personal Thermal Cycler (Bio-Rad, USA). 
- TE 70 SemiPhorTM Semi-dry blotter (Hoefer Scientific Instruments, UK). 
- UVItec and UVI Photo Version 99.03 (UVITEC, UK). 
 
2.1.2 Chemicals, kits and consumables list 
CHEMICAL / STANDARD DISTRIBUTOR 
30% Acrylamide, 0.8% Bis-acrylamide National Diagnostic  EC-890 
40% Acrylamide, 3.3% Bis-acrylamide Sigma-Aldrich A7803 
Acetic Acid VWR-BDH 10001CU 
Agar Invitrogen 15510-027 
Agarose Sigma-Aldrich A9539 
Ammonium Acetate Sigma-Aldrich A1542 
Ammonium Hydrogen Carbonate VWR-BDH 103025E 
Ammonium Persulphate VWR-BDH 100323W 
Ammonia (NH3) Bio Lab 01250501 
Ampicillin Sigma-Aldrich A9518 
AnaeroGen Anaerobic bag  OXOID AN0025 
Anti-His HRP Conjugate Solution Sigma-Aldrich A7058 
Anti-human IgG Peroxidase Sigma-Aldrich A8792 
Anti M13 Monoclonal Antibody BioLabs E8033S 
Avidin/Biotin Blocking Kit VECTOR Laboratories SP-2001 
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Bacto-Agar Sigma-Aldrich A5054 
β-mercaptoethanol Sigma-Aldrich M7154 
Bovine Collagen Type II (CII) Sigma-Aldrich C7806 
Bovine Serum Albumin (BSA) Sigma-Aldrich A7906 
Brij 35 Sigma-Aldrich 858366 
Bromophenol Blue VWR-BDH 44305 
Buffered Formalin 5% Bio LAB 693101 
Calf Skin Collagen Type I (CI) Sigma-Aldrich C9791 
Carbonate-Bicarbonate Sigma-Aldrich C3041 
CHAPS Thermo Fisher Scientific 17593 
Citric Acid Sigma-Aldrich C0759 
Collagen Type III (CIII) from human placenta Sigma-Aldrich C4407 
Colour Protein Marker Ultra Low Range Sigma-Aldrich C6210 
Coomassie
®
 Brilliant Blue R-250 Bio-Rad 161-0400 
Copper Chloride Sigma-Aldrich C3279 
Cyanogen Bromide (CNBr) Sigma-Aldrich 481432 
DAB substrate DAKO K3468 
DAKO Protein Blocking Solution DAKO X0909 
DIASTAT Anti-CCP Axis-Shield Diagnostics FCCP200 
Digest-All3 Invitrogen 00-3009 
DL-Dithiothreitol (DTT)  Sigma-Aldrich D0632-56 
Dried Skimmed Milk MARVEL 
D-(+) Glucose Sigma-Aldrich G5767 
D-ribose Sigma-Aldrich R7500 
DryStrip Cover Fluid GE Healthcare 17-1335-01 
ECL Chemiluminescent Substrate Reagent Kit Invitrogen WP20005 
Econo-Column Chromatography Columns Bio-Rad 737-1022 
EDTA Sigma-Aldrich 431788 
ELISA plate – F96 Maxisoap NUNC 442404 
Ethanol Sigma-Aldrich E7023 
Ethidium Bromide Sigma-Aldrich E1510 
Ettan IPGphor Strip Holder Cleaning Solution GE Healthcare 80-6452-78 
FD-SEC Sigma-Aldrich SY0906055720-042 
Formaldehyde (37%) Sigma-Aldrich PS2031 
Formic Acid Sigma-Aldrich F0507 
Gluteraldehyde Merck 1.04239.1000 
Glycerol VWR-BDH 101186M 
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Goat Polyclonal IgG anti-rabbit HRP Abcam AB6721-1 
GVA mount Zymed 00-8000 
HRP-anti-M13 GE Healthcare 27-9421-01 
Human IgA ELISA Quantitation Set Bethyl Laboratories E80-102 
Hydrogen Peroxide Solution (30%) VWR-BDH 101284N 
Hyperfilm Amersham GE Healthcare 28-9068-3T 
Hyper Ladder I Bioline  BIO-33025 
Immobiline DryStrip (pH 3-10NL) GE Healthcare 17-6001-15 
ImmunoPure Recomb Protein L Peroxides, Pierce Thermo Fisher Scientific 32420 
Isopropyl β-D-thiogalactoside (IPTG) Sigma-Aldrich 81260 
Kanamycin Sigma-Aldrich K0254 
KAPA HiFi™ HotStart DNA Polymerase KAPA Biosystems KK2501 
LAB3 Sigma-Aldrich A4624-062 
L-Cysteine Sigma-Aldrich 168149 
Magnesium Sulfate VWR-BDH 1015144 
Mayer’s Haematoxylin Sigma-Aldrich MHS16 
Methanol Thermo Fisher Scientific M/4000/17 
Microscope Slides, Super Frost Plus VWR-BDH 631-0108 
MMP-1 Sigma-Aldrich C6885 
2,7 Napthalendisulphanate (NDS) Thermo Fisher Scientific 41523-2500 
Nitrocellulose Membrane Filter Paper Sandwich Invitrogen LC2001 
NUNC Immuno Plates Maxisoap Thermo Fisher Scientific 442404 
NUNC Immuno Test Tube Maxisoap Thermo Fisher Scientific 444202 
PAP pen Zymed 00-8877 
PCR Grade Water Sigma-Aldrich W4502 
Peroxynitrite Calbiochem 516620 
Phosphate Buffer Saline (PBS) Sigma-Aldrich P4417 
Polyethylene Glycol 6000 Sigma-Aldrich 81260 
Ponceau S Solution Sigma-Aldrich P7170 
Pre Cast Gradient 4-20% SDS PAGE Gel Bio-Rad 161-1105 
Precision Plus Marker Bio-Rad 161-0373 
Protein A-HRP Sigma-Aldrich P8651 
Protein A-Sepharose CL-4B Amersham 71-7090-00 
Protein Diluent Solution DAKO S3022 
QIAquick PCR Purification Kit Protocol QIAGEN 28-104 
Rabbit anti-myc  Sigma-Aldrich C3956 
Ribose Sigma-Aldrich R7500 
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Silver Nitrate (AgNO3) Sigma-Aldrich  20,913-9 
Silver Stain Kit, Pierce Thermo Fisher Scientific 24612 
Slide-A-Lyzer 10k Dialysis Cassettes, Pierce Thermo Fisher Scientific 66380 
Sodium Acetate VWR-BDH 102364Q 
Sodium Cheloride Sigma-Aldrich S5886 
Sodium Dodecyl Sulfate (SDS) Calbiochem 428015 
Sodium Hypochlorite VWR-BDH 230393L 
Sodium Phosphate, dibasic Sigma-Aldrich S7907 
Sodium Phosphate Monohydrate, monobasic Sigma-Aldrich S8282 
Sterivex-HV 0.45µm filter unit, Millipore CORNING 431097 
Sucrose VWR-BDH 102745C 
Sulphuric Acid Sigma-Aldrich 93124 
TE Buffer Invitrogen 60191 
3,3',5,5'-tetramethylbenzidine Substrate Sigma-Aldrich T2885 
Tetramethylethylenediamine (TEMED) VWR-BDH 443083G 
Tricine Sigma-Aldrich T0377 
Triton X-100  Sigma-Aldrich T8787 
Tris Sigma-Aldrich T1503 
Tris-Borate EDTA (TBE) Buffer  Sigma-Aldrich T4415 
Tris Glycine SDS (TGS) Buffer x10 Sigma-Aldrich T7777 
Trypsin Sigma-Aldrich T1426 
Tryptone Sigma-Aldrich T9410 
Tween
®
 20 Sigma-Aldrich P1379 
Urea Sigma-Aldrich U5378 
Wilkins -Chalgren Anerobe Broth OXOID CM0643 
Xylene VWR-BDH 28975.325 
Yeast Extract Sigma-Aldrich Y1625 
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2.2 Methods 
2.2.1 Chemical modification of collagen 
 Post-translational modification of collagen type I, II and III were performed 
using reactive oxidants (ROS).  Initially the work focused on optimising the 
modifications so that the native protein was indeed oxidised but not entirely destroyed 
or aggregated. Thus, each of the modifications was done under different concentrations 
of free radicals and under different intervals of time, while monitoring the proteins 
changes by: 
1. 1D SDS-PAGE electrophoresis to detect degradation through a time and 
concentration range. 
2. Fluorescence spectrophotometery was used to detect minor changes in the 
fluorescence profile of proteins to monitor structural changes as well as the 
degree of aggregation. 
 
2.2.1.1 Chemical modification of collagen type I & II 
 Calf skin collagen type I and bovine collagen type II (1 mg/ml) in 0.1M aq. 
acetic acid pH 6 were incubated overnight at 37°C with the following ROS generating 
systems: 
108 
1. Sodium hypochlorite (HOCl) is a strong oxidant that can directly attack the peptide 
bond and modified amino acid side chain such as cysteine which is converted to 
disulfides and methionine which is converted to sulfoxide.
30,57,58
  
Native CI and CII were exposed to 1mM sodium hypochlorite for one hour and 
overnight. 
Other HOCl condition studied: 0.1mM, 0.5mM, 1mM, 2mM, 5mM, 10mM. 
2. To modify by OH., 1mM CuCl2 and 20mM hydrogen peroxide (H2O2) were added 
to 1mg/ml of CI or CII for one hour and overnight. OH
.
 is produced by reduced 
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metal ion such as Fe
2+
 or Cu
2+
 with H2O2 in a reaction called Fenton reaction. OH∙ 
attacks proline (Pro) amino acid resulting in hydrolysis of Pro and generation of 
new N-terminal glutamate.
55
 
Other hydrogen peroxide concentrations studied: 2.5mM, 5mM, 10mM. 
3. To modify CI and CII by peroxynitrite (ONOO∙), 2mM ONOO∙ (supplied as a 
200mM stock solution dissolved in 4.7% NaOH) with 200mM phosphate buffer, 
pH 7.2, added to adjust the pH to 7.2, were added to 1mg/ml of the proteins. At a 
pH less than 8 the stock is isomerizes and decomposed to a highly reactive radical 
species.
138
  
Other peroxynitrite concentrations studied: 10mM, 50mM. NaOH was tested alone 
to make sure that the solution without peroxynitrite is not reacting with CI. 
4. Glycation was performed by incubating v/v CI & CII with 4M ribose for 2 days.12   
Additional studies were performed over 1 and 3 days. 
 Bovine serum albumin (BSA) in 0.1M acetic acid pH 6 was also modified as 
above and was used as negative control antigen.108 
 
2.2.1.2 Chemical modification of collagen type III 
 Collagen type III from human placenta (1 mg/ml) in 0.1M aq. acetic acid pH 6 
was incubated for 5 min with the following ROS generating systems: 
108 
1. 0.05mM sodium hypochlorite (HOCl).30,57,58 
Other conditions tested: 0.1mM for 5 min, 10 min, 1 hour and overnight.  
2. 1mM CuCl2 and 0.5mM hydrogen peroxide (H2O2), which was used to modify CIII 
with hydroxyl radical (OH∙).55 
Other hydrogen peroxide conditions tested: 10min, 1hour, over night. 
3. 2mM peroxynitrite (ONOO∙) (supplied as a 200mM stock solution dissolved in 
4.7% NaOH) with 200mM phosphate buffer, pH 7.2, added to adjust the pH to 7.2. 
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Other peroxynitrite conditions tested: 10 min, 1 hour, over night. 
4. Glycation by incubating at 37°C CIII with 4M ribose for 2 days.12 
Other glycation conditions tested: 1 and 3 days. 
 
2.2.1.3 Chemical modification of collagen by a mixture of reagents  
In order to create mixed ROS modification by all the free radical together, stocks 
were made of the final concentration of each reaction as in the protocols above (1:1) or 
at a dilution of 1:100 with dH2O. Then all of the chemicals were mixed together, at a 
same volume of each one. The mix free radical solution was then added to the different 
proteins and followed by overnight incubation at 37°C (CI) or 10min (CIII).  
 
2.2.2 Monitoring of the modifications 
To monitor changes in the molecular mass and/or fragmentation after ROS 
modification of CI, CII and CIII 8% reducing SDS-PAGE was used. Modifications of 
the control BSA were monitored by 12% SDS-PAGE, followed by parallel staining with 
Coomassie brilliant blue and silver.  
Structural changes were monitored by fluorescence spectra following ROS 
modification of CI, CII, CIII and BSA. 3-D scanning fluorescence spectra were 
obtained using a Hitachi F-4500 spectrofluorometer. Samples were briefly centrifuged 
prior to scanning to remove aggregated material. Simultaneous excitation (200-900 nm) 
and emission (200–900 nm) spectra were recorded. 
 
2.2.2.1 SDS-PAGE 
System used: Mini-PROTEAN
®
 3 Cell (Bio-Rad).  
Glass plates were cleaned with soap and water then ethanol. Plates were placed 
into the plate holder. Resolving gel was made according to the table 2.1 just before 
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pouring the mixed media, 10% ammonium persulphate and 100% TEMED were added. 
The mixture was poured up to the green line on the gel apparatus. Resolving gel mixture 
was covered with dH2O and left until the gel solidified. The gels were cast according to 
the percentage needed and according to table 2.1:
128
 
 
Table 2.1: Solutions for preparing resolving gels for tris-glycine SDS-PAGE 
 
After the gel was cast, the water was removed from the top of the gel and the 
stacking gel was added on the top of the gel. Just before pouring the mixture 10% 
ammonium persulphate and TEMED were added. Stacking gel was made according to 
the table below:
128
 
 
 
 
 
 
 
Table 2.2: Solutions for preparing 5% stacking gels for tris-glycine SDS-PAGE 
 
A comb was placed on the top of the gel before it was cast. The gel was left to 
polymerise for 15-30 min. 
 6% 8% 10% 12% 15% 
H2O  5.3 4.6 4 3.3 2.3 
30% Acrylamide, 0.8%Bis-acrylamide 2 2.7 3.3 4 5 
1.5M Tris (pH 8.8) 2.5 2.5 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 0.1 0.1 
10% Ammonium Persulfate 0.1 0.1 0.1 0.1 0.1 
100% TEMED  0.008 0.006 0.004 0.004 0.004 
 Volume in ml of components required to cast gels. 
H2O 6.8 
30% Acrylamide 1.7 
1M Tris (pH6.8) 1.25 
10% SDS 0.1 
10% Ammonium persulfate 0.1 
100% TEMED 0.01 
 Volume in ml  
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The cast gel was clamped into the electrode chamber with smaller plate facing 
inwards. The middle space was filled with 1xTGS (25mM Tris, 192mM glycine, 0.1% 
SDS, pH8.3). 5µl of loading buffer (25ml 0.5M Bis-Tris pH 6.8, 20ml glycerol, 40ml 
10% SDS, 40mg bromophenol blue; add 10µl β-mercaptoethanol to 1ml just before use) 
was added to 15-25µl samples, and was heated at 95°C for 5 min to denature the 
proteins.  
Samples were loaded using a fine-tipped pipette and 11µl of marker was loaded 
into one of the outer wells. The apparatus was filled to the top with 1xTGS and the 
electrophoresis was run as followed:  1 gel  => 40mA, 150V for 90 min. 
      2 gels => 80mA, 250V for 90 min. 
 Once the gel finished running the gel was removed and stained with Coomassie 
(0.5g Coomassie Blue, 250ml methanol, 200ml dH2O and 50ml acetic acid). It was left 
in the stain for 0.5-1 hour on a gentle shaker. Once the stain was over the gel was 
transferred for several hours to the destain (250ml methanol, 50ml acetic acid and 
700ml 2 dH2O). 
Pre-cast gradient (4-20%) SDS PAGE gels were used as well. 
 
2.2.2.2 Tricine SDS-PAGE
 
System used: PROTEAN
®
 2 Cell (Bio-Rad). 
1. Glass plates were cleaned with soap and water, then ethanol.  
 
Casting the gel: 
60
 
2. 16% separation gel was overlaid (up to 3cm from the top) with some water on top 
and left to set. Then 10% separation gel was added directly on the 16% gel (up to 
1cm from the top), covered with water and left to set. Final step was adding the 
4% sample gel to the top of the plates and placing a comb. 
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4% sample 
gel 
10% gel 16% gel 
16%/6M 
Urea 
40% acrylamide, 3.3% bisacrylamide ml 1 6 10 10 
Gel buffer (3X) 
(3M Tris, 1M HCl, 0.3%SDS, pH8.45) 
ml 3 10 10 10 
Glycerol g - 3 3 - 
Urea g - - - 10.8 
Add water to final volume ml 12 30 30 30 
10% Ammonium Persulphate µl 90 150 100 100 
100% TEDMA µl 9 15 10 10 
 Add the Ammonium Persulphate and the TEDMA just before pouring each layer. 
Table 2 3: Table for casting two 16X16cm Tricine gels 
 
Sample preparation and protein loading: 
3. Gels were clamped into the electrode apparatus with the smaller plate facing 
 inwards. 
4. Sample buffer protocol for SDS-PAGE (2.2.2.1) or the following was used: 
 5µl sample buffer (150mM Tris/HCl (pH 7), 12% SDS, 30% glycerol 0.05% 
Coomassie blue G-250 with 30µl β-mercaptoethanol (which was added to 0.5ml 
of the buffer just before use) was added to 15µl of samples and the mixture  
incubated at 37°C for 15-60 min. 
5. The middle compartment was filled with 1 x cathode buffer. Cathode buffer 
(10X): 1M Tris, 1M Tricine, 1% SDS. pH should be  ~8.25. 
6. 41µl of samples were loaded using a fine-tipped pipette. 11µl of Colour Marker 
Ultra Low Range (M.W 1,060-26,600) were loaded to one of the outer wells. The 
aliquot marker was heated for 2 min at 65°C before loading. 
7. The outer chamber was filled with 1 x Anode buffer. Anode buffer (10X): 1M 
Tris, 0.225M HCl. Adjust pH to 8.9. 
8. The electrophoresis was run as followed:  
 Initial step (0.5h)     30V  50mA      10W 
  Next step (5h)          200V    100mA     20W  
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Protein Visualization: 
9. Gel was removed from the plate and transferred to a box. Stains were done with 
the following protocol for Coomassie or Silver stain. 
10. Coomassie staining: 
a. Fixing solution: 50% methanol, 10% acetic acid, 100mM ammonium acetate 
(added up to several hours before using). Fixing time was for 15-60 min 
depended on the % and thickness of the gel. 
b. Stain: 0.025% Coomassie dye in 10% acetic acid was used for twice the time 
of the fixation. 
c. Destain: twice in 10% acetic acid for 15-60 min. 
 
2.2.2.3 Highly sensitive Silver Stain Protocol 
 All solutions should be prepared just before use. The developing was done on a 
shaker. All solutions were kept in 4ºC till use. 
1. 10 min in dH2O. 
2. 60 min in 40% Ethanol + 10% Acetic Acid. 
3. 2 hours (can be left over night) in 5% Ethanol + 5% Acetic Acid. 
4. 10 min in dH2O. 
5. 30 min in 0.5M Sodium Acetate + 2% Gluteraldehide, store at 4ºC before use. 
6. 3 x 10 min in dH2O from 4ºC. 
7. 2 x 30 min in 0.05% 2,7 Napthalendisolphanate (NDS), store at 4ºC before use. 
8. 4 x 15 min in dH2O from 4ºC. 
9. Solution A was prepared in a small measuring tube: 4ml dH2O + 0.8gr AgNO3. 
Solution B was prepared in a large measuring tube: 1.33ml 25% NH3 + 0.2ml NaOH 
10N + 21.33ml dH2O. 
Solution A was added slowly into solution B while stirring (solution’s A colour 
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should disappeared). dH2O was added to a final volume of 100ml. The gel was left 
for 30 min in this staining solution. 
10. 4 x dH2O in 37ºC. 
11. Developing: 0.1ml Formaldehyde (37%) + 5mg Citric Acid were added to dH2O to 
a final volume of 100ml. 
12. Stop solution: 15% Acetic Acid for 10 min. 
 
2.2.2.3 2-D Electrophoresis 
System used: Ettan IPGphor Isoelectric Focusing System (GE Healthcare). 
 Stock solutions: 
A) Rehydration stock solution with IPG Buffer: 
 The following was mixed: 12g Urea, 0.5g CHAPS, 125µl IPG Buffer (added 
before use) and 50µl of 1% stock solution of Bromophenol blue. dH2O was added 
to a final volume of 25ml. The solution was stored in 2.5ml aliquots at -20°C. 7mg 
DTT (DL-Dithiothreitol) was added per 2.5ml aliquot just prior to use. 
 Bromophenol blue stock solution: 100mg of Bromophenol blue were added to 
 60mg of Tris-base. They were dissolved in a final volume of 10ml of dH2O. 
B) SDS equilibration Buffer: 
 The following was mixed: 10ml of Tris-HCl (pH 8.8), 72.07g Urea, 69ml 
glycerol, 4g SDS and 400µl of 1% stock solution of Bromophenol blue. dH2O was 
added to a final volume of 200ml. The solution was stored in 10ml aliquots at -
20°C. DTT (DL-Dithiothreitol) was added just prior to use. 
C) Agarose sealing solution: 100ml of TGS were mixed with 0.5g Agarose and 200µl 
of Bromophenol blue. The mixture was steered and heated until the solution 
became clear and completely dissolved (do not boil). Aliquots of 2ml were stored 
at room temperature. 
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First-dimension Isoelectric Focusing (IEF) 
Prepare/Clean the strip holder: 
The strip holder was rinsed with mild liquid soap. A few drops of Ettan IPGphor 
strip holder cleaning solution were squeezed into the strip holder slots for cleaning. 
Then the strip holder was rinsed well with dH2O and dried. 
 
Sample and Rehydration solution preparation: 
2.5ml aliquots of stock solution A (rehydration stock solution) were added 
slowly to 125µl of IPG Buffer and 7mg DTT. 100µl of 0.5-1mg/ml of protein was 
added to 250µl of final rehydration solution. 
 
Apply the rehydration solution: 
1. 350µl of sample+rehydration solution were pipetted into a 13cm IPG strip holder. 
2. The strip was positioned with the gel side down and the pointed (anodic) end of 
the strip directed toward the pointed end of the strip holder. The strip holder was 
genteelly tilted to assure complete and even wetting. 
3. DryStrip cover fluid was applied to cover the IPG strip and the plastic cover was 
placed over the strip holder. 
4. The strip holder was located on the Ettan IPGphor unit platform and rehydration 
under  voltage protocol for 13cm Immobiline DryStrip (pH 3-10NL) was done as 
followed: 
a. Rehydration for 10h minimum, 30V. 
b. 1 step and hold 500V   1 hour 
c. 2 step and hold 1000V   1 hour 
d. 3 step and hold 8000V   2 hours 
e. 4 step and hold 100V   x hours, till strip is used for second dimension  
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Second-dimension SDS-PAGE 
Equilibration steps: 
5. 100mg DTT was added to 10ml of solution B (SDS equilibration Buffer) just prior 
to use. The strip was placed in a box with 10ml solution (the gel facing upwards) 
and equilibrated for 15 min on a gentle rocker. 
6. 250mg Iodoacetamide was added to 10ml of solution B (SDS equilibration 
Buffer) just prior to use. The strip was placed then in a box with 10ml solution 
(the gel facing upwards) and equilibrate for 15 min on a gentle rocker. 
 
Preparation of SDS-PAGE gel: 
7. A 16x16cm SDS-PAGE (2.2.2.1) or Tricine-SDS-PAGE (2.2.2.2) were prepared 
without a sample gel layer. Two wells were prepared, at both sides, of the gel for 
marker. 
 
Position of IPG strip: 
8. The equilibrated IPG strip was dipped in the TGS buffer to lubricate it. Then the 
strip was placed with the acidic end to the left and the gel surface up onto the 
protruding edge of the longer plate. The strip was pushed down so that the entire 
lower edge of the IPG strip was in contact with the top surface of the slab gel. 
9. 10-15µl of molecular weight marker was applied to the gel. 
 
Seal the IPG strip in place: 
10. An aliquot of Agaros sealing solution (solution C) was melted in a 100°C heat 
block and allowed to cool until the tube could be held by fingers (~60°C). Then, 
the amount required to seal the IPG strip in place was slowly poured, avoiding 
any bubbles. The Agaros was left to cool and solidify (1 min minimum). 
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Electrophoresis conditions: 
11. The recommended conditions in the gel section preparation (2.2.2) were followed. 
 
Visualization and Evaluation of results: 
12. Both Coomassie and Silver Stains were used. 
 

2.2.2.4 Capillary Electrophoresis 
Capillary Preparation: 
A 40cm length of 50µm capillary was cut using a ceramic tile. The ends were 
inspected with magnifier to ensure a straight cut. A window was made in the capillary 
by burning the polyimide coating 8.5cm from one end using an electrical capillary 
electric burner. Removing charred remains was done using a methanol soaked tissue. 
The capillary was placed into the cassette with the window properly aligned with the 
detector interface. Cleaning of the capillary was done as followed: 30 min with 1M 
NaOH at 45ºC followed by 10 min with dH2O at 30ºC. 
 Samples were centrifuged at 13,000g for 5 min at 4ºC to remove particulates. 
 
CE Analysis: 
 ChemStation method analysis was set as follows: 
a. Preconditioning: capillary was flushed with 0.1M NaOH for 2 min and then 
with BGE (50mM NaH2PO4, adjusted to pH 2.5 with NaOH ) for 2 min. 
b. Temperature: 30ºC. 
c. Injection: 150mbars-1. 
d. Detection: 215nm. 
e. Voltage: 25kV. 
f. Analysis time: 20 min. 
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2.2.3 Patient Samples 
Serum and saliva samples 
Serum and saliva samples from AgP (n=25), CP (n=14) and G (n=18) were 
collected from new patients attending the Periodontal Consultant Clinic, Institute of 
Dentistry, Barts & The London School of Medicine & Dentistry (Table 2.1).
68
 Clinical 
diagnosis of Generalised AgP was done according to World Workshop in 
Periodontology criteria.
8
 Approval was granted by the City and East London Health 
Authority Local Research Ethics Committee (05/Q0601/80). All participants signed a 
written consent form. In addition, controls sera from patients with RA (n=12) from a 
previous study
108
 and with unknown periodontal disease status were tested. 
 N 
Age 
(mean±sd range) 
Males 
Sites with 
PD < 5mm 
Plaque score 
(mean±sd) 
Current 
Smoker 
Gingivitis 18 
38.3 ±11.5 
24 – 60 
8 (43%) 0 64 ± 45% 2  (11%) 
Chronic PD 14 
52.3 ± 10.06 
43 – 62 
7 (50%) 21 ± 18.4 70.1 ± 28.1% 3 (21%) 
Aggressive 
PD 
25 
32.6 ± 4.8; 
22 – 39 
12 (48%) 27 ± 15.4 49 ± 20% 5 (20%) 
Rheumatoid 
Arthritis 
44
60.4 ± 12.5; 
38 – 83 
4 (66%) na na na 
 
Table 2.4: Clinical data of the patient groups with periodontal disease 
Twenty-five aggressive periodontitis (AgP), 14 chronic periodontitis (CP), and 18 
gingivitis (G) patients were tested. AgP samples were from patients under the age of 40, 
having a minimum of 6 teeth with pockets deeper than 5 mm and a clinical diagnosis of 
Generalized AgP according to World Workshop in Periodontology criteria (Armitage, 
2000). Patients with CP were over the age of 40, with a minimum of 2 teeth affected by 
pockets deeper than 5 mm. Gingivitis patients exhibited gingival bleeding and no sites 
deeper than 5 mm pocket depth. AgP samples were taken from a subset of patients from 
a previously reported study (Hughes et al., 2006). na= data is not available. 
 
AgP samples were from patients under the age of 40, had a minimum of 6 teeth 
with pockets deeper than 5mm and a clinical diagnosis of Generalised AgP according to 
World Workshop in Periodontology criteria. Exclusion criteria were patients with a 
history of periodontal treatment or antimicrobial therapy within the previous 6 months, 
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affected by any systemic condition likely to affect the periodontal tissues (including 
pregnancy), or were taking any medication which might have the same effects
.9
 Patients 
with CP were over the age of 40, had a minimum of 2 teeth affected by pockets deeper 
than 5mm. Gingivitis patients exhibited gingival bleeding and no sites deeper than 5mm 
pocket depth. 
Blood samples were collected as peripheral venous blood from all participants 
on the day of the intraoral examination (AgP, CP and G groups). The fresh whole blood 
was centrifuged at 3,000 revolutions per minute (rpm) for 10 minutes and, the cellular 
and plasma phases have been separated, the plasma was aliquot and stored at -80°C 
until further analysis. Saliva sample were collected as stimulated whole saliva which 
was aliquot and stored at -80°C until further analysis 
Some of the AgP sera samples were available as well post-treatment, however 
the samples were used on several experiments previously to ours. At baseline subjects 
received a full clinical assessment. Full mouth 6-point probing depths, and recession 
measured from the cemento-enamel junction were recorded in 0.2mm increments using 
an electronic probe (Florida probed, Florida Probe, Gainsville, FL, USA) and clinical 
attachment levels also calculated by addition of probing depth with recession 
measurements. The presence or absence of plaque, bleeding on probing, and 
suppuration was recorded for all sites. The presence of furcation lesions and mobility 
were also recorded for all teeth. Patients received four visits of nonsurgical periodontal 
treatment of 30 minutes duration each at weekly intervals. At these appointments, 
patients received oral hygiene instruction and full mouth subgingival scaling and 
debridement using hand and ultrasonic instrumentation, one quadrant at a time, using 
local anesthesia where necessary. This was carried out by experienced periodontists and 
on completion of treatment patients were then seen 10 weeks later for a further clinical 
examination including recording of all variables assessed at baseline.
68 
Chapter 2: Materials & Methods
46 
 
2.2.4 Testing the reactivity of sera 
2.2.4.1 Enzyme-linked immunosorbent assay (ELISA) 
Autoantibodies to native and ROS modified collagen were tested by 
immunoassay. An ELISA of the serum samples was performed using the modified and 
native CI, CII, CIII and BSA.  Both CI and CIII were also tested after modified with 
ROS mixture.  
In order to optimize the protocol several sera samples concentration where used: 
1:20, 1:40, 1:80, 1:160. Coating of plates with the different proteins was optimized by 
using a dilution of stock protein of 1mg/ml and diluted it by 2:1, 1:1, 1:2, 1:4, 1:8, 1:16, 
1:32, 1:64, 1:1128, 1:256, 1:512, 1:1024, 1:2048. The final conditions are in the 
following protocols:
108
 
Coating: after calibrating the ELISA system with several protein dilutions, 96 
wells ELISA plates were coated with 10μg/ml of modified or native protein in 0.1M 
acetic acid and incubated at 4°C overnight.  
1. Plates were washed 3 times with PBS and then air dried. 
2. Blocking: 100μl of 2% Marvel (dried skimmed milk) in PBS was added to each 
well for 1.5 hours at 37°C. 
3. Plates were washed 3 times with PBS and dried.  
4. Reaction with sera: 100μl of 1:100 diluted serum samples in 2% Marvel in PBS 
was added to each well, followed by 1.5 hour incubation at 37°C. 
5. Plates were then washed 3 times with PBS plus 0.1% Tween, followed by 3 
washes with PBS and drying.  
6. Anti-human IgG peroxidase (HRP) / Anti-human IgA peroxidase (HRP) /  Anti-
human IgA peroxidase (Alkaline Phosphatase Conjugate) was then added at 
1:1,000 dilution in 2% Marvel in PBS for another 1.5 hour incubation at 37°C.  
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7. Plates were then washed 3 times with PBS plus 0.1% Tween, followed by 3 
washes with PBS and drying.   
8. ELISA was developed by adding 100μg/ml 3,3’,5,5’-tetramethylbenzidine 
substrate in 100mM sodium acetate, pH 6.0 and 10μl of 30% hydrogen peroxide. 
Reaction was stopped after 10 minutes by adding 50μl of 1M sulphuric acid to 
each well. 
9. The optical density (OD) was measured at 450nm using a GENios plate reader 
and Magellan software. 
When developing with alkaline phosphatase a different developing system was 
used. A substrate solution consisted of 10ml of bicarbonate buffer adjusted to pH 
9.6 with 2.1g sodium hydrogen carbonate and 2.66g anhydrous sodium carbonate 
to 1l dH2O was used. Just before used, 2 tablets of alkaline phosphates conjugate 
were added to the substrate solution. 100µl of this solution was added to each well 
and left at room temperature for 10-30 min till a yellow colour developed. The 
reaction was stopped by adding 50µl of 3M sodium hydroxide. The optical OD 
was measured at 405nm.   
 
2.2.4.2 Protein Binding evaluation to ELISA Plates 
Coating: 
1. ELISA plates 96 wells were coated with 10µg/ml of modified or native protein in 
PBS (100µl in each well) and left overnight incubation at 4
o
C. 
Coomassie evaluation: 
2. Plates were washed 3 times with PBS. 
 Plates were incubated with 100µl Coomassie brilliant blue stain (0.12% w/v 
Coomassie G-250, 45% v/v methanol, 10% v/v/ 1M acetic acid) for 1 hour. 
3. Plates were washed 6 times with PBS. 
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      100µl Coomassie destain (45% v/v methanol, 10% v/v 1M acetic acid) solution 
added and incubated at room temperature for 2 hours with gentle agitation. 
4. Absorbances of the plates with destain solution were read at 595nm. 
 
2.2.4.3 Western blotting  
Native and modified proteins as target antigen: 
1. Modified and native proteins were run on denaturing SDS-PAGE gels.  
2. Gels were soaked in western blot buffer (1xTGS + 20% methanol) for 20 min. 
 
Transfer proteins into nitrocellulose: 
3. Nitrocellulose membrane filter paper sandwich 0.45µm Pore Size was used. The 
nitrocellulose and filter sheets were soaked in western blot buffer. 
4. A sandwich was made in the semi-dry transfer unit as follows:  
   - Positive electrode (bottom) 
   - 2 filter sheets 
   - Nitrocellulose 
   - Gel 
   - 2 filter sheets 
   - Negative electrode (top) 
5. Electrophoreses took place at 200mA, 10V, for 2 hours. 
6. After electroelution, the nitrocellulose was removed from apparatus and marked. 
 Elution was confirmed by: 
- Staining of SDS-PAGE gel with Coomassie Brilliant Blue to show that the 
proteins are not in the gel anymore. 
- Stain of nitrocellulose with Ponceau S Solution to show that the proteins are in 
the nitrocellulose membrane. 
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Reaction and detection with antisera: 
8. Nitrocellulose was blocked by incubated with 5% MPBS (PBS + 5%Marvel) in 
0.05% Tween, for 20 min on gentle gel rocker. 
9. Serum samples were added as followed: 1ml of 1:25 serum in 5%MPBS in 0.05% 
Tween over nitrocellulose, incubated for 2 hours in room temperature. 
10. Membrane was washed 3 times in PBS + 0.1% Tween, for 10 min and then 3 
times in PBS, for 10 min. 
11. 10ml of 5% MPBS in 0.05% Tween with 1:1000 dilution of anti-human IgG-HRP 
was added and incubated for 2 hours.  
12. Membrane was washed 3 times in PBS + 0.1% Tween, for 10 min and then 3 
times in PBS, for 10 min. 
13. ECL chemiluminescent substrate reagent kit was used. A mix of Reagent 1 with 
an equal volume of Reagent 2 was added to the nitrocellulose for 1 min. 
14. A film was exposed for the required time in a hypercassette in a dark room, then 
developed in the film processor. 
 
2.2.4.4 Stripping and Reprobing Nitrocellulose Membrane 
Nitrocellulose membrane was put in stripping buffer (62.5mM Tris pH 6.7, 2% 
SDS, 100mM β-mercaptoethanol) for 5-10 min in 56oC. Then the membrane was 
washed 3 times with 0.05% TPBS for 10 min and 3 times with PBS for 10 min. The NC 
membrane was blocked again and the reaction and detection with antisera were done 
once more. 
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2.2.4.5 Detection of autoantibodies to cyclic citrullinated peptide (CCP) 
The DIASTAT™ Anti-CCP test was used in order to detect autoantibodies 
specific to cyclic citrullinated peptide (CCP). Standards (1-5), positive and negative 
controls, and samples were run as followed: 
1. 100µl of reference control/standards were put in duplicate, pre-diluted (1:100) 
positive and negative controls, and pre-diluted (1:100) patient samples were put as 
well into appropriate strips. The strips were incubated for 60±10 min at 18-25°C. 
2. Strips contents were decanted by a quick inversion over and blotted with paper 
towels. Wells were washed three times with a minimum of 200µl diluted Wash 
Buffer, and then they were decanted and blotted after each wash step. 
3. 100µl conjugate was added to the wells and then incubated for 30 min at 18-25°C. 
4. Strips contents were decanted by a quick inversion over and blotted with paper 
towels. Wells were washed three times with a minimum of 200µl diluted wash 
buffer, then they were decanted and blotted after each wash step. 
5. 100µl substrate was added to each well and then incubated for 30 min at 18-25°C. 
6. 100µl stop solution was added to each well, in the same order and rate as the 
substrate. 
7. Strips were read within 24 hours at 550nm (540-565nm). 
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2.2.4.5 Detection of IgA levels 
An ELISA method was used for the detection of Human IgA in sera samples. 
1.  100µl of 1:100 diluted coating antibodies in 0.05M Carbonate-Bicarbonate, pH 
9.6 was added to each well. Each was run in duplicates. Incubation was done at 
room temperature for 1 hour or over night at 2-8°C. 
2.  Plate was washed five times with 50mM Tris, 140 mM NaCl, 0.05% Tween 20, 
pH 8.0. Removing of the ELISA wash solution was done by aspirating of the plate 
contents. Then plate was blotted onto paper towels. 
3.  200µl of blocking solution (50mM Tris, 140 mM NaCl, 1% BSA, pH 8.0) was 
added and the plate was incubated at room temperature for 30 min or overnight at 
2-8°C. 
4.  Plate was washed five times with 50mM Tris, 140mM NaCl, 0.05%Tween 20, pH 
8.0.  
5.  100µl of standard or sample in 50mM Tris, 140mM NaCl, 1% BSA, 0.05% 
Tween 20 was added to each well.  
 
Standards and Samples: 
  The standards in sample/conjugate diluent were diluted according to table 2.5: 
 
Table 2.5: Dilutions of the standards in Sample/Conjugate Diluent 
 
Diluents were prepared, one for each standard curve point: 500 ng/ml, 250 ng/ml, 
125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml, 7.8 ng/ml and 0 (blank). 
6.  Plate was incubated at room temperature for 1 hour and then was washed five 
 Standard  ng/ml  3(1.2 mg/ml IgA)-110-RS10 ntSample Dilue 
   1             500          4 µl          9.6 ml 
       2           250         500 µl from std 1         500 µl 
        3           125         500 µl from std 2         500 µl 
       4           62.5         500 µl from std 3         500 µl 
       5          31.25         500 µl from std 4         500 µl 
       6           15.6         500 µl from std 5         500 µl 
       7           7.8         500 µl from std 6         500 µl 
       8           0         Blank         500 µl 
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times with 50mM Tris,140mM NaCl, 0.05%Tween 20, pH 8.0. 
7.  100µl of diluted HRP detection antibody in 1% BSA + 0.05% TPBS was added to 
each well. Dilution of the HRP detection antibody was done in sample/conjugate 
diluent. The recommended starting dilution is 1:75,000. 
8.  Plate was then incubated at room temperature for 1 hour and then was washed five 
times with 50mM Tris, 140mM NaCl, 0.05%Tween 20, pH 8.0. 
9.   100µl of TMB substrate solution was added to each well. 
10.  Developing the plate was done in the dark at room temperature for 15 min. When 
the colour developed the reaction was stopped by adding 100µl of stop solution 
(0.18M H2SO4) to each well. 
12.  The absorbance levels were measuring on a plate reader at 450nm. 
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2.2.5 Enzyme Digestion of Protein 
2.2.5.1 Production of Porphyromonas Gingivalis (PG) Enzymes 
  Wilkins - Chalgren Anaerobe Broth was prepared for the incubation of the PG: 
33g of Wilkins in 1l of 2dH2O mixed well and sterilized by autoclaving at 121ºC for 15 
min. The broth was reduced by putting the medium in a chamber with an anaerobic bag 
at 37 ºC for one night. 1:10 of PG (33277) was transferred to the Wilkins in sterile 
conditions and incubated at 37ºC overnight. The level of PG alive was evaluated by 
looking at them under microscope. 1:100 of the PG was transferred to a new Wilkins in 
sterile conditions and incubated at 37ºC for 6 days. After the long incubation the 
suspension was spun down (10,000g, 60min). The upper translucent fluid was taken and 
divided to aliquots and keep in -20ºC.
123
 
 
2.2.5.2 Argingipain (Arginine-specific Cysteine Proteinase) digestion: 
In order to digest proteins (e.g. CI, CIII) the following was put in 1ml of 20mM 
sodium phosphate buffer (SPB) (16ml of 1M monobasic sodium phosphate 
monohydrate with 84ml of 1M dibasic sodium phosphate in order to get to a pH of 7.5): 
1. 1mg of protein. 
2. 0.04mg of Argingipain (self produced according to the protocol above). 
3. 5mM L-Cysteine. 
The pH was adjusted to 7.5 and the media was incubated for 2 hours in 37°C. 
When there was a need to terminate the reaction, 100µg/ml of Leupeptin was added. 
 
2.2.5.3 MMP-1 (collagenase) Digestion: 
Different collagenases can be found in the inflamed periodontal tissue, among 
them MMP-1, MMP-8 and MMP-13.
18
 MMP-1 was chosen as an enzymatic cleavage 
system for digesting CI and CIII.  
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 The following reaction was set up for digestion of 1ml: 
1. 500µl of 1mg/ml of CI or CIII. 
2. 100µl of 10mg/ml of MMP-1. 
3. 100µl 10xMMP buffer: 20mM Tris-HCl [pH 7.4], 5mM CaCl2, 140mM NaCl and  
    0.1% Brij 35. 
4. 300µl of dH2O. 
All of the above were mixed and incubated overnight at 37°C. The digestion was 
terminated by adding 5mM EDTA (final concentration) to the samples. Evaluation of 
the digestion was by electrophoresis on a 15% SDS-Gel. 
 
2.2.5.4  Cyanogen Bromide (CNBr) digestion: 
To digest collagen by CNBr, the following reaction was made for 4 hours in 
room temperature in a N2-flushed flask: 2mg collagen in each 1ml of solution 
containing 70% Formic Acid, 13mg/ml CNBr, 1.54mg/ml DTT. Cleavage was 
evaluated by Capillary Electrophoresis or SDS -PAGE. 
 
2.2.5.5 Trypsin digestion: 
To cleave collagen by trypsin 1mg/ml of protein was dissolved in 2mg/ml 
Trypsin in dH2O and 0.5M Ammonium Hydrogen Carbonate. The pH was adjusted to 
8.5 and the media was left at 37°C for 3 hours. To stop the reaction, the pH was lowered 
to 6.4 by adding acetic acid and immersing the mixture in ice. 
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2.2.6 Raising human antibodies by phage display human antibody library  
 Antibody fragment specific to ROS-CI and ROS-CIII was developed using 
semi-synthetic phage display single chain fragment variable library, namely Tomlinson 
I library while following the protocol described in (www.lifesciences.sourcebioscience 
.com/media/143421/tomlinsonij.pdf).  
 
2.2.6.1 Growing the libraries 
The libraries are generally stored at -70˚C as bacteria harboring phagemid or 
phage DNA (about 10
8
 bacteria per 10µl in 2xTY-15% glycerol). To make the phage for 
selection, the primary library is grown and the phage harvested. 
1.  The library stock was added to 200ml pre-warmed 2xTY (16g Tryptone, 10g 
Yeast Extract and 5g NaCl in 1l of dH2O) containing 100μg/ml ampicillin and 1% 
glucose. 
2.  While shaking it was grown at 37°C until the OD 600 is 0.4 (1-2 hours). 
3. 50ml of the grown bacteria was taken and 15μl (2x1011) of KM13 helper phage 
was added. The remaining 150ml was used to make a secondary bacterial stock of 
the library by following protocol 2.2.6.2. 
4.  The media was incubated without shaking in a 37°C water bath for 30 min. 
5.  The media was spun at 3,000g for 10 min and the pellet was resuspended in 100ml 
of 2xTY containing 100μg/ml ampicillin, 50μg/ml kanamycin and 0.1% glucose. 
6.  Once more the media was incubated shaking at 30°C but this time overnight. 
7.  The next day the culture was spun down at 3,300g for 30 min. 
8.  20ml PEG/NaCl (20% Polyethylene glycol 6000, 2.5M NaCl) was added to 80ml 
supernatant, it was mixed well and left for 1 hour on ice. 
9.  The culture was spun at 3,300g for 30 min, the supernatant poured away. Another 
brief spin was done and any remaining dregs of PEG/NaCl were aspirated. 
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10.  The pellet was re-suspended in 4ml PBS and spun at 11,600g for 10 min in a 
micro centrifuge to remove any remaining bacterial debris. 
11.  The phage was stored at 4°C for short term storage or at -70°C in PBS with 15 % 
glycerol for longer term storage. 
12.  In order to titre the phage stock, dilutions were done of 1μl phage in 100μl PBS, 
1μl of this in 100μl PBS and so on until there were 6 dilutions in total. 900μl of 
TG1 at an OD 600 of 0.4 were added to each tube and incubated at 37°C in a 
water bath for 30 min. 10μl of each dilution was spotted on a TYE (Bacto-Agar, 
8g NaCl, 10g Tryptone, 5g Yeast Extract in 1l of dH2O) plate containing 
100μg/ml ampicillin and 1% glucose and grown on at 37°C.  
 
2.2.6.2 Growing secondary stocks of the libraries 
 Secondary bacterial stock was prepared from the primary library growths above. 
The remaining 150ml from 2.2.6.1(3) was grown for a further 2 hours shaking at 37°C. 
The cells were spun down at 10,800g for 10 min and re-suspended in 10ml of 2xTY 
containing 15% glycerol. The secondary stock was stored in 20x500μl aliquots at -70°C.  
 
2.2.6.3 Selection on Immunotubes 
 Selection was done by using immunotube to immobilize CI or CIII using 
standard selection protocol,
33,91
 except that subtraction of phage binders to native 
proteins was added. The protocol includes several steps of subtraction before selecting 
against the ROS modified CI or CIII. 
1.  Nunc Maxisorp immuno test tubes were coated overnight with 10μg/ml in 4ml 
PBS of the native CI, CII or CIII proteins for subtraction steps and ROS-CI or 
ROS-CIII to which I wanted to develop specific scFv. 
2.  The next day, the tubes were washed 3 times with PBS. 
Chapter 2: Materials & Methods
30 
 
3.  The tubes were filled to brim with 2% MPBS and incubated standing at room 
temperature for 2 hour to block. 
4.  The tubes were washed 3 times with PBS. 
5.  On the first round of selection 0.6ml of phage from library (2.2.6.1(11)) was 
added to 3.4ml of 2%MPBS. From the second round of selection, 1ml of phage 
from the previous round of selection (2.2.6.4(11)) was added to 3ml of 2%MPBS. 
Then I incubated the tubes as described below for each round of selection: 
 Round 1:  Subtraction against CII was done for 30 min on a rotating table at 37ºC 
following that, I transferred the subtracted phage to a second tube with CII for 30 
min standing at room temperature. Then the subtracted phage was transferred to a 
tube coated with either CI or CIII for subtracting against the native form of the 
target antigens. The incubation was for 30min standing at 37ºC. Then the 
subtracted phage was transferred to a second tube coated with the same protein for 
another 30 min standing at room temperature. 
 Round 2: No subtraction was done, the phage from the first round of selection was 
selected against the target proteins. 
 Round 3: Phage from round 2 (2.2.6.4(11)) was used and subtracted first. It was 
put in a tube coated with native CI or CIII for 30 min standing at 37ºC. Unbound 
phage was then transferred to another tube coated with native CI or CIII for 
additional subtraction step. Once more the phage was left for 30 min standing at 
room temperature. 
 After subtraction,  phage was transferred to immunotube coated with the target 
ROS-CI or ROS-CIII (ROS modification include glycation, HOCl, OH∙ or 
ONOO∙ modification used as target antigen) at room temperature for 60 min a 
rotating table and then for another 60min standing. 
6.  The supernatant was discarded and the tube washed 10 (round 1) - 20 (rounds 2 or 
Chapter 2: Materials & Methods
34 
 
3) times with 0.1% Tween-PBS. 
7.  The helper phage has been modified to contain a trypsin-cleavable site which 
upon cleavage transforms the phage to non-infective form.
84 
The excess PBS was 
thrown away and phage was eluted by adding 500μl of trypsin-PBS (50μl of 
10mg/ml trypsin stock solution (made up in 50mM Tris-HCl pH7.4, 1mM CaCl2) 
added to 450μl PBS) and rotating the tube for 10 min at room temperature. 
8.  1.75 ml of TG1 was (OD600nm of 0.4) infected by adding 250μl of the eluted 
phage. The mixture was incubated for 30 min at 37°C in a water bath without 
shaking.  10μl, 10μl of a 1:102, 1:104 and 1:106 dilutions were spotted on TYE 
plates containing 100μg/ml ampicillin and 1% glucose. The plates were left to 
grow overnight at 37°C. 
 In each round 50μl of 1:1 bacteria was plated on a big size TYE plate containing 
100μg/ml ampicillin and 1% glucose. 
 
2.2.6.4 Further rounds of selection 
1.  The next day 7ml of 2xTY 15% glycerol was added to the large square Bio-Assay 
dish and the cells were loosened with a glass spreader, mixing them thoroughly. 
 50μl of the scraped bacteria was added to 50ml of 2xTY containing 100μg/ml 
ampicillin and 1 % glucose, another 1 ml of the remaining bacteria was stored at -
70°C in 15% glycerol for further selection. 
2.  The scraped bacteria were left to grow by shaking at 37°C until the OD 600 was 
0.4 (1-2 hours). 
3.  10ml of this culture was taken and 5x10
10
 helper phage was added to it. 
4.   Incubation without shaking was done in a 37°C water bath for 30 min. 
5.  The culture was spun down at 3,000g for 10 min and re-suspended in 50ml of 
2xTY containing 100μg/ml ampicillin, 50μg/ml kanamycin and 0.1% glucose. 
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6.  The re-suspended culture was incubated shaking at 30°C overnight. 
7.  The overnight culture was spun at 3,300g for 15 min. 
8.  10ml PEG/NaCl  was added to 40ml supernatant, mixed well and left for 1 hour 
on ice. 
9.  Once done it was spun at 3,300g for 30 min, the PEG/NaCl was poured away and 
another briefly spun was done so any remaining dregs of PEG/NaCl could by 
aspirated.  
10.  The pellet was re-suspended in 2ml PBS and spun at 11,600g for 10 min in a 
micro centrifuge to remove the remaining bacterial debris.  
11.  1ml of this phage was used for the next round of selection (protocols 2.2.6.3-4) 
and 1ml was stored at 4°C or at -80°C with 15% glycerol. 
12.  The selection steps were repeated twice more. 
 
2.2.6.5 Screening phage particles by ELISA 
2.2.6.5.1 Polyclonal phage ELISA 
 Populations of phage produced at each round of selection were screened for 
binding by ELISA to the selected antigen, to identify "polyclonal" phage antibodies. To 
avoid non-specific binding of phage to surfaces, I used 2% MPBS during the ELISA. 
MPBS is a good blocker for hard plastic surfaces. It is compatible with Protein A and 
exhibits little cross reactivity with typical immunoassay components. 
1.  A 96 well plate was coated overnight with 100μl per well of antigen in the same 
buffer and at the same concentration as used for selection. 
2.  The next day the wells were washed 3 times with PBS.  
3.  200μl per well of 2% MPBS was added to each well to block and the plate was 
incubated for 2 hours at room temperature. 
4. Wells were washed 3 times with PBS.  
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5. 10μl PEG precipitated phage (2.2.4(11)), from the end of each round of selection, 
was added to 100μl 2% MPBS and a control well with 1:5000 of anti M13 
monoclonal antibody was put in as well.  
3. The plate was incubated for 1 hour at room temperature.  
4. Phage solution was discarded and the plate was wash 3 times with 0.1% TPBS. 
5. 1 in 5,000 dilution of HRP-anti-M13 in 2% MPBS was added. 
6. The plate was incubated for 1 hour at room temperature. 
7. The fluids were discarded and the plate was washed 3 times with 0.1% TPBS. 
8. 100μl of substrate solution (100μg/ml TMB in 100mM sodium acetate, pH 6.0. 
with 10μl of 30 % hydrogen peroxide added to 50 ml of this solution directly 
before use) was added to each well and left at room temperature for 2-15 min, till 
a blue colour developed. 
9. The reaction was stopped by adding 50μl 1M sulphuric acid and the blue colour 
turned yellow. 
10. The OD at 650 nm and 450 nm was read and the result of the 650 nm was 
subtracted from the 450 nm. 
 
2.2.6.5.2 Monoclonal phage ELISA 
 Phage from single infected bacterial colonies from the “polyclonal” populations 
was screened by ELISA to identify monoclonal phage antibodies specificity. To avoid 
non-specific binding of scFv to surfaces, I used 3% BSA-PBS during the ELISA, which 
is less stringent blocker in comparison to marvel. BSA is a good blocker of non-specific 
protein-surface binding.  
1. Individual colonies from the titration plates from each round of selection were 
inoculated into 100μl 2xTY containing 100μg/ml ampicillin and 1% glucose in 96 
cell-well plates. Plates were grown shaking (250 rpm) overnight at 37°C. 
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2. After growing a small inoculum was transferred from this plate to a second 96 
cell-well plate containing 200μl of 2xTY with 100μg/ml ampicillin and 1% 
glucose per well and grown shaking (250 rpm) at 37°C for 2 hour.  
3. Then, 25μl 2xTY containing 100μg/ml ampicillin, 1% glucose and 109 helper 
phage was added to each well. 
4. Plates were left shaking (250 rpm) at 37°C for another 1 hour. 
5. The plates were spun at 1,800 g for 10 min and then the supernatant was 
aspirated. 
6. The pellet was re-suspended in 200μl 2xTY containing 100μg/ml ampicillin and 
50μg/ml kanamycin and grown shaking (250 rpm) overnight at 30°C. 
7. A 96 well plate was coated overnight with 100μl per well of antigen in the same 
buffer and at the same concentration as used for selection.  
8. The next day, the plate was washed 3 times with PBS.  
9. 200μl per well of 3% BSA-PBS was added to block and the plate was incubate for 
2 hours at room temperature. 
10. Wells were washed 3 times with PBS.  
11. The overnight incubated plate was spun at 1,800g for 10 min.  
12. Each well was filled with 50μl of supernatant and 50μl 6% BSA-PBS. 
13. Incubation of the plate was for 1 hour at room temperature.  
14. The scFv solution was discarded and the plate was washed 3 times with 0.1% 
TPBS. 
15. 100μl of 1 in 1,000 dilution of Protein A-HRP peroxidase conjugated + Protein L-
HRP peroxidase conjugated in 3% BSA-PBS was added to each well. 
16. The plate was left for incubation for 1 hour at room temperature.  
17. A 3 times wash with 0.1% TPBS was done. 
18. 100μl of substrate solution (100μg/ml TMB in 100mM sodium acetate, pH 6.0. 
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with10μl of 30 % hydrogen peroxide added to 50 ml of this solution directly 
before use) was added to each well and left at room temperature for 2-15 min till a 
blue colour developed. 
19. The reaction was stopped by adding 50μl 1M sulphuric acid and the blue colour 
turned yellow. 
20. The OD at 650 nm and 450 nm was read and the result of the 650 nm was 
subtracted from the 450 nm. 
 
2.2.6.6 Production of soluble antibody fragments 
 After identifying polyclonal or monoclonal antibody fragments with binding 
activities it is necessary to grow a larger culture in order to make enough antibodies to 
use as a reagent. The fragments can be purified or used directly. 
 From last selection I took 10μl of eluted phage (last selection 2.2.6.3(8)) and 
infected 200μl exponentially growing HB2151 bacteria (OD 600 of 0.4) for 30 min at 
37°C in a water bath. Then the infected bacteria were plated as followed: 50μl, 50μl of a 
1:10
2
, 1:10
4
 and 1:10
6
 dilution on TYE plates containing 100μg/ml ampicillin and 1% 
glucose and grown overnight at 37°C. 
 The next day individual colonies were picked into 100μl 2xTY 100μg/ml 
ampicillin and 1% glucose in 96 cell-well plates and grown shaking (250 rpm) 
overnight at 37°C. The following day a 96 well transfer device was used to transfer a 
small inocula (about 2μl) from the plate to a second 96 cell-well plate containing 200μl 
2xTY containing 100μg/ml ampicillin (50μl in 50ml) and 0.1% glucose (250μl of 20% 
stock in 50ml) per well. The new plate was grown shaking (250 rpm) at 37°C until the 
OD 600 is approximately 0.9 (about 3 hours). Once the OD reached 0.9, 25μl 2xTY 
containing 100μg/ml ampicillin and 9mM IPTG was added and the plate was left 
shaking (250 rpm) at 30°C overnight. 
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 To evaluate the soluble antibody fragments which were produced, a 96 well 
flexible assay plate was coated overnight with 100μl per well of antigen at the same 
concentration (10μl/ml) in PBS as used for selection. The overnight growing plate was 
spun down  at 1,800g for 10 min and 50μl of the supernatant containing antibodies was 
used for ELISA in 3% BSA-PBS (final concentration) according to protocol 2.2.6.5.2. 
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2.2.7 Evaluations of clones 
2.2.7.1 PCR screening of selected clones 
For each 25μl reaction, the following was assembled: 
 PCR grade water      Up to 25.0μl 
 5x KAPAHiFi Fidelity Buffer*     5.00μl 
 dNTP mix        0.75μl 
 Forward primer – LAB3      0.75μl 
 Reverse primer – FD-SEC      0.75μl 
 Dilute primers in TE Buffer  
 Template DNA            As needed 
 KAPAHiFi HotStart DNA Polymerase (1 U/μl)   0.50μl 
 Final volume        25.0μl 
 
 The reagents were mixed and centrifuged briefly, the thermal cycling was 
initiated immediately. The cycling parameters for the reaction were: 
 Initial Denaturation:     95ºC  2 – 5 min 
Denaturation      98ºC  20 sec 
 Annealing:     Tm+/- 10ºC  15 sec            15-35 cycles 
 Extension      72ºC  30 sec/kb 
 Final Extension     72ºC  1 – 5 min 
 
2.2.7.2 PCR product purification protocol for sequencing 
 For purifying the PCR product a QIAGEN (QIAquick) purification kit was used 
according to the manufacturer instruction. All centrifugation steps were carried out at 
17,900g in a conventional microcentrifuge. 
 Procedure: 5 volumes of Buffer PB were added to 1 volume of the PCR sample 
and mixed. A QIAquick spin column was placed in a provided 2ml collection tube. To 
bind DNA, the sample was applied to the QIAquick column and centrifuge for 1 min. 
Once done, the flow-through was discarded and the QIAquick column was placed back 
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into the same tube. In order to wash the DNA samples, 0.75ml Buffer PE was added to 
the QIAquick column and centrifuge for 1 min. Once more the flow-through was 
discarded and the QIAquick column was placed back in the same tube. The column was 
centrifuged for an additional 1 min. 
 The QIAquick column was placed in a clean 1.5ml microcentrifuge tube. To 
elute the DNA, 50μl Buffer EB (10mM Tris·Cl, pH 8.5) or water (pH 7.0–8.5) was 
added to the centre of the QIAquick membrane and centrifuged for 1 min.  
 
2.2.7.3 DNA Gel 
  Evaluation of PCR products was done by DNA gel according to the following 
protocol. Gels were made by adding 1% w/v of agarose to Tris-borate EDTA (TBE; 
0.045M Tris-borate, 0.001M EDTA) and microwaving for 2-5 min until all the agarose 
dissolved. This was left to cool slightly before adding the intercalating agent, ethidium 
bromide, to a final concentration of 0.3g/ml. The agarose was then poured into a cast 
(with combs dipping into the gel to form wells), and left to set. 
  When solid, the gel was placed in a tray filled with 1xTBE. Samples were 
loaded onto the gel after addition of 10x loading buffer (0.25% bromophenol blue in 
40% sucrose). The colour of the bromophenol blue facilitates loading the gel, and also 
can be used to measure the progress of the sample across the gel. Marker DNA 
fragments of known length was loaded alongside the samples to provide a reference, 
and gels were typically run at 120 volts for about 20 min. 
  The DNA was visualized by exposing the gel to UV which causes the ethidium 
bromide (bound to the DNA) to fluoresce. Permanent records of gels were made by 
photographing using UVItec camera and software. 
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2.2.8 Production and Evaluation of scFv 
2.2.8.1 Preparation of Antibody fragments 
Cultures: 
  Single colonies (after on grow) were inoculated into 2xTY containing ampicillin 
and 0.1% glucose. They were left to grow to OD 0.9 and induced with 1mM IPTG. An 
overnight incubation was done at 30˚C before harvesting the antibody fragments 
secreted into culture supernatant. 
 
Harvesting Fragments from the Culture Supernatant: 
  The induced bacterial culture was spun at 10,800g for 15 min and collected 
since the supernatant contained the antibodies. For large scale preparations the antibody 
containing supernatant was purified further (see below). However, beforehand the 
supernatants from an original culture volume of up to 1 L were filtered through a 
Sterivex-HV 0.45 µm filter unit and kept in 4°C after filtration. 
 
Harvesting Fragments from the Periplasm: 
  The induced bacterial culture was spun at 10,800g for 15 min. Then, it was re-
suspended in 1/20 the original volume of 30mM Tris, pH 7.0 containing 20% sucrose, 
1mM EDTA and fresh protease inhibitor 1:100 of final volume and left for 20 min on 
ice. Another spin was done at 10,800g for 15 min and the supernatant (periplasmic 
fraction) was collected into a new tube. The pellet was re-suspended in 50ml 5mM 
Magnesium Sulphate and incubated for 20 min on ice. The supernatant was taken and 
spun at 10,800g for 15 min. The supernatant (osmotic shock fraction) was added add to 
the periplasmic fraction. The concentrated periplasmic and osmotic shock frictions were 
filtered as described below (2.2.8.2.).  
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2.2.8.2 Purification of Antibody Fragments by Protein A Column 
  The Protein A-Sepharose beads were pre-swelled in PBS for several hours. A 
10ml plastic column was filled with about 1 ml Protein A-Sepharose and equilibrated 
with about 50ml of PBS. Once done, the column was washed with the following: 5 
column volumes of firstly PBS, secondly PBS + 0.5M NaCl, thirdly 0.2M glycine, pH 
6.0 and finally with 0.2M glycine, pH 5.0. 
  The elution of the protein was with 4ml of 0.2M glycine, pH 3.0, 1ml fractions 
were collected into 0.2ml 1M Tris-HCl, pH 7.4 and immediately mixing. Then the OD 
was measured at 280 nm (1 OD = 0.8mg/ml) and the fractions were dialysised overnight 
against PBS (10 kDa cut off). 
 
2.2.8.3 Dialysis of Antibody Fragments 
  The different fractions of scFv were dialysed separately against PBS using 
Slide-a-lyser dialysis cassettes according to the manufacturer’s instructions. First, the 
cassettes were left in a box with at least 100 times PBS volume of the sample at 4°C for 
30 min. Then the samples were inserted with a syringe to the cassette and left in the 
PBS for at least 2 hours at 4°C. When done, the cassettes were filled using a syringe 
with air at the same volume of the sample, then the sample gently drawn back to the 
syringe. Dialysed scFv was removed from the Slide-a-lyser and stored at –80˚C. 
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2.2.8.4 Western Blotting for scFv with anti-His HRP conjugated 
 Polyclonal or monoclonal phage antibodies can be used as reagents to detect 
antigens on WB. First, the target proteins were run on a SDS-PAGE gel and transferred 
to a WB membrane (see 2.2.2.1). 
 The membrane was washed twice for 10 min, with TBS buffer at room 
temperature, following an incubation for 1 hour in blocking buffer (supplied as part of 
the Anti-His antibody kit) at room temperature or on at 4°C. 
 The membrane was washed twice for 10 min each time in TBS-Tween/Triton 
buffer at room temperature and then with TBS buffer for 10 min at room temperature. 
Following the washes the membrane was incubated with 1:20 of scFv in blocking 
buffer, at room temperature for 2 hours. Anti-His HRP Conjugate blocking buffer 
consist of 5ml of Blocking Reagent buffer, 45ml of dH2O, 50µl of Tween 20 and 0.25g 
of Blocking Reagent Powder which were dissolved in 70°C water bath. 
 Once more the membrane was washed twice with TBS-Tween/Triton buffer for 
10 min each time at room temperature and then with TBS buffer for 10 min at room 
temperature. Final incubation was with Anti-His HRP Conjugate solution (1:1000 
dilution) in blocking buffer at room temperature for 1 hour. Once done, the membrane 
was washed twice for 10 min in TBS-Tween/Triton buffer at room temperature and then 
with TBS buffer for 10 min at room temperature.  
  Detection was done with ECL Chemiluminescent substrate reagent kit. A mix of 
Reagent 1 with an equal volume of Reagent 2 was added to the nitrocellulose for 1 min. 
Then a film was exposed for the required time in a Hypercassette in a dark room and 
developed in the film processor. 
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2.2.9 Statistical Analysis 
Analyses of data were performed with Prism software (GraphPad, San Diego, CA, 
USA). Differences in levels of autoantibodies were tested by one-way ANOVA and 
Bonferroni post hoc corrections. To ensure equal variances between groups, a natural 
log transformation of the data was carried out prior to analysis. P values shown 
throughout represent adjusted values for pair-wise comparisons. To determine 
diagnostic discrimination between AgP and CP, a cut-off point of 0.1 OD units was set, 
post hoc, to construct a contingency table of positive autoantibodies against clinical 
diagnosis (AgP or CP) and tested it by Fisher’s Exact Test. 
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Chapter 3: Experimental Modification of Collagens 
3.1 Monitoring modification of proteins posttranslationally modified 
by reactive oxidant (ROS) 
Optimization of the in vitro post-translational modification of CI CII, CIII and 
BSA by ROSs, such as HOCl, OH∙, ONOO∙ and glycation, present in the inflamed 
periodontium was performed. In order to decide on the optimised protocol, confirmation 
of the modification was done by SDS-PAGE and 3D- fluorescence analysis. 
 CI, CII, CIII and BSA were modified according to appropriate protocols 
involving different concentrations of ROS and different times of incubation. The stock 
amount of native protein was 0.5mg/ml for all the experiments unless marked 
otherwise. After ROS modification, ROS modified CI (ROS-CI), CII (ROS-CII), CIII 
(ROS-CIII) and BSA (ROS-BSA) were separated using SDS-PAGE. The SDS-PAGE 
gels were then stained both by Coomassie and Silver Stain. Fragmentation and 
aggregation were observed in all cases. When loading gels with proteins, 25µg of 
protein was loaded into each well, unless  otherwise stated. 
 Coomassie is a relatively rapid and straightforward staining process in which 
Coomassie Brilliant Blue binds non-specifically to proteins but not to the gel, thereby 
allowing visualization of the proteins as blue bands within the translucent matrix of the 
gel. Coomassie stain is capable of detecting as little as 0.1-1ng of polypeptide in a 
single band. Coomassie stain is an aminotriarylmethane dye that forms strong 
complexes with protein, by combination of van-der-Waals forces and electrostatic 
interaction with NH3
+
 groups. The uptake of the dye is approximately proportional to 
the amount of protein. Coomassie blue is preferable when relative amounts of protein 
are to be determined by densitometry.
105
 
 Silver staining, although somewhat more difficult to perform, allows detection 
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of proteins resolved by gel electrophoresis at concentration nearly 100-fold lower than 
those detected by Coomassie staining. The identification of proteins by silver staining is 
based on the differential reduction of silver ions that are bound to the side chains of 
amino acid.
132 
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3.1.1 SDS-PAGE analysis 
3.1.1.1 SDS-PAGE analysis of chemically modified CII 
Aim: CII modification by ROS has been already established in the lab in the 
WHRI. CII was used as a control collagen with the assumption that it is a specific 
cartilage protein. The aim of this section was to re-establish the protocol for collagen 
modification by ROS by reproducing the result shown in Nissim et al (2005).
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: 8% SDS–PAGE gel electrophoresis analysis of chemically modified CII 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified type II collagen (CII). Samples containing CII were incubated 
overnight at 37°C with or without the various free radical generators. Equal amounts of 
protein were boiled with loading buffer containing β-mercaptoethanol for 5 minutes 
before loading on the SDS–PAGE. Each lane represents different native or modified CII 
according to Nissim et al (2005).
108
 Left lane of α-chain polypeptide of native untreated 
CII. Lane of glycation by ribose caused a shift in the CII α-chain band to a position of 
slightly higher molecular weight, as well as fragmentation. Lane of Hydroxyl radical 
caused a loss of the intact CII polypeptide, together with both fragmentation and 
formation of high molecular weight aggregates that did not migrate from the sample 
loading slot. Lane of Hypochlorous acid treatment resulted in both aggregation and 
fragmentation. Lane of Peroxynitrite treatment resulted in a loss of intact CII 
polypeptide, together with fragmentation. Stain was with Coomassie. The migration 
position of the molecular weight markers (in kDa) is indicated on the left-hand lane of 
the gel. 
225
150 
102 
76 
52 
38 
31 
kDa
Marker
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Results:  Using SDS-PAGE, native CII showed a major electrophoretic band 
that migrated to the region below the 150 kDa protein marker, as well as traces of 
higher molecular weight aggregates (Figure 3.1. native CII lane). The major band that 
was evident at ~130 kDa corresponds to the constituent α-chains of CII (actual 
molecular mass of ~95 kDa), and the apparent molecular mass of ~130 kDa reflects the 
well-known slow migration of the collagen α-chains relative to the globular protein 
markers. Glycation by ribose involved a shift in the position of the CII α-chain band to a 
region of slightly higher molecular mass, as well as fragmentation to bands in the region 
of 50–150 kDa. Treatment with hypochlorous acid resulted in small CII polypeptide 
fragments between those of native CII and those at the 31 kDa marker, and a higher 
percentage of cross-linked CII migrating slower than the 225 kDa marker, as well as 
aggregates that were observed in the stacking gel or in the loading slot. The degree of 
fragmentation varied according to the concentration and freshness of HOCl (results not 
shown). Exposure of CII to the hydroxyl radical–generating system caused extensive 
aggregation, with aggregates trapped in the loading slot and in the stacking gel. Loss of 
intact CII polypeptides and fragmentation into 2 major products in the electrophoretic 
region of 120–150 kDa were also observed. Treatment with peroxynitrite resulted in a 
loss of intact CII in conjunction with a smear of protein through the entire lane, 
indicating extensive fragmentation. 
 
Conclusion: The same ROS-CII modification profiles, as previously described 
by Nissim el al
108
,
 
were obtained.
 
It is possible to cleave CII by different ROS and to 
evaluate the changes of the native bands in SDS-PAGE. 
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3.1.1.2 SDS-PAGE analysis of chemically modified CI  
Aim: To optimize the time and the concentration of the oxidants needed to 
modify CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: 8% SDS–PAGE gel electrophoresis analysis of different concentrations 
of the oxidants in CI modifications 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified type I collagen (CI). Samples containing CI were incubated at 
37°C with or without the various free radical generators. Equal amounts of protein were 
boiled with loading buffer containing β-mercaptoethanol for 5 minutes before loading 
on the SDS–PAGE. Each lane represents different native or modified CI with different 
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chemical concentrations as shown at the bottom of each lane. The α- and β- chains of 
native untreated CI can be seen in the second lane on the upper gel. The third lane on 
the same gel presented the untreated CI after an overnight incubation. Glycation by 
ribose for one night showed a minor shift in the native protein chains to a position of 
slightly higher molecular weight, as well as fragmentation. After 3 nights the changes in 
the bands were more noticeable. Hypochlorous acid treatment caused a loss of the intact 
CI polypeptide in both concentrations, together with fragmentation. Hydroxyl radical 
caused a loss of some of the intact CI together with some smear along the lane of the 
high hydroxyl radical concentration. Peroxynitrite treatment resulted in an increase loss 
of intact CI polypeptide as the concentration was elevated. Sodium hydroxide (NaOH) 
did not change the native bands of CI in all the concentrations. Stains were done with 
Coomassie. The migration position of the molecular weight markers (in kDa) is 
indicated on the left-hand lane of each gel. 
 
Results: With SDS-PAGE, native CI showed two major electrophoretic bands 
that migrated to the region below the 150 kDa protein marker and one major 
electrophoretic band that migrated to the area above 225 kDa protein marker (Figure 
3.2.). The major bands that were evident below 150 kDa corresponded to the constituent 
α1 and α2 chains of CI, and the band above 225 kDa corresponded to the β chain of CI.  
The α- and β- chains of native untreated CI can be seen in the second lane on the upper 
gel. The third lane on the same gel presented the untreated CI after an overnight 
incubation, no changes where noticed. Glycation by ribose for one night showed a 
minor shift in the native protein chains to a position of slightly higher molecular weight, 
as well as fragmentation along the entire scale of the marker. After 3 nights the changes 
in the bands were more noticeable and the native protein band partially disappeared (the 
high molecular band was hardly seen). 
Hypochlorous acid treatment caused a loss of the intact CI polypeptide in both 
concentrations, together with fragmentation presented as a smear in the 1mM 
concentration. Hydroxyl radical caused a loss of some of the intact CI polypeptide in all 
the concentrations together with some smear along the lane of the high hydroxyl radical 
concentration. Peroxynitrite treatment resulted in an increase loss of intact CI 
polypeptide as the concentration was elevated, in the high level concentration of 
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peroxynitrite the lane lost all native bands and smear. Sodium hydroxide (NaOH) did 
not change the native bands of CI in all the concentrations, meaning that the NaOH in 
which the peroxynitrite was dissolved in did not disturb or manipulate the reaction. 
 
Conclusion: The optimized time and concentration for posttranslational 
modification of CI by ROS was established. It is possible to digest native protein at 
different levels. Newly formed bands of highly digested proteins can hardly be noticed 
in SDS-PAGE stained by Coomassie. 
 
3.1.1.2.1 Comparative SDS-PAGE analysis of chemically modified CI by 
Coomassie versus silver stain 
As described above, silver stains proteins by different chemical reaction and is a 
more sensitive method to detect polypeptide on SDS-PAGE.  
 
 Aim: Compare the differences in the sensitivity of coomassie versus silver stain 
in SDS-PAGE of chemically modified CI.  
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Figure 3.3: 8% SDS–PAGE gel electrophoresis analysis of chemically modified CI 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified type I collagen (CI). Samples containing CI were incubated at 
37°C with or without the various free radical generators. Equal amounts of protein were 
boiled with loading buffer containing β-mercaptoethanol for 5 minutes before loading 
on the SDS–PAGE. Each lane represents different native or modified CI with different 
chemical concentrations as shown at the bottom of each lane. Glycation by ribose 
caused a slight shift in the CI α and β-chain bands to a position of higher molecular 
weight. Peroxynitrite treatment resulted in a loss of some of the intact CI polypeptide, 
together with fragmentation. Hypochlorous acid and hydroxyl radical treatments 
resulted in some loss of the intact CI polypeptide together with fragmentation. Stains 
were done with Coomassie (left figure) and Silver (right figure). The migration position 
of the molecular weight markers (in kDa) is indicated on the left-hand lane of the gels. 
 
Results: The differences observed between the two SDS gels in Figure 3.3 were 
due to the difference in the staining. As expected, more bands of fragmentation in the 
silver stain were observed since it is more sensitive. This was especially so in the 
glycation lane. The bands of the native CI looked stronger in the native lane in 
comparison to the modified lanes, this implies that some of the native protein was 
cleaved, degraded or fragmented. These changes can be seen in the Coomassie stain 
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better since the uptake of the dye is approximately proportional to the amount of 
protein.
105
  
 
Conclusion: The result of post-translational modification by ROS could be 
detected and monitored by SDS-PAGE followed by either Coomassie or silver staining. 
With silver stain it was possible to detect lower concentrations of peptides. Mostly, the 
Coomassie stain and the silver stain detected some of the same profile of peptides. In 
order to fully exhibit peptides in SDS-PAGE there is a need to stain the gels with both 
(Coomassie stain and the silver stain). 
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3.1.1.3 SDS-PAGE analysis of chemically modified CIII  
Aim: To optimize the concentration of the chemicals and the time of exposure of 
the chemical needed to modify CIII.  
 
 
 
Figure 3.4: 8% SDS–PAGE gel electrophoresis analysis of different concentrations 
of the oxidants and different time exposure of the oxidants in CIII modifications 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified type III collagen (CIII). Samples containing CIII were incubated at 
37°C with or without the various free radical generators. Equal amounts of protein were 
boiled with loading buffer containing β-mercaptoethanol for 5 minutes before loading 
on the SDS–PAGE. Upper gel (a) represents the modifications of CIII with 
hypochlorous and hydroxyl radical. The concentrations used were as in the optimized 
protocol for modifying CI, the incubation time was after 1 hour and overnight. In all of 
these gel lanes the native band disappeared. The lower gel (b) represents the 
modifications of CIII for 10min with chemical of double concentration than the 
optimized protocol of CI. Glycation by ribose caused a slight shift in the CIII α chain 
band to a position of higher molecular weight. Peroxynitrite treatment resulted in a loss 
of some of the intact CIII polypeptide, together with fragmentation. Hypochlorous acid 
and hydroxyl radical treatments resulted in some loss of the intact CIII polypeptide 
together with fragmentation. Stains were done with Coomassie. The migration position 
of the molecular weight markers (in kDa) is indicated on the left-hand lane of the gels. 
 
 
a b 
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Results: Native CIII in SDS-PAGE (figure 3.4.a,b) showed one major 
electrophoretic band that migrated to the region below the 150 kDa protein marker. The 
major band that was evident corresponds to the constituent α chain of CIII. 
Upper gel (figure 3.4.a) represents the modifications of CIII with hypochlorous 
and hydroxyl radical. The concentrations used were the same as in the optimized 
protocol for modifying CI, the incubation time was after 1 hour and overnight. In all of 
these experiments the native band disappeared which means that it was digested and 
modified totally.  
The lower gel (figure 3.4.b) represents the modifications of CIII for 10min with 
chemical of double concentration than the optimized protocol of CI, the concentrations 
were written under each lane. Glycation by ribose caused a slight shift in the CIII α 
chain band to a position of higher molecular weight. Peroxynitrite treatment resulted in 
a loss of some of the intact CIII polypeptide, together with fragmentation spread along 
the marker scale. Hypochlorous acid and hydroxyl radical treatments resulted in some 
loss of the intact CIII polypeptide depending on the concentration of the radicals 
together with fragmentation presented as a light smear. 
  Since the exact fragmentation pattern following ROS modification was unclear  
with Coomassie but rather disappearance of the major band silver staining which is a 
more sensitive method was subsequently used. 
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Figure 3.5: 8% SDS–PAGE gel electrophoresis analysis of chemically modified 
CIII 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified type III collagen (CIII). Samples containing CIII were incubated at 
37°C with or without the various free radical generators. Equal amounts of protein were 
boiled with loading buffer containing β-mercaptoethanol for 5 minutes before loading 
on the SDS–PAGE. Each lane represents different native or modified CIII with different 
chemical concentrations as shown at the bottom of each lane. Glycation by ribose 
caused a slight shift in the CIII α-chain band to a position of higher molecular weight, as 
well as some fragmentation. Peroxynitrite treatment resulted in a loss of some of the 
intact CIII polypeptide, together with fragmentation. Hypochlorous acid and hydroxyl 
radical treatments resulted in a loss of the intact CIII polypeptide together with 
fragmentation. Stains were done with Coomassie (left figure) and Silver (right figure). 
The migration position of the molecular weight markers (in kDa) is indicated on the 
left-hand lane of the gels. 
 
 
Results: As shown in the CI gels, it was possible to see the fragmented CI band 
in the silver stain gel. Glycation by ribose caused a slight shift in the CIII α-chain band 
to a position of higher molecular weight, as well as some light fragmentation along the 
scale of the marker. Peroxynitrite treatment resulted in a loss of some of the intact CIII 
polypeptide, together with fragmentation spread along the marker scale.  
Hypochlorous acid and hydroxyl radical treatments resulted in a loss of the 
intact CIII polypeptide depending on the concentration of the radicals together with 
fragmentation presented as a light smear. 
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Conclusion: Optimizing the concentration of the oxidants needed to modify 
CIII was achieved. In SDS-PAGE it is possible to present the optimized protocol but not 
as noticeable as in CI (Figure 3.5). Other method should be used to show these changes.  
The optimized chosen protocol is summarized in material and methods.  
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3.1.1.4 SDS-PAGE analysis of chemically modified BSA 
Aim: To evaluate the degree of chemically modified albumin, the most abundant 
protein in blood plasma, BSA was used as a control to collagen to evaluate the 
reactivity.
121
 
 
Results: With SDS-PAGE, native BSA showed a major electrophoretic band 
that migrated to the region below the 75 kDa protein marker (Figure 3.6. native BSA 
lane). Due to the lower molecular weight of BSA in comparison to the other examined 
proteins, BSA was evaluated on a 12% concentration SDS-PAGE gels in order to show 
the lower molecular protein bands in a better resolution. 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: 12% SDS–PAGE gel electrophoresis analysis of chemically modified 
BSA 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified BSA. Samples containing BSA were incubated at 37°C with or 
without the various free radical generators. Equal amounts of protein were boiled with 
loading buffer containing β-mercaptoethanol for 5 minutes before loading on the SDS–
PAGE. Each lane represents different native or modified BSA with different chemical 
as shown at the bottom of each lane. Glycation by ribose caused a slight shift in the 
BSA bands to a position of higher molecular weight. Peroxynitrite treatment resulted in 
some fragmentation. Hypochlorous acid treatments resulted in a loss of the intact BSA 
polypeptide together with fragmentation. Hydroxyl radical treatments resulted in a loss 
of the intact BSA polypeptide together with fragmentation only in the Silver stain gel. 
Stains were done with Coomassie (left figure) and Silver (right figure). The migration 
position of the molecular weight markers (in kDa) is indicated on the left-hand lane of 
the gels. 
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 The modifications were done according to the CII protocol (details of time and 
concentration are in material and methods section). Glycation by ribose involved a shift 
in the position of the BSA chain band to a region of slightly higher molecular mass. 
Treatment with hypochlorous acid resulted in BSA polypeptide fragments and smearing 
in the region between 20-50 kDa markers. Exposure of BSA to the hydroxyl radical–
generating system caused a slight decrease in the molecular weight level of the native 
protein and the formation of fragments and smear on the Coomassie stain. In the silver 
stain there was a loss of most of the intact BSA. Treatment with peroxynitrite resulted 
in low level of fragmentation. 
 
Conclusion: Using 12% SDS-PAGE it was possible to optimize the protocol for 
BSA modification. The optimized chosen protocol is summarized in material and 
methods. 
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3.1.2 3-D fluorescence profile analysis  
The second test to evaluate the occurrence of the modifications was a 3-D 
fluorescence profile study of both native and ROS modified CI, CII, CIII and BSA. The 
modification of proteins by ROS is known to change the fluorescent profile of collagen 
as a result of structural changes.
125
  
Fluorescence is the emission of light by a substance that has absorbed light or 
other electromagnetic radiation. In terms of energy transitions and energy levels, the majority 
of molecules have electrons that rise to a higher energy level than that of their ground state by 
the absorption of electromagnetic radiation and then fall back down to their ground state by heat 
energy transfer to the solvent.  Some molecules, however, only lose some of the absorbed 
energy by heat transfer to solvent whilst the rest is emitted as electromagnetic radiation, this is 
otherwise known as fluorescence. Therefore not all of the energy absorbed will be emitted as 
fluorescence due to the energy dissipation during the excited state lifetime, hence the loss of non 
radiant energy, and therefore the wavelength of the fluorescent light is longer than the absorbed 
light (longer wavelength equals lower energy). 
Fluorimeters are extremely sensitive and therefore capable of detecting suitable 
fluorescent species at low concentrations. With two separate detection parameters, 
namely the excitation and emission wavelengths, fluorescence is highly specific. Protein 
structure-function studies have benefited greatly from the use of fluorescence 
techniques.  Light in the ultraviolet light range is absorbed by three aromatic amino 
acids: phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp).
125
 Trp is an indole 
amino acid, the number of Trp residues in a protein is generally limited.
96
 The nature of 
fluorescence of the Trp residue differs in accordance with the surrounding intra-
molecular environment. It is possible to predict molecular structural difference 
according to the different fluorescent wavelengths that are measured. Even a slight 
change in the microenviroment or structure of one of these amino acids can influence 
and be detected with 3-D fluorescence.
125 
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Samples were briefly centrifuged (5min at 2000g) prior to scanning, to remove 
aggregated material. The 3D fluorescence spectral data was recorded using a F4500 
fluorescence spectrophotometer (Hitachi, Japan), set at scanned excitation wavelength 
intervals of 10nm and scanned emission wavelength intervals of 10nm, scan wavelength 
speed of 1200nm/min. The range of excitation and emission wavelengths was both 200–
900nm. 
Figures 3.7 and 3.8 show an example of an annotated 3-D fluorescence scans of 
glycated CI.  Figure 3.7 shows a contour view and figure 3.8 a bird's eye view of a 3-D 
fluorescence scan of glycated CI.   
The fluorescence peak of glycated CI is approximately at a maximum excitation 
(Exmax) of 330nm and a maximum emission (Emmax) of 420nm.  The fluorescence peak 
can be confirmed by analysis of the peak height data which accompanies 3-D 
fluorescence scans, when the excitation wavelength is shifted, the peak height changes 
but the peak wavelength position remains constant.  Figure 3.7 shows that the 
fluorescence peak consists of a dense network of contour lines, this indicates that there 
is a steep increase in peak height and therefore fluorescence intensity. 
When a beam of light interacts with a material, part of it is transmitted, part of it is 
reflected, and part of it is scattered. The Raleigh scatter peak is caused by the solvent used 
in the sample, in this case 0.1M acetic acid.  Raleigh scatter appears at the same 
wavelength as the excitation wavelength and is indicated in figures 3.7 and 3.8. 
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Figure 3.7: Annotated contour view 3-D fluorescence scan of glycated CI 
Three-dimensional fluorescence profile of glycated CI. The fluorescence peak of 
glycated CI is approximately at a maximum excitation (Exmax) of 330nm and a 
maximum emission (Emmax) of 420nm. The second order scatter begins at an excitation 
wavelength of approximately 250nm. The third order scatter occurs at a wavelength 
three times as long as the excitation wavelength. The Raleigh scatter peak appears at the 
same wavelength as the excitation wavelength. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Annotated bird's eye view 3-D fluorescence scan of glycated CI 
Three-dimensional fluorescence profile of glycated CI. The fluorescence peak of 
glycated CI is approximately at a maximum excitation (Exmax) of 330nm and a 
maximum emission (Emmax) of 420nm. The second order scatter begins at an excitation 
wavelength of approximately 250nm. The third order scatter occurs at a wavelength 
three times as long as the excitation wavelength. The Raleigh scatter peak appears at the 
same wavelength as the excitation wavelength. 
Fluorescence 
Raleigh scatter 
Scatter 
Scatter 
Fluorescence 
Scatter 
Raleigh Scatter 
Scatter 
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Other scatters can also be mistaken for fluorescence peaks.  They appear at the 
wavelength that is twice as long as the excitation wavelength.  This is illustrated in 
figure 3.7, where the second order scatter begins at an excitation wavelength of 
approximately 250nm.  At the top of figure 3.7 another cascade of scattered radiation is 
emerging, this is known as third order scatter where the scatter occurs at a wavelength 
three times as long as the excitation wavelength. 
The presentation of the fluorescence is in 3D format, however, the analysis of 
the scans were performed by the 2D format. In that way, it is easier to make the analysis 
of the Exmax and Emmax. 
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3.1.2.1 Fluorescence profile of native and modified CII 
Aim: Test the ability to reproduce the previous result shown in Nissim et al 
(2005)
108
 of the comparative analysis of fluorescence profile of CII after exposure to 
ROS. 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Three-dimensional fluorescence profile of native and modified CII 
For native CII, a relative fluorescence intensity (RFI) of 18.8 at a maximum excitation 
(Exmax) and maximum emission (Emmax) of 326 nm and 386 nm, respectively, was 
detected. Modification of CII with HOCl resulted in an increase in the RFI to 21 at the 
same excitation and emission maxima. The highest value of fluorescence was detected 
for CII treated with ribose, with an RFI of 33.4 at an Exmax of 332 nm and Emmax of 404 
nm, as a result of pentosidine formation. No fluorescence was detected for CII modified 
with hydroxyl radicals or with peroxynitrite. Extensive light scattering was detected in 
all CII samples, which could be attributed to collagen fibers and aggregates being more 
extensive after collagen modification. 
 
Results: Some native fluorescence was detectable in the native CII, with relative 
RFI of 18.8 at an Exmax of 326 nm and Emmax of 386 nm. Modification of CII with 
hypochlorous acid resulted in only a slight increase in the RFI at the same excitation 
and emission wavelengths. Treatment with ribose caused an increase in fluorescence 
intensity (RFI 33.4) and a shift in the maximum excitation (Exmax) and maximum 
emission (Emmax) to 356 nm and 404 nm, respectively. There was no major fluorescence 
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change for CII modified with hydroxyl radical or peroxynitrite. The increased scattering 
seen is associated with aggregation whereas changes in the fluorescence spectra are due 
to chemical modification of the aromatic and other amino acids.  
 
Conclusions: Both ribose and hypochlorous acid exposure to native CII caused 
a change in their light scattering which implies that there was a change in the structure 
of the native protein. These results are consistent with the previous results of Nissim et 
al (2005).
108 
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3.1.2.2 Fluorescence profile of native and modified CI 
Aim: Comparative analysis of fluorescence profile of CI after exposure to ROS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Three-dimensional fluorescence profile of native and modified CI 
For native CI, a relative fluorescence intensity (RFI) of 134.9 at a maximum excitation 
(Exmax) and maximum emission (Emmax) of 310 nm and 310 nm, respectively, was 
detected. CI treated with ribose presented a RFI of 117.2 at an Exmax of 330 nm and 
Emmax of 420 nm, as a result of pentosidine formation. Modification of CI with 
peroxynitrite resulted in a decrease in the RFI, to 23.9, at an Exmax of 280nm and Emmax 
of 420nm. There was a slight change in the fluorescence for CI modified with 
hypochlorous acid and no change in the fluorescence with hydroxyl radical. Light 
scattering was detected in all CI samples, which could be attributed to collagen fibers 
and aggregates being more extensive after collagen modification. 
 
 
Results: Some native fluorescence was detectable in the native CI, with relative 
fluorescence intensity (RFI) of 134.9 at an Exmax of 310nm and Emmax of 310nm. 
Treatment with ribose caused a decrease in fluorescence intensity (RFI 117.2) and a 
shift in the Exmax and Emmax to 330nm and 420nm, respectively. Modification of CI 
with peroxynitrite resulted in a decrease in the RFI, to 23.9, at an Exmax of 280nm and 
Emmax of 420nm. There was a slight change in the fluorescence for CI modified with 
hypochlorous acid and no change in the fluorescence with hydroxyl radical. 
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Conclusions: Ribose, peroxynitrite and hypochlorous acid exposure to native CI 
caused a change in their light scattering which implies that there was a change in the 
dimensional structure of the native protein. 
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3.1.2.3 Fluorescence profile of native and modified CIII 
Aim: Comparative analysis of fluorescence profile of CIII after exposure to 
ROS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Three-dimensional fluorescence profile of native and modified CIII 
Native fluorescence was detectable in the native CIII, with RFI of 591 at an Exmax of 
310 nm and Emmax of 310 nm. Modification of CIII with ribose resulted in a change of 
the RFI to 138, at an Exmax of 370 nm and Emmax of 320 nm. Treatment with 
peroxynitrite caused a change in fluorescence intensity (RFI 119) and a shift in the 
Exmax and Emmax to 420 nm and 460 nm, respectively. No fluorescence was seen for 
CIII modified with hydroxyl radical or with hypochlorous acid.  
 
 
Results: Some native fluorescence was detectable in the native CIII, with RFI of 
591 at an Exmax of 310 nm and Emmax of 310 nm. Modification of CIII with ribose 
resulted in a change of the RFI to 138, at an Exmax of 370 nm and Emmax of 320 nm. 
Treatment with peroxynitrite caused a change in fluorescence intensity (RFI 119) and a 
shift in the Exmax and Emmax to 420 nm and 460 nm, respectively. There was no 
fluorescence for CIII modified with hydroxyl radical or with hypochlorous acid. 
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Conclusions: Exposure of native CIII to both, ribose and peroxynitrite, caused 
vast changes in their light scattering which implies that there was a change in the 
structure and fluorescence profile of the native protein. With fluorescence it was easier 
to present that the native structure of CIII had changed as a result of exposure to ROS. 
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3.1.2.4 Fluorescence profile of native and modified BSA 
Aim: Comparative analysis of fluorescence profile of BSA after exposure to 
ROS.  
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Three-dimensional fluorescence profile of native and modified BSA 
Native fluorescence was detectable in the native BSA, with RFI of 261 at an Exmax of 
340 nm and Emmax of 280 nm. Modification with ribose caused an increase in 
fluorescence intensity (RFI 577) at the same wavelength. Modification with 
hypochlorous acid resulted in a decrease in the RFI, to 118, at the same emission and a 
slight increase in the Exmax of 330 nm. Treatment with hydroxyl radical and 
peroxynitrite caused a change in the RFI to 357 and 261 respectively with minor 
changes in the wavelength. 
 
 
Results: Some native fluorescence was detectable in the native BSA, with RFI 
of 261 at an Exmax of 340 nm and Emmax of 280 nm. All of the modification of BSA 
showed changes in the RFI and some changes in the wavelength as well. Modification 
with ribose caused an increase in fluorescence intensity (RFI 577) at the same 
wavelength. Modification with hypochlorous acid resulted in a decrease in the RFI, to 
118, at the same emission and a slight increase in the Exmax of 330 nm. Treatment with 
hydroxyl radical and peroxynitrite caused a change in the RFI to 357 and 261 
respectively with only minor changes in the wavelength. 
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Conclusions: All of the chemicals used for the modification of BSA caused a 
generation of fluorescence. The changes in the light scattering imply that there was 
aggregation and the changes in the fluorescence spectra are due to chemical 
modification of amino acids.   
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3.2 Summary 
Modification of proteins is a key part of this thesis. First the ability of ROS to 
chemically modify collagen is one of the basic assumptions in order to show that there 
are autoantibodies against post-translational modified CI and CIII as well as the native 
form. Optimization of the in vitro post-translational modification of CI, CIII and BSA 
as a control protein by ROSs, such as HOCl, OH∙, ONOO∙ and glycation, present in the 
inflamed periodontium was done. In order to decide on the optimised protocol, 
confirmation of the modification was done by SDS-PAGE and 3D- fluorescence 
analysis. 
The different SDS-PAGE was stained by Coomassie and silver. Coomassie stain 
usually was enough to determine that the native form changed however not always was 
able to show the newly formed low molecular weight peptides. Silver stain, which is 
considered to be a more sensitive technique than Commassie, was able to detect lower 
molecular weight peptides and at a lower concentration.  
 
 
 
 
 
 
 
 
Figure 3.13: CIII modified by peroxynitrite 
2mM peroxynitrite was used to modified CIII at 37ºC for 10 min. Evaluation was done 
by: a. 8% SDS–PAGE stained by coomassie, b 8% SDS-PAGE stained by silver and c. 
Three-dimensional fluorescence scan of native and modified CIII by peroxynitrite. In 
the SDS-PAGE stained with silver (b), there were new peptides formed as a result of the 
fragmented native CIII. No fragmentation was seen in the coomassie stain (a). The 3D 
fluorescence scan (c) presented major structural changes of the native form of the 
protein.  
a        b                   c 
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In some cases, SDS-PAGE was not enough to show the modification of the 
proteins or that the native form of the protein have changed (e.g. ROS-CIII, 3.1.1.3), 
then 3D fluorescence analysis was very useful to show that the structure of the native 
molecule changed. An example of the difference between SDS-PAGE stained by 
Coomassie, silver and 3D fluorescence can be seen in figure 3.13. CIII was modified by 
peroxynitrite according to protocol 2.2.1.2. In the SDS-PAGE the silver stain (figure 
3.13.b) was much more sensitive than the Coomassie stain (figure 3.13.a), it was easier 
to see the new peptide formed as a result of the fragmented native CIII. These structural 
changes looked weak, but when evaluating the 3D fluorescence scan, there was no 
doubt that a major structural change had occurred to the native form of the protein. 
These increased scattering is associated with aggregation whereas changes in the 
fluorescence spectra are due to chemical modification of the aromatic and other amino 
acids.  
The radical concentrations used in this chapter usually exceed the physiological 
ROS concentration. However, in order to be able to totally cleave, or change the native 
form of the protein at a detectable level, such high levels of ROS were used. By doing 
so, the majority of the molecules were modified, rather than the normal, physiological, 
one in a million amino acid modifications.
146
 Further in the work, a high level of 
cleavage was needed as well, beyond the in vivo conditions, when no native form of the 
proteins were suppose to remain (e.g. selection of phage). 
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Chapter 4: Reactivity of Clinical Samples 
4.1 Introduction 
In an attempt to test the hypothesis that patients with periodontal disease show 
autoimmune responses to native and post-translationally modified extracellular matrix 
proteins, sera and saliva samples of AgP, CP, G and RA patients were evaluated. The 
main target self antigens chosen were the major structural protein of the periodontal 
tissue and hence the most prominent target for ROS, i.e. CI and CIII. About 20% of the 
adult collagens of the periodontal tissue are CIII while the rest of the periodontal 
collagens are mostly CI.
21
 These collagens with their high proline/hydroxyproline 
content and triple helix structure are particularly susceptible to damage by ROS. 
Albumin, the most abundant protein in blood, was used as negative control antigen.108 
We also used CII as negative control as another protein of the collage family, which is 
specific to articular cartilage and hence is a known auto-antigen in RA.
108
 
Detection of specific antibodies against the target self antigen was performed by 
antigen-based enzyme-linked immuno-sorbent assay (ELISA) using sera and saliva 
from AgP, CP, G and RA patients as control. In order to analyze the samples with high 
sensitivity, specificity and reproducibility the ELISA systems and protocols had to be 
optimized first. Horseradish peroxidase-conjugated (HRP) goat anti-human IgG or IgA 
was used to detect bound antibodies.  
IgG antibodies are found in all body fluids and they are the smallest and most 
common antibody (75% to 80%) in the human body. They are very important in 
fighting bacterial and viral infections. The detection of IgA antibodies was chosen as 
IgA antibodies are present in higher
 
percent in the saliva (around 90% of saliva 
immunoglobulins).
39
 
  
In each ELISA test the background of the plate was evaluated. The background 
well were not coating with target proteins, just blocked by the same blocker of the 
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experiment (for example 2% MBPS). The reason was to make sure that the connection 
of the second antibody was to the target protein and not to the plate's well. These control 
wells were incubated with the same second antibody concentration and for the same 
time as the tested wells. Moreover, the background reading level was reduced from the 
final reading of each well tested in order to correlate between different plates and days 
of experiments. 
 
4.2 Results 
 The different ELISA experiments were performed according to protocol 2.2.4.1. 
Sera and saliva samples were tested. When there was a need to do adjustments to the 
protocol in order to calibrate or improve the sensitivity and specificity of the system, the 
detailed changes are mentioned in the result section. 
 
4.2.1 Sera samples reactivity 
4.2.1.1 Binding to modified CI in sera from patients with AgP, CP and G 
Aim: This was a small pilot experiment to assess ELISA protocol 2.2.4.1 and to 
test in small scale the potential binding to native and ROS modified CI in two sera 
samples from each AgP, CP and G patients.  
Methods: The plate was coated with 10g/ml CI or ROS-CI, followed by 1:100 
dilutions of sera samples, and then probed with anti-human IgG HRP conjugated and 
followed by TMB substrate and development as described in protocol 2.2.4.1 
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Figure 4.1: Binding of serum samples to native and reactive oxygen species (ROS) 
modified CI 
ELISA detection of antibodies to modified and native CI in serum samples from 
patients with aggressive periodontitis (AgP), chronic periodontitis (CP) and gingivitis 
(g). A significant increase in the binding to native and modified CI was detected only in 
the AgP sera. 
 
Results:  Binding to both native and ROS modified CI was observed only in the 
AgP samples, whilst no binding was observed in either CP or G (figure 4.1). 
Conclusions: Binding to both native and ROS modified CI was observed only 
in the AgP samples. The evaluated protocol of the pilot experiment seemed to work. 
The samples were chosen randomly, since only two samples were taken from each 
group, nothing can be determined yet about the AgP which were the only reactive 
group. A much larger cohort must be examined and after other parameters of the 
experiment are optimized (protein coating level, sample dilutions etc.). 
 
4.2.1.2 Evaluation of dilutions of proteins in ELISA 
Aim: The following experiment was designed to investigate the possibility that 
better ELISA OD and better stratification of samples will be observed if different 
concentration of CI and ROS-CI will be used for coating the ELISA plate.  CI and ROS-
CI (500µg/ml) was diluted as shown in figure 4.2.  
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Figure 4.2: Optimization of CI and ROS-CI concentration on ELISA plate coating 
ELISA assays were performed for several sera samples (AgP, CP and G). The coating 
of the ELISA plates was done by a serial dilution of the various proteins, starting at 
500µg/ml of protein and up to a dilution of 1:128 (~3.9 µg/ml), x axis. Protein level of 
10µg/ml was in the plateau of most of the different native and modified protein tested. 
 
Results: ELISA assays were performed for 11 sera samples of patients with 
different periodontal disease (7 AgP, 2 CP and 2 G), figure 4.2 shows a representative 
sample from each group. The coating of the ELISA plates was done by a serial dilution 
of the various proteins, starting at 500 µg/ml of protein and up to 1:128 dilution (~3.9 
µg/ml), x axis.  
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Each sera sample reacted at a different level as determined by the measured OD 
but kept a trend of higher reactivity as the protein level decrease until the plateau 
usually achieved at around the dilution of 1:32 or 1:64. The difference between the 
sample themselves was more substantial around that level than at lower dilutions. 
Conclusions: Protein level of 10µg/ml was in the plateau of most of the 
different native and modified protein tested, it gave a good separation between the 
different samples.  
 
4.2.1.3 Evaluation of serum dilution in the ELISA 
Aim: To determine at which sera dilution the highest specific ELISA OD will be 
observed. 
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Figure 4.3: Evaluating dilutions of sera on the reactivity of it against proteins in 
ELISA 
ELISA assays were performed for four aggressive periodontitis sera samples. The 
coating of the ELISA plates was done by different proteins at a dilution of 500 µg/ml. 
Sera were diluted from 1:20 up to 1:160, as mentioned below the x-axis. A gradient of 
reducing reactivity was noticeable when a higher dilution level of sera was evaluated. 
 
 
Results: Figure 4.3 present an example of an ELISA plate done in order to 
determine the level of sera samples to be used. Based on the limited aliquot of sample 
we obtained sera were diluted from 1:20 up to 1:160, as mentioned below the x-axis. In 
all samples, a gradient of reducing reactivity was noticeable when a higher dilution level 
of sera was evaluated. Each sample reacted at a different level but below a dilution of 
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1:100 on average the difference between the sera samples and in between the same 
sample was less noticeable.  
Conclusions: The blood samples used were of fresh whole blood which was 
centrifuged and the plasma was aliquot and stored at -80°C. Some of the samples were 
frozed and defrozed many times and it might be that some of the reactivity was lost 
during this repetitive use of the samples. Bearing in mind this limitation, a dilution of 
1:100 of sera sample was used in the following ELISA experiments. Such a dilution was 
high enough for the evaluation of the sample reactivity and not too high to exhaust the 
sample for the following experiments planned. 
 
4.2.1.4 Serum Antibody binding to modified CI and CIII in patients with AgP, CP, 
G and RA 
 Aim: Evaluate the auto-reactivity of sera of AgP, CP, G and RA patients to 
native and ROS modified CI and CIII which are the major structural protein of the 
periodontal tissue and hence the most prominent target for ROS, as well as control CII.  
Serum samples from patients with aggressive periodontitis (AgP, n=25), chronic 
periodontitis (CP, n=14), Gingivitis (G, n=18) and rheumatoid arthritis (RA, n=12) were 
tested. 
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Figure 4.4: Binding of serum samples to native and reactive oxygen species (ROS) 
modified CI (left figure) and CIII (right figure) 
Binding of serum samples to native and reactive oxygen species-modified CI and CIII. 
Serum samples from patients with aggressive periodontitis (AP, n = 25), chronic 
periodontitis (CP, n = 14), gingivitis (G, n = 18), and rheumatoid arthritis (RA, n = 12) 
were tested. AgP samples bound to both CI and CIII whether native or ROS-modified (a 
and b, respectively). 
 
Results: Binding to both native and ROS modified CI and CIII was observed 
only in the AgP samples, whilst no binding was observed in either CP or G samples (p < 
0.01) (Figure 4.4). Although there was a trend to greater binding to native collagens 
compared to ROS modified collagens, there was no statistically significant difference in 
the binding of AgP sera samples to native CI or CIII versus ROS-CI and ROS-CIII 
(p>0.5).  As shown in fig 4.5 Binding to both CI and CIII was significantly higher in 
AgP in comparison to CP and G (* p < 0.01, figure 4.5). Hence no reactivity to CI, CIII 
or ROS-CI or CIII was observed in RA serum samples (n=12, figure 4.5), while they 
bind specifically to CII (* p<0.001, figure 4.6). 
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Figure 4.5: Binding of serum samples to native CI (left fig.) and CIII (right fig.) 
Binding of serum samples to native and reactive oxygen species-modified CI and CIII. 
Serum samples from patients with aggressive periodontitis (AP, n = 25), chronic 
periodontitis (CP, n = 14), gingivitis (G, n = 18), and rheumatoid arthritis (RA, n = 12) 
were tested. Binding to CI and CIII was significantly higher in AgP in comparison with 
CP and G (*p < 0.01). In addition, control sera from patients with RA showed no 
significant binding to either CI or CIII. 
 
 
 
 
 
 
 
Figure 4.6: Binding of serum samples to native CII (left fig.) and BSA (right fig.) 
Binding of serum samples to native and reactive oxygen species-modified CI and CIII. 
Serum samples from patients with aggressive periodontitis (AP, n = 25), chronic 
periodontitis (CP, n = 14), gingivitis (G, n = 18), and rheumatoid arthritis (RA, n = 12) 
were tested. Sera from patients with RA showed no significant binding to either CI or 
CIII, but bound strongly to CII in comparison with AgP, CP, and G (*p < 0.001). No 
significant binding was seen to BSA. 
 
Control sera from patients with RA showed no statistically significant binding to 
either CI or CIII (figure 4.5) but bound strongly to CII (* p<0.001, figure 4.6) and not to 
AgP, CP or G. No statistically significant binding was seen to BSA (figure 4.6). 
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Figure 4.7: Contingency analysis 
A cut off point of 0.1 OD ELISA units was set post-hoc based on the data to test the 
specificity of the binding to native CI in AgP, versus CP. Autoantibodies in AgP 
compared to CP had an Odds Ratio of 20.6 (95% CI 3.6 – 118) with sensitivity of 0.87 
and specificity of 0.76. 
 
To test the specificity of the binding of autoantibodies to native CI in AgP a cut 
off point of 0.1 OD ELISA units was set post-hoc based on the data. Using this cut off 
point, detection of autoantibodies in AgP compared to CP had an Odds Ratio of 20.6 
(95% CI 3.6 – 118) with sensitivity of 0.87 and specificity of 0.76 (Figure 4.7).  
Conclusions: Binding to both native and ROS modified CI and CIII was 
observed only in the AgP samples, whilst no binding was observed in either CP or G 
serum samples (p < 0.01). As control target proteins I used CII and BSA, both of which 
did not show any reactivity with periodontal patients’ samples. No statistically 
difference was observed between the smokers and  non-smokers groups of each disease 
tested. Since most of the AgP samples were reactive, including the few smokers. And 
since the non reacting samples of CP and G included several smokers, it is likely that 
being a smoker did not influence the results. 
Sera from patients with RA showed statistically significant reactivity to CII, but 
not to CI or CIII. 
Most of the AgP samples showed stronger binding to native CI or CIII, only few 
reacted better to ROS-CI or ROS-CIII.  
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Though the samples were extensively used before, almost all of the AgP were 
reactive while most of the CP and G were negative. With this statistically difference, the 
difference between the groups is believed to be the same, also with fresh samples. 
 
4.2.1.5 ELISA of pre-adsorbed sera against CI and CIII 
 
Most of the AgP samples reacted stronger to native CI or CIII compared to 
ROS-CI or ROS CIII (chapter 4.2.1.4).  
Aim: To test the possibility that the binding to ROS-CI and CIII was, in fact, 
binding to residual native epitopes in the ROS modified protein, sera were pre 
adsorbing on native CI or native CIII and then tested for their reactivity on ROS-CI or 
ROS-CIII.  
Methods: Samples were incubated for 2 hours at 37ºC in immunotubes which 
had been previously coated with native proteins (1mg/ml) over night, then blocked with 
2% MPBS for 2 hours. The sera were then transferred to react on an ELISA plate 
according to the ELISA protocol (2.2.4.1.).  
Results: Figure 4.8 presents pre-adsorption of sera for 2 hours on immunotubes 
coated with native CI (a) and native CIII (b). In that case, the reactivity of pre-adsorbed 
sera to ROS-CI was more or less the same as to native CI and ROS-CIII was a little 
higher then to native CIII, the difference was not statistically significant.  
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Figure 4.8: ELISA of pre-adsorbed AgP sera on immunotubes for 2 hours 
Sera samples were incubated for 2 hours at 37ºC in immunotubes which had been 
previously coated with native proteins (1mg/ml) over night. The pre-adsorbed sera were 
then transferred to react on an ELISA plate according to the ELISA protocol. The 
reactivity of pre-adsorbed sera to ROS-CI (a) was similar to native CI and ROS-CIII 
and (b) a little higher then to native CIII. 
 
 
A different adsorption protocol is presented at figure 4.9. The sera samples were 
incubated for 1 hour at 37ºC on immunotubes which were previously coated with native 
proteins (1mg/ml) over night then blocked with 2% MPBS for 2 hours and then 
transferred to another immunotubes under the same condition only this time the sera 
was left in the immunotubes overnight at 4ºC. In that case the reactivity of pre-adsorbed 
sera against native CI (a) or native CIII (b) was, in most cases, slightly but not 
significantly higher than the native CI and CIII.  
 
a 
b 
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Figure 4.9: ELISA of pre-adsorbed AgP sera on immunotubes for a) 1 hour and b) 
over night 
Sera samples were incubated for 1 hour at 37ºC on immunotubes which were previously 
coated with native proteins (1mg/ml) over and then transferred to another immunotubes 
under the same condition only this time the sera was left in the immunotubes overnight 
at 4ºC. The pre-adsorbed sera were then transferred to react on an ELISA plate 
according to the ELISA protocol. The reactivity of pre-adsorbed sera to ROS-CI (a) and 
ROS-CIII (b) was similar to native CI and CIII (b). 
 
 
 
The last pre-adsorption (figure 4.10) was done with immunotubes coated with 1 
mg/ml and 10 mg/ml of native CI. The sera samples were put in the tubes in serial 
dilutions from 1:50 till 1:6400. The sera were left in the immunotube for 1 hour and 
then taken for ELISA. The reactivity of the sera reduced as the samples were more 
diluted. The binding to native and ROS-CI were almost identical with no statistically 
significant difference. 
a 
b 
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Figure 4.10: ELISA of serial dilutions of pre-adsorbed AgP sera on immunotubes 
for 1 hour 
Sera samples were incubated for 1 hour at 37ºC on immunotubes which were previously 
coated with 1 mg/ml and 10 mg/ml of native CI. The sera samples were put in the tubes 
in serial dilutions from 1:50 till 1:6400. The sera were left in the immunotube for 1 hour 
and then taken for ELISA. The reactivity of the sera reduced as the samples were more 
diluted. 
 
Conclusions: Pre-adsorption of sera antibodies to native CI or CIII did not 
change the reactivity of the sera against ROS-CI or ROS-CIII. The sera almost always 
reacted to the native form of the protein at least as good as to the ROS modified one. 
Changing the dilution of the sera sample did not change the reactivity. The reason could 
be that the pre-adsorption was not effective and thus residual anti-native CI and CIII 
were still left to bind to native epitopes in ROS-CI and CIII. In addition, it is possible 
that the affinity of the auto-antibodies is high and thus small proportion of anti-native 
antibodies left in the samples are sufficient to bind to the coated protein on the ELISA 
plate. 
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4.2.1.6 Evaluating the level of protein binding to the ELISA plates 
 
Many of the experiments involved coating of ELISA plate wells with different 
proteins and newly formed peptides.  
Aim: Evaluate whether the concentration of the coating protein was optimal and 
whether the wells were being coated with the same amount of proteins so it is possible 
to compare between the reactivities. 
Methods: A protocol for evaluating the level of protein binding to the ELISA 
plates was established with the use of Commassie stain (according to protocol 2.2.4.2.). 
ELISA plates of 96 wells were coated with 10µg/ml of modified or native protein in 
PBS (100µl in each well) and left overnight incubation at 4
o
C. The following day, after 
washing the wells with PBS, they were incubated with 100µl Coomassie brilliant blue 
stain for 1 hour. Then the wells were washed with PBS and were destained. Following 
that the plates were read at 595nm. 
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Figure 4.11: ELISA of serial dilutions protein binding to plate 
ELISA plates 96 wells were coated with 10µg/ml of CI or ROS-CI in PBS and left 
overnight incubation at 4
o
C. After washing the wells with PBS, they were incubated 
with 100µl Coomassie brilliant blue stain for 1 hour. Then the wells were washed with 
PBS and were destained. 
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Results: Figure 4.11 presents the level of protein binding to ELISA plate at 
different dilutions of proteins. The concentration of protein used at the first dilution was 
10mg/ml. The lowest dilution was around 0.1mg/ml which is at least 10-folds lower 
then what was used in any of the experiments. All of the different proteins binded 
almost at the same level and with hardly any difference with the different dilutions.  
 
Conclusions: It is possible to determine that all the concentrations of proteins 
used during the work were high enough to totally coat the wells of the ELISA plates. 
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4.2.2 Anti-ROS-CI IgG vs anti-ROS-CI IgA reactivity in sera and saliva of AgP 
The rational for the following set of experiment was based on the fact that saliva 
has high percent of IgA (around 90% of saliva immunoglobulins).
39
  
Aim: To assess the contribution of IgA versus IgG in the periodontal samples in 
both sera and saliva. The presence of sera IgG and IgA antibodies against ROS-CI was 
compared by probing with anti-IgG-HRP and anti-IgA-HRP according to protocol 
2.2.4.1. 
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Figure 4.12: Comparing the reactivity of sera to target antigens by anti-IgG and 
anti-IgA in ELISA in two serum samples from AgP patients 
ELISA detection of antibodies to modified and native CI in serum samples from 
patients with aggressive periodontitis (AgP) probing the sera with anti-IgG-HRP and 
anti-IgA-HRP. The anti-CI, ROS-CI specific IgG were at higher level in the sera of 
AgP. 
 
Results: As mentioned in the introduction to this chapter, the most abundant 
antibody in human sera is IgG. In figure 4.12 it is clear that sera with anti-IgG was 
much more reactive then sera with anti-IgA in AgP sera samples presented. This means 
that there were more IgG in sera of the selected patients then IgA with CI, CII, CIII and 
ROS-CI specificity.  Other sera samples studied showed the same profile (data not 
shown).  
Conclusions: The anti-CI, ROS-CI specific IgG were more abundant in the sera 
of AgP. This complies with the higher level of IgG in sera. 
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4.2.3 Saliva samples reactivity 
4.2.3.1 Anti-ROS-CI IgG vs anti-ROS-CI IgA reactivity in saliva of AgP 
To determine the reactivity in the saliva samples, a pilot experiment shown in 
figure 4.12 was done using the same protocol used to determine reactivity in sera by 
ELISA (protocol 2.2.4.1). 
The samples evaluated were chosen arbitrarily for the pilot experiments or when 
there was a high reactive sera patient and the same patient had also saliva sample, its 
samples were chosen as well. The rationale behind  was that a highly reactive patient 
will be reactive in both sera and saliva. 
 
Aim: To evaluate the reactivity in saliva samples. 
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Figure 4.123: Comparing the reactivity of saliva to target antigens by anti-IgG and 
anti-IgA in ELISA 
ELISA detection of antibodies to glycated and native CI in saliva samples from three 
patients with aggressive periodontitis (AgP). Saliva was probed with anti-IgG-HRP and 
anti-IgA-HRP. The anti-IgA-HRP detected a higher level of antibodies. 
 
Results: Figure 4.13 presented the reactivity of saliva sample against native and 
glycated CI. The reactivity measured with anti-IgA in the three AgP samples was higher 
than with anti-IgG. Nevertheless, the ELISA with the saliva was difficult and with high 
background as shown below. 
The optimal saliva dilution for the ELISA was then tested. 
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Figure 4.14 presents serial dilutions of saliva between 1:10 to 1:320. Each 
sample was evaluated with anti-IgA and anti-IgG antibodies. The plates were coated 
with two target proteins (CI and glycated CI).  
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Figure 4.14: Evaluating dilutions of saliva and anti-IgA or anti-IgG antibodies by 
ELISA 
ELISA detection of antibodies to glycated and native CI in saliva samples from three 
patients with aggressive periodontitis (AgP). Saliva samples were diluted 1:10 to 1:320 
and probed with anti-IgG-HRP and anti-IgA-HRP. Most reactions decreased with the 
saliva dilutions. The reaction with anti–IgA was usually stronger then with anti-IgG. 
 
All the samples contained antibodies against CI and glycated CI. Most readings 
correlated with the decreasing saliva dilutions, the reactivity reduced as the sample was 
more diluted. The reaction with anti–IgA was almost always stronger then with anti-IgG 
in the saliva.  
Conclusions: IgA, which can be found in higher levels in human saliva, reacted 
stronger than IgG. A dilution of 1:100 of saliva is enough for evaluating the samples 
against auto-antigens. A larger group of samples needs to be evaluated and against more 
proteins in order to reassure that statement. 
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4.2.3.2 Evaluation of reactivity of saliva with different blockers  
In the pilot experiment the background in the ELISA was high and the protocol 
needed modification to reduce it.  
The two major classes of blocking reagents available are: proteins and 
detergents. An ideal blocking reagent should: inhibit non-specific binding (passive and 
covalent) of assay components to the surface, inhibit non-specific protein-protein 
interactions and exhibit no cross-reactivity with other assay components. Moreover, it 
should act as a stabilizer for biomolecules by minimizing the effects of denaturation 
caused by phase transitions associated with solid phase assays and exhibit low enzyme 
activity (or other activity that may interfere with the detection method). The blocker 
should not disrupt the bonds that immobilize the specific protein or biomolecule to the 
surface and be consistent, reproducible performance with every lot. The reversibility of 
a blocker depends on its binding strength, which is determined by its size, charge and 
structure in relation to the other assay ingredients. The use of detergent should be 
optimized for each separate application.
42
 
The blockers used were MPBS, BSA and Tween at different concentrations and 
combination. All three are known blockers to use in ELISA. MPBS and BSA both were 
used in other parts of the projects. Tween with his stability and relative non-toxicityis 
was used as well. The only limitation with those blocking buffers was when using 
alkaline phosphatase conjugates, a blocking buffer with no PBS was needed. Inorganic 
phosphate is a strong competitive inhibitor of alkaline phosphatase.
42 
  
Aim: Compare different blocking systems in the ELISA in order to evaluate 
saliva auto-reactivity. 
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Results: Figure 4.15 a-c present ELISA test of saliva with different blockers. 
The blockers checked are noted below the x-axis and includes: 1% BSA in PBS, 3% 
BSA in PBS, 0.1% BSA + 0.05% Tween in PBS, 0.1% BSA + 0.1% Tween in PBS, 3% 
BSA + 0.05% Tween in PBS, 1% dried skimmed milk, for example Marvel in PBS 
(MPBS) and 2% MPBS. In most of the experiments the control no collagen wells 
reacted at least as good as the tested saliva. Using 1% or 2% MPBS seem to reduce the 
reactivity of saliva to tested antigens to low levels (figure 4.15 c). It is a strong blocker 
which gives a low background but blocks the sample as well. The combination of BSA 
and Tween gave better saliva reactivity, with different level of reactivity between the 
different antigens tested, but the background was usually too high. 
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Figure 4.15: Reactivity of saliva with proteins using different blocking systems in 
ELISA 
ELISA test of saliva with different blockers. The blockers checked are noted below the 
x-axis and includes: 1% BSA in PBS, 3% BSA in PBS, 0.1% BSA + 0.05% Tween in 
PBS, 0.1% BSA + 0.1% Tween in PBS, 3% BSA + 0.05% Tween in PBS, 1% dried 
skimmed milk, for example Marvel in PBS (MPBS) and 2% MPBS. In most of the 
experiments the control (no collagen) reacted at least as good as the tested saliva. The 
background was usually too high. 
  
Conclusions:  Marvel was a strong blocker which lowered the background but 
masks the saliva reactivity as well. With BSA + Tween the reactivity (OD level) of the 
samples was higher than the other blockers. BSA + Tween are a better blocker to use 
though sometimes the background was a little too high. The chosen blocker to use was 
0.1% BSA + 0.05% Tween. 
 
4.2.3.3 Evaluation of reactivity of whole and centrifuged saliva  
In order to remove any potential bacterial and food particles that might change 
the reactivity measured or the blocker’s ability to work, saliva can be centrifuged before 
use. The centrifugation step also separates the neutrophils from the fluid tested. The 
neutrophils may be responsible for an unspecific reactivity against the target antigens. 
 
c
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Aim: To compare the reactivity of whole saliva and centrifuged saliva by 
ELISA. 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
whole saliva centrifuge
EL
IS
A
 U
n
it
s 
O
D
 (
4
5
0
n
m
)
CI
CI glycation
CI HOCl
CI OH-
CI onoo-
no CI
CII
Clll
 
Figure 4.136: Reactivity of saliva (whole and centrifuge) in ELISA 
Saliva was centrifugation for 5 minutes at 1000g. The upper clear fluid was used for 
evaluation. The whole and centrifuged saliva samples show only a slight difference 
between them. 
 
 
 
Results:  Saliva samples were cleaned by centrifugation for 5 minutes at 1000g. 
The upper clear fluid was used for evaluation, avoiding any sediment that may have 
accumulated. Figure 4.16 compares whole and centrifuged saliva samples, it shows that 
there was only a slight difference between the two samples. The centrifuged saliva 
sample is more reactive but the difference is not statistically significant. Once again 
there was a high background in no protein and in both cases the background of the 
reading was higher than the reactivity measured.  
 
Conclusions: Cleaning saliva by centrifugation did not make a significant 
change in the reactivity saliva against the target proteins. It is possible that debridement 
of cells and other enzymes were still part of the suspension tested, and as a result the 
background was still high. 
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4.2.3.4 Evaluation of reactivity of saliva using alkaline phosphatase as a developing 
system 
In order to develop the ELISA plate it is possible to use a detection enzyme or 
tag that can be linked directly to the primary antibody or introduced through a 
secondary antibody that recognizes the primary antibody. The two most commonly used 
enzyme labels are horseradish peroxidase (HRP) and alkaline phosphatase (AP). Since 
the HRP ELISA experiments had a high background, a different developing system was 
investigated. Inorganic phosphate is a strong competitive inhibitor of alkaline 
phosphatase. As a result PBS could not be used for washes in the AP ELISA protocol. 
The idea was to test a different substrate for the ELISA to test the possibility that this 
will overcome the background. 
 
Aim: Evaluate AP as a developing system for ELISA of saliva samples. 
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Figure 4.147: Reactivity of saliva dilutions with proteins under dilutions of 
different blocking systems in ELISA, developed using alkaline phosphatase (AP) 
AgP saliva sample (AN) under different saliva dilutions (1:20, 1:40 and 1:80), different 
secondary antibody (IgA-AP) dilutions (1:10, 1:100 and 1:1000) and different blocking 
systems 0.1% TPB (a) and 0.1% BSA + 0.05% TPBS(b). The background in both 
experiments was high. 
 
Results: Figures 4.17.a-b presents AgP saliva sample (AN) under different 
saliva dilutions (1:20, 1:40 and 1:80), different secondary antibody (IgA-AP) dilutions 
(1:10, 1:100 and 1:1000) and different blocking systems (a. 0.1% TPB and b. 0.1% BSA 
+ 0.05% TPBS). Unfortunately, the background was still high. 
When a bigger cohort of AgP saliva samples were evaluated - the reactivity was 
very low with hardly any difference in the reactivity and still with high non-specific 
background. 
a 
b 
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Conclusions: AP was evaluated as alternative substrate for developing ELISA 
plates which were covered by proteins and reacted with saliva. The results of the 
different plates were not reproducible even though the first experiment looked 
promising. None of the tested protocols reduced the background.  
 
4.2.3.5 Saliva Antibody binding to native and modified CI in patients with AgP, CP 
and G 
Aim: Evaluate the auto-reactivity of saliva of AgP, CP and G patients to native 
and ROS modified CI as well as control proteins were still tested knowing the 
background problem on no antigen. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.158: Evaluating binding of saliva samples to native reactive oxygen 
species (ROS) modified proteins by anti-IgA antibody 
Binding of saliva samples to native CI, CII and CIII and reactive oxygen species-
modified CI. Saliva samples from patients with aggressive periodontitis (AgP), post-
treatment AgP, chronic periodontitis and gingivitis were tested. The evaluation was 
done with anti-IgA antibody. The readings were low and with no statically difference. 
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Figure 4.169: Evaluating binding of saliva samples to native reactive oxygen 
species  
(ROS) modified proteins by anti-IgG antibody 
Binding of saliva samples to native CI, CII and CIII and reactive oxygen species-
modified CI. Saliva samples from patients with aggressive periodontitis (AgP), post-
treatment AgP, chronic periodontitis and gingivitis were tested. The evaluation was 
done with anti-IgG antibody. The readings were low and with no statically difference. 
 
 
Results: saliva samples from patients with AgP (n=17), post-treatment AgP 
(n=28), CP (n=13) and G (n=18) were tested. The post-treatment AgP patients received 
a standardized course of non-surgical treatment and were followed up prospectively to 
determine treatment outcomes 10 weeks post-operatively. 
The evaluation (figure 4.18) was performed with anti-IgA antibody and the 
evaluation of figure 4.19 was performed with anti-IgG antibody according to protocol 
2.2.4.1. In general the binding was very low and below the detection threshold of the 
ELISA.  The significant of the data in regard to saliva reactivity is thus questionable, 
especially as background was still high.  
Conclusions: At this point, no conclusions about the reactivity of saliva against 
the target proteins (CI, ROS-CI, CII or CIII) can be reached. The saliva samples have 
been previously extensively used in separate experiments before being given to us and 
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possibly the reactivity had decayed. Fresh new samples need to be evaluated to study 
properly the reactivity in the saliva of periodontal patients.  
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4.2.4 ELISA for anti-citrullinated filaggrin-derived peptides (CCP) 
Breach of tolerance in the autoimmune disease may be initiated by enzymatic 
post-translational modification e.g. cleavage of extracellular proteins by matrix 
metalloproteases (MMP)
103
 or by post-translational modification (citrullination) via  
peptidylarginine deiminase (PAD).
143
 These two enzymatic post-translational 
modifications are of particular interest in periodontitis, since Porphyromonas gingivalis 
produces both RgP argingipain
72
 and peptidylarginine deiminase (PAD).
94
 The peptide 
is generated by citrullination of protein-bound arginine by PAD.
 
Although anti-CCP is used for the diagnosis of rheumatoid arthritis, 
Porphyromonas gingivalis is the only bacterium known to express a PAD enzyme,
148
 
suggesting that periodontitis could be associated with the production of citrullinated 
proteins.   
The kit used is a semi-quantitative and qualitative ELISA assay for the detection 
of the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in 
human serum.  It is intended to aid in the diagnosis of RA. 
Aim: Evaluate the association of anti-CCP levels in AgP, CP and G samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2017: Binding to citrullinated filaggrin-derived peptides (CCP) in ELISA 
The peptide is generated by post-translational modification (citrullination) of protein-
bound arginine by peptidylarginine deiminase (PAD). P. gingivalis express a PAD, an 
enzyme that has been reported to be significantly associated with RA. We observed 
binding to CCP only in AgP serum samples; 2 had high anti-CCP autoreactivity, and 
another 4 samples had a borderline titer. No reactivity was detected in either CP or G 
samples. 
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Results: Out of 25 AgP serum samples, 2 had high anti-CCP autoreactivity, and 
4 samples had a borderline titre (figure 4.20). No reactivity was detected in either C or 
G samples. 
 
Conclusions: The data demonstrated that only sera from AgP patients have 
autoreactivity against citrullinated peptide. Therefore, the breach of tolerance in AgP 
patients may result from aberrant enzymatic activity. 
Though all patients claimed to be healthy, apart of their oral disease, they still 
might suffer from a sub-clinical or pre-diagnosis disease. The presence of another 
disease might be the cause of the anti-CCP autoreactivity. However, the fact that only 
several AgP demonstrated autoreactivity against citrullinated peptide and the other 
groups did not, might imply that there was a breach of tolerance. To overcome this, a 
larger cohort is needed, with a fully health history, including former hospitalizations, a 
full list of recommended drugs from their doctor and a blood test. All of which, to be 
able to subclassify the different reacting groups. 
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4.2.5 Reactivity of AgP and CP to ROS-CI in Western Blot 
Aim: To test a range of serum samples that bound most strongly in the ELISA to 
CI and ROS-CI by Western blotting (WB) in order to identify the exact molecular 
pattern to which serum and saliva from AgP bind (chapters 5.2.1.4. and 5.2.3.5). WB 
was performed according to protocol 2.2.4.3.  
Modified and native proteins were run on denaturing SDS gel, which separated 
the peptides based on their different molecular weight. Then the gels were electroblotted 
onto a nitrocellulose membrane. After blocking with 5%MPBS in 0.05% Tween, 
membranes were incubated with a 1:25 dilution of serum or saliva samples in 5%MPBS 
in 0.05% Tween for 2 hours at room temperature, followed by incubation with anti-
human IgG-HRP reagents (for sera samples) and anti-human IgA-HRP reagents (for 
saliva samples). Membranes were washed extensively with 0.1% TPBS for different 
periods of time, to reduce the background, before development with enhanced 
chemiluminescence. 
 
 
 
 
 
 
 
 
 
Figure 4.181: Binding of serum to modified CI as determined by Western blotting 
Modified and native bovine CI were run on a 8% sodium dodecyl sulphate gel under 
reducing conditions, blotted onto a nitrocellulose membrane, and probed with a 1:25 
dilution of sera followed by incubation with anti-human IgG–horseradish peroxidase 
reagents. Representative results are shown for the pattern of binding to native and 
modified CI, using serum samples from CP and AgP. Lane 1, native CI; lane 2, glycated 
CI; lane 3, HOCl; lane 4, H2O2; lane 5, peroxynitrite. Patterns of binding to either 
bands, fragmented or smear of CI were seen only with the AgP samples and not with the 
CP samples. The position of molecular weight markers (in kDd) is shown on the left. 
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 Results: Figure 4.21 shows the results from 2 AgP (216, 224) serum sample and 
one CP serum sample (49). AgP 216 reacted better then AgP 224 however they both 
bind to similar pattern of polypeptides. In the case of glycated CI (lane 2), the AgP 
serum samples showed a smear of binding to forms of the CI chains with lower mobility 
in comparison with the native CI bands (lane1) and similar smear along most of the 
lane. Lane 4, which contains CI treated with OH
.
, presents a smear along most of the 
lane. In case of peroxynitrite (lane 5) the binding pattern is different and sera bind 
mainly to the bands at the 150 kDa marker. CP sera sample 49 did not react with the 
native CI or with any of the modifications. 
 When WB was done, each SDS-GEL was performed in duplicates to confirm that 
the loaded proteins run as expected. In the next step the elution was confirmed by 
staining of the SDS-PAGE gel with Coomassie Brilliant Blue to show that the proteins 
were not in the gel anymore. In parallel the nitrocellulose was stained with Ponceau S 
Solution to show that the proteins were in the nitrocellulose membrane. These steps 
were done in order to confirm that the results of the WB (also the negative results) were 
true. 
 
In general, patterns of binding to either bands, fragmented or smear of CI were 
different from one serum sample to another. Most of the AgP samples scanned reacted 
at a certain level while the CP samples tested were negative. The results also 
demonstrated a correlation between strong ELISA binders and samples that showed 
strong binding to various fragments and aggregates of CI in Western blots.  
Although ELISA with saliva was not promising, WB was performed with some 
samples. Unfortunately, saliva samples from the AgP group had a very low reactive 
profile in WB with high background, which correlated with the low ELISA OD shown 
above. 
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Conclusions: Analysis of autoantibody binding to ROS-modified collagens by 
WB suggested that some of the autoantibodies present bound specifically to ROS-
modified epitopes in serum samples from AgP. No reactivity was seen in sera of CP 
patients.  
With WB the sera was reacting to the denatureded form which is not the natural 
form of the molecules. With ELISA sera was reacting against the native, soluble form 
of the proteins. In spite of that, in both examines the sera samples from the AgP patients 
were reacting. The denturation of the protein did not harm the sites to which the Ig from 
the sera recognized. Hence it enabled us to show in WB that the recognition was to 
ROS-CI peptides and not only to the native form.     
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4.3 Summary 
In this chapter, the immune response in serum and saliva from three different 
groups of patients with periodontal diseases was tested with a group of RA patients as a 
control to two major components of the periodontal attachment structures, CI and CIII. 
In addition, CI and CIII were exposed in vitro to ROS which are involved in acute and 
chronic inflammation.
108
  
The samples evaluate were chosen arbitrarily at first for the pilot experiments or 
when there was a high reactive sera patient and the same patient had also saliva sample, 
its samples were chosen as well. The rationale behind that was that a highly reactive 
patient will be reactive in both sera and saliva. It might be that sometimes during the 
optimization of the protocol, not the best sample was used. However, after the protocol 
was optimized all the samples were scans and nice distribution of the result was seen.  
With sera samples, binding to both native and ROS modified CI and CIII was 
observed only in the AgP samples, whilst no binding was observed in either CP or G 
serum samples (p < 0.01). Out of 25 AgP samples tested 19 showed a positive reaction 
and only 6 were negative to CI. In contrast, only 2 samples with CP and 1 with G 
reacted against CI. Similarly, only samples from AgP responded to CIII but not CP and 
G samples. As control target proteins CII was used, which is a known auto-antigen in 
RA, as well as BSA, both of which did not show any reactivity with periodontal 
patients’ samples. The fact that no reactivity was observed against collagen type II, 
which is the major component of articular cartilage and a known autoantigen in RA 
suggest that the autoreactivity towards CI and CIII in the AgP samples is diseased tissue 
specific. Hence, sera from patients with RA showed statistically significant 
autoantibody titres to CII. 
No statistically difference was observed between the smokers and  non-smokers 
groups of AgP, CP and G tested. Most of the AgP samples were reactive, including the 
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few smokers. None of the CP and G samples were reactive, included several smokers. It 
seems that being a smoker did not influence the results even though the number of 
smokers in each group was limited. A bigger cohort of smokers is needed to validate 
these results. 
The blood samples used were of fresh whole blood which was centrifuged and 
the plasma was aliquot and stored at -80°C until further analysis. Some of the AgP 
samples were frozed and defrozed for many times, however they were still reactive. It 
might be that some of the reactivity was lost during this repetitive use of the sample, but 
since the deviation between the AgP, CP and G group was so remarkable it is possible 
to believe that all the samples were still holding a substantial amount of Ig to scan. 
During the first experiment the concentration of the protein coating the ELISA 
plates and the concentration of the second antibody (sera or saliva) were evaluate and 
optimized. By doing so, I hoped that no limitation of binding would occur during the 
reactions. The wells of the ELISA plates were suppose to be coated at the higher level 
possible. The second antibody was suppose to be at such a level that, on one hand,  
there would be enough to detect and, on the other hand, it would not be exhausted for 
further experiments. The third antibody used to detect the reactions (mainly HRP 
conjugated antibodies) was over concentrated so it would not limit the detection as well.  
Using WB, autoantibody binding to ROS-modified CI was seen in sera from 
AgP patients. Autoantibodies against native CI were seen as well in AgP samples. With 
saliva, which the quality and availability of the sample were low, the results implied on 
the presence of autoantibodies to  ROS-modified CI but a fresh new samples need to be 
re-evaluated. 
While evaluating the immune response in saliva samples, a problem of high 
background in the ELISA emerged so several ELISA protocols were tested. When the 
protocol was optimised and a blocker based on BSA with Tween was chosen, the saliva 
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samples presented very low reactivity in the AgP as well as the other groups. Minor 
differences between the groups and in each group were not statistically significant.  The 
saliva samples were forwarded to us after a major clinical experiment and it is possible 
that some reactivity was lost.  Also the samples used were of whole saliva which 
contains many proteins and enzymes that can influence and disrupt the Ig integrity. 
Fresh set of samples needs to be used to test if there are auto-reactivity to CI, ROS-CI, 
CIII and ROS-CIII. 
To address the possibility of additional aberrant post-translational modification 
of self-proteins, the reactivity against citrullinated peptides was measured. The presence 
of antibodies directed toward citrullinated proteins in the serum of patients with RA has 
been described in detail. Anti-CCP can be detected in up to 80% of RA patients with 
98% specificity.
153
 
Analysis of the data demonstrated that only sera from AgP patients have 
autoreactivity against citrullinated peptide, out of 25 AgP serum samples, 2 had high 
anti-CCP autoreactivity, and 4 had a borderline titer. No reactivity was demonstrated in 
either C or G samples. Since Porphyromonas gingivalis is the only bacteria that is 
known to express PAD
148
 and to similar inflammatory processes in RA and 
periodontitis, citrullination might also be involved in breaching the tolerance in 
periodontitis. 
Overall these results suggest that autoantibody production is seen specifically in 
sera of patients with AgP and suggest a potentially very significant mechanism in the 
pathogenesis of this condition.  
Though only few of the AgP samples had shown higher reactivity of sera to 
ROS-CI than to CI, it was decided to go forward and try to investigate this newly 
subtype group of AgP. Strengthening our theory was the WB scans that showed 
reactivity of sera to other bands of ROS-CI and not only to native α and β bands. 
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Chapter 5: Enzymatic Cleavage of Collagens 
5.1 Enzymatic Cleavage 
Enzymatic cleavage of the CI and CIII was used to identify the exact neoepitope 
of the immune response by Mass Spectrometry (MS). For such analysis proteins need to 
be reduced to lower molecular weight polypeptides. Cleavages of CI and CIII, ROS-CI 
and ROS-CIII was done by proteases known to be present in the inflamed periodontal 
tissue such as argingipain
123
 and MMP-1 but in combination with CNBr and trypsin
110 
was included to obtain small fragments.
 
 Cleavage of CI and CIII, ROS-CI and ROS-
CIII with each protease was firstly optimised for different concentration and different 
time of incubation and then used in combination with CNBr and trypsin. The cleavage 
of the proteins was monitored by SDS-PAGE at first but when low molecular peptides 
were observed analysis was done by 2D-SDS-PAGE, tricine SDS-PAGE, Capillary 
Electrophoresis (CE) and fluorometric scanner. In this chapter the approaches used to 
achieve small CI and CIII fragments will be shown, and then the western blotting 
approach was performed in the attempt to identify the fragment to which serum from 
AgP binds.  
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5.2 Results  
5.2.1 Optimization of the digestion of CI by MMP-1 
MMP are proteases that participate in the normal turnover of periodontal tissues. 
Hence, increased levels of MMP during periodontal diseases result in degradation of the 
tissue. Most cells in normal and inflamed periodontal tissues synthesize various MMPs 
that together have the capacity to initiate and complete the degradation of connective 
tissue matrixes. The extra cellular matrix collagenase, known as matrix 
metalloproteinase-1 (MMP-1) or collagenase-1, is an enzyme that breaks down the 
interstitial collagens, such as CI, CII and CIII. MMP-1 can be detected in the gingival 
crevicular fluid (GCF) of periodontitis patient.
70,141
 
The MMP-1 I used was a crude collagenase (mostly proteases) secreted by 
Clostridium histolyticum. It contains 10 to 18 components, the most important of which 
are two collagenases: clostripain (which cleaves proteins on the carboxyl peptide bond 
of arginine) and a neutral protease. When there was a need to terminate the reaction 
after a certain time I added 5mM EDTA (final concentration) to the samples. MMP was 
left in the solution when evaluation was done. A control was done to differentiate the 
MMP bands in SDS-PAGE from the bands of the newly formed peptides. The fact that 
the enzymes were left in the solutions mimic the in vivo conditions which were 
optimized in vitro. 
 
Aim: To optimized the digestion of CI by MMP-1. 
 
 
 
 

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Figure 5.1: Digested CI by MMP-1 separated on a 15% SDS–PAGE 
Each lane represents different CI digested with a gradient of MMP-1. 500µg/ml and 50 
µg/ml of MMP-1 by itself are presented on the two right lanes. Native CI showed major 
electrophoretic bands that migrated to the region below the 150-kDa protein marker. 
The native CI bands disappeared in the three highest concentrations of MMP-1, while in 
the lower three concentrations the bands are appearing again. MMP-1 at low 
concentration can hardly be observed in the gel. Stain was done with Coomassie. The 
position of the molecular weight markers (in kDa) is shown on the first lane on the left. 
 
Results: Native CI showed major electrophoretic bands of the native form that 
migrated to the region below the 150-kDa protein marker. CI was cleaved with an 
increasing concentration of MMP-1. Figure 5.1 shows that the native CI bands 
disappeared in the three highest concentrations of MMP-1, while in the lower three 
concentrations the bands are appearing again. The cleaved peptides lie in bands in the 
area up to 50 kDa. In this case the gradient goes from the 0.5mg added of MMP-1 and 
disappears as moving to the low levels of MMP-1. In the lane in which 0.5mg of MMP-
1 was added to CI, the lane is darker than the other lanes and contains several bands 
below the 50 kDa marker, some of which are the MMP-1 mix when comparing to the 
500µg/ml lane of only MMP-1. MMP-1 at lower concentrations can hardly be observed 
in the gel and thus the other bands and smear in the lower concentrations of MMP-1 
used to cleaved CI can be attributed to newly formed CI peptides. 
Marker       CI      500µg/ml    50µg/ml      5µg/ml      0.5µg/ml   0.05µg/ml      5ng/ml 
MMP-1 amount added to 1mg/ml of CI 
 500µg/ml    50µg/ml 
MMP-1 loaded 
to gel 
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Conclusion: A ratio of 5µg/ml of MMP-1 to 1mg collagen was enough to 
completely cleave the native CI. The next step was to test the influence of MMP-1 on 
ROS-CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: 15% SDS–PAGE of digested CI by ROS and MMP-1 
Each lane represents different ROS-CI or mix ROS-CI digested with 5µg/ml of MMP-1. 
The different ROS-CI that undergo digestion with MMP-1 show different molecular 
weight bands, changes in the molecular weight of bands, disappearance of bands and 
some smear. Stain was done with Coomassie. The position of the molecular weight 
markers (in kDa) is shown on the first lane on the left. 
 
CI digestion mod (co) 9.9 final 
 
 
 
 
 
 
 
 
 
 
 
5µg/ml of MMP-1 was add to ROS-CI 
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Figure 5.3: 15% SDS–PAGE of ROS-CI cleaved by MMP-1 
Each lane represents different ROS-CI or mix ROS-CI digested with 5µg/ml of MMP-1. 
The different ROS-CI that undergo digestion with MMP-1 show different molecular 
weight bands, changes in the molecular weight of bands, disappearance of bands and 
some smear. Stain was done with silver. The position of the molecular weight markers 
(in kDa) is shown on the first lane on the left. 
 
Cleavage pattern of ROS-CI is different from the one of native CI. Hence there 
was alteration in the pattern at different modification (figure 5.2-5.3). The different 
ROS-CI that undergo digestion with MMP-1 show different molecular weight bands, 
changes in the molecular weight of bands, disappearance of bands (especially in the 
hypochlorous acid and peroxynitrite) and some smear. The silver stain gel shows more 
bands as the sensitivity of this method is greater. Mix ROS modified CI that was 
digested by MMP-1 showed different cleavage profile. 
5µg/ml of MMP-1 was add to ROS-CI 
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5.2.2 ELISA of cleaved CI by MMP-1 and then by ROS 
Aim: Evaluate the auto-reactivity of sera to CI digested by MMP and then 
modified by ROS. 
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Figure 5.4: Binding of AgP sera to MMP-1 cleaved CI and ROS-CI 
ELISA detection of antibodies to modified and native CI cleaved by MMP-1 overnight 
at 37°C. Serum samples from patients with aggressive periodontitis (AgP), chronic 
periodontitis (CP) and gingivitis (g) were tested. All but one of the different sera 
samples reacted better to native CI than to MMP-CI or to ROS-MMP-CI. 
 
 
Results: Native CI was cleaved by MMP-1 (protocol 2.2.5.3) and then exposed 
to different ROS (protocol 2.2.1.1). Figure 5.4 shows that the different sera samples 
reacted better to native CI than to MMP-CI or to ROS-MMP-CI. Except one G sample 
the AgP samples reacted better than G or CP samples. 
 
Conclusions: Cleavage of CI by MMP before exposing the proteins to ROS did 
not change the autoreactivity profile and AgP serum sample still binds stronger to native 
CI.  
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5.2.3 Reactivity of AgP and CP sera to CI cleaved by MMP-1 in Western blot 
 Aim: To identify the auto-antigen polypeptide recognised by the AgP sera a 
western blotting was performed. 
 
Figure 5.5: Binding of sera to CI 
digested with MMP-1 as determined by 
Western blotting 
 Binding of AgP 221 and CP 49 sera 
samples to native CI and CI digested by 
10µg/ml of MMP-1. Results are shown for 
the pattern of binding to the proteins. The 
native CI reacted with AgP sera (221), 
presented as bands. The AgP sera (221) 
reacted as well with aggregates stuck at the 
SDS slot, at the beginning of the lane (black 
arrow). A weak staining around the 20 and 
37 kDa markers was also observed. The CP 
sera (49) did not react with the proteins. 
The position of molecular weight markers 
(in kDd) is shown on the left. 
 
In figure 5.5 CI was cleaved by 10µg/ml of MMP-1 according to the established 
protocol (2.2.5.3). The native CI reacted with AgP sera (AgP 221), presented as bands 
at the area above and below the 150 kDa areas. Strangely, the AgP patient reacted with 
aggregates that resulted from the MMP-1 cleavage of CI, presented as a dark band stuck 
at the SDS slot, at the beginning of the lane (black arrow). A weak staining around the 
20 and 37 kDa markers was also observed. The CP sera (CP 49) did not react with the 
native or cleaved protein. 
 
Conclusions: Most of the cleaved CI by MMP-1 did not enter the SDS-PAGE. 
The samples were gently mixed before loading the gel to avoid any aggregates. Still the 
reactivity was only of the AgP sample and not of the CP sample. The MMP-1 exposure 
to CI did not eliminate, at least some of the sera reactivity sites.   
  CI CI          CI        CI 
           MMP-1             MMP-1 
 
   AgP 221              CP 49 
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5.2.4 CI digestion by Argingipain 
In the previous section we showed that MMP-1 can cleave CI. Nevertheless the 
approach needed further modifications a) to use Argingipain which is more disease 
relevant protease b) to improve the digest protocol so that smaller polypeptides will be 
dominant. Argingipain got its name due to it cleaving peptides specifically at arginine 
residue. It is an extracellular cysteine proteinase produced by Porphyromonas 
gingivalis, which is known as a major pathogenic factor of the progressive periodontal 
disease. The enzyme has three main forms, all contain a chain of 54 kDa with the same 
N-terminal amino acid sequence.
123
 Proteins, including collagens have been shown to be 
degraded by proteases from P. gingivalis.
17,79 
In order to produce Argingipain I incubated P. gingivalis (strain 33277) in a 
sterile culture media overnight. 1:10 of the incubated media was transferred to a fresh 
media and incubated at 37ºC overnight. 1:100 of the media was transferred to a new 
fresh media and incubated at 37ºC for 6 days. After the long incubation the suspension 
was spun down at 10,000g for 60min and the upper translucent fluid which contained 
the Argingipain was taken and keep in -20ºC.
123
 
P. gingivalis has a wide range of virulence factors such as fimbriae, capsular 
polysaccharide, outer membrane vesicles, hemagglutinin, lipopolysaccharides (LPS), 
enzyme activity and protein antigens that all potentially contribute to its pathogenicity 
in periodontal disease. It produces a wide variety of enzymes. Of these, the Arg-X and 
Lys-X specific extracellular cysteine proteinases which can degrade serum proteins 
including immunoglobulin and complement factors as well as extracellular matrix 
proteins (e.g. fibrinogen, laminin) and activate cytokines (e.g. tumor necrosis factor-α, 
interleukin-6). Since I wanted to produce Argingipain in order to digest proteins (mainly 
CI), using the "soup" from the incubation was possible. It contained many proteolitic 
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enzymes which can help in the digestion, mainly Argingipain, and it mimics the in vivo 
conditions.    
CI digestion by Argingipain was done at 37ºC overnight according to protocol 
2.2.5.2. When there was a need to terminate the reaction, 100µg/ml of Leupeptin was 
added. 
 
Aim: To evaluate the Argingipain production and ability to digest CI. 
Figure 5.6 shows digestion of CI by two batches of Argingipain enzymes (PG02 
and PG08) which were produced in the lab according to protocol 2.2.5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: 10% SDS–PAGE of digested CI by Argingipain 
Each lane represents different CI digested with a different dilution of Argingipain from 
batch PG02 and batch PG08. Stain was silver. The different Argingipain peptides are 
marked with the black arrows on the right. The Argingipain enzyme showed major 
bands around the 50 kDa and 70-80 kDa markers and lower molecular bands around 40 
and 50 kDa. Both PG02 and PG08 were able to digest the native protein, illustrated as 
the disappearing of the native protein bands and appearing of smears and new bands 
along the gels. The position of the molecular weight markers (in kDa) is shown on the 
first lane on the left. 
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Results:  Following SDS-PAGE, native CI showed major electrophoretic bands 
of the native form that migrated to the region below the 150 kDa protein marker (Figure 
5.6-5.7, native CI lane). The Argingipain enzyme (marked in black arrows) showed 
major bands around the 50 kDa and 70-80 kDa markers which corresponded to the two 
catalytic polypeptides of the enzyme, lower molecular bands around 40 and 50 kDa 
corresponded to low molecular mass peptides of the enzyme which have been reported.  
Both PG02 and PG08 were able to digest the native protein, illustrated as the 
disappearing of the native protein bands and appearing of smears and new bands along 
the gels. It was easier to observe the new peptides, resulting from the digestion, in the 
silver stain gel since it is more sensitive than Coomassie stain. Batch PG08 seemed like 
better for digesting CI in comparison to PG02. The 1:10 dilution of PG08 digested all 
the native protein and the bands of the enzyme were hardly noticeable.PG08 was the 
chosen Argingipain batch to work with at a dilution of 1:10 at most. Incubation time for 
digestion was then optimised. 
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Figure 5.7: 8 and 15% SDS–PAGE of digested CI by Argingipain 
Each lane represents different CI digested with 1:10 and 1:100 dilutions of Argingipain 
from batch PG08 for different incubation times. The digestion was done under two 
dilutions of 1:10 and 1:100 of the enzyme for three different time of incubation: 30 min, 
2 hours and overnight. In all the lanes cleavage and appearance of peptides is presented. 
Stain was silver. The media in which the Argingipain was produced in is presented on 
the right lane. The position of the molecular weight markers (in kDa) is shown on the 
first lane on the left. 
 
In figure 5.7, lane 2 is PG08 only and the far right is medium only. Both lanes 
are empty and implying that the bands seen in the CI lanes are cleaved fragments. The 
digestion was done under two dilutions of 1:10 and 1:100 of the enzyme for three 
different time of incubation: 30 min, 2 hours and overnight. In all the lanes it is 
noticeable that the enzyme worked and cleaved the native protein at a certain level but 2 
hours seems to result in more polypeptide products. Overnight incubation resulted in 
major los of the visualised.  
 
Conclusion for next step:  1:10 dilution of PG08 preparation for 2 hours for 
Argingipain digestion of CI seems optimal. The other proteins and enzymes that were 
secreted from the P. Gingivalisi during the production of the Argingipain mimic the in 
vivo conditions and thus, there was no need to separate them from the Argingipain. 
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5.2.5 Reactivity of AgP sera to CI cleaved by Argingipain 
 
Aim: Evaluate the reactivity profile of AgP sera to CI digested by Argingipain. 
 
 
   a        b      c 

 
 
 
 
 
 
 
 
 
 
Figure 5.8: Binding of sera to CI digested with Argingipain as determined by 
Western blotting 
Gels a & b are 8% SDS-PAGE presenting the binding of two different pools of five 
AgP sera samples to native CI and CI digested Argingipain (Arg) for 30 min. Gel c is a 
15% SDS-PAGE containing the same samples as used in gel a lane 3 (CI cleaved by 
Arg for 30 min).  Results are shown for the pattern of binding to the proteins. In gels a 
& b the native CI bands are seen in the native lane. In gel b, Argingipain lanes, binding 
to aggregates CI at the beginning of the lane are seen. Small MW fragment are seen in 
gel a. In gel c several bands at low MW are present. The position of molecular weight 
markers (in kDd) is shown on the left. 
 
 
 Two 8% SDS-PAGE gels were done of CI cleaved by Argingipain for 30 min 
and over night (Figure 5.8). Gel c is a 15% SDS-PAGE which was done under the same 
conditions of gel a, containing CI cleaved by Argingipain for 30 min. The gels were 
incubated with two different pools of five AgP sera samples. 
 In both of the gels a & b the native CI bands are seen in the native lane above 
the 150 kDa marker. In gel b, Argingipain lane, binding to aggregates CI was observed 
at the beginning of the lane. Interestingly, small MW fragment were detected by the 
AgP samples seen as a smear at low molecular weight (below the 37 kDa marker), 
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which was stronger in the 30 min cleavage. Those bands were not seen in the second 
pool shown in panel b. In gel c I ran the same sample of CI digested by Argingipain for 
30 min on a 15% SDS-PAGE. Now at a higher separation level the band which looked 
as one dark big band at gel a is consisting from several bands between 14-37 kDa.  
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5.2.3 CI digestion by a combination of Argingipain, CNBr and Trypsin  
 Aim:  To digest collagen to lower molecular weight fragments by combining 
PG08 digest with trypsin and CNBr.  
CNBr is a colourless solid that is widely used to fragment proteins and peptides. 
CNBr hydrolyzes peptide bonds at the C-terminus of methionine residues. Trypsin is 
one of the most common used proteases which cleave proteins mainly at the C-terminus 
of the amino acids lysine or arginine.
142
 To stop the reaction, the pH was lowered to 6.4 
by adding acetic acid and immersing the mixture in ice. 
With CNBr digestion, the CNBr was left in the solution after the reaction took 
place. In some cases it changed the ability to evaluate the digestion changes, since 
CNBr is a strong reactive material that influences the SDS-PAGE for example. CNBr 
was still used in several of the experiments despite its limitations since it is a known 
material to digest collagen with.
110 
  
Results: Figures 5.3 a & b present SDS-PAGE gels of experiments in which CI 
was cleaved by several digesting systems. The systems used are Argingipain, CNBr and 
trypsin, in different order of exposing the CI to them and after optimising the time and 
concentration of each one. Due to the peptide sizes of the cleaved proteins large gels 
were done which gives a better separation level of bands. Several gels were done with 
concentrations of 8% at first and then 16% tricine SDS-PAGE (Protocol 2.2.2.2) which 
have high separation ability at sizes below 50 kDa. Most of the stains were silver, for 
their high sensitivity. 
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Figure 5.9: 8% & 16% SDS–PAGE of digested CI 
Each lane represents different protein cleavage conditions (CNBr = cyanogen bromide, 
Try = Trypsin, Arg = argingipain) as written under the lanes, the order of the cleavage is 
as written top to bottom. Gel a is an 8% SDS-PAGE and gel b is a 16% tricine SDS-
PAGE. In each lane a different pattern of bands are noticeable. Stain was silver. The 
position of the molecular weight markers (in kDa) is shown on the first lane on the left. 
 
A a 
b 
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Figures (5.3 a & b), present a summary of the different combination of cleavage 
at a high molecular (8% SDS-PAGE) and low molecular (16% tricine SDS-PAGE) 
separation. The lane of Argingipain digestion of CI looks almost clear apart of the 
native bands, this was not consistent with previous experiment shown above in which it 
cleaved the native CI (chapter 5.2.3). CNBr seems to improve the digest which result in 
a smear through the lane which was strengthen by the addition of the trypsin. The 
problem with the trypsin digest however was the strong trypsin background band. In 
addition, it seems like the order of the digest results in different band pattern. 
Furthermore, as seen in the figure, CI digested with CNBr did not run on the gel 
smoothly, maybe because of the low pH of the reaction. Bands in the area of the 1 kDa 
marker indicated that indeed small fragments were formed. Therefore the next step will 
include a) methods for higher resolution of the polypeptide products and b) methods 
where low molecular weight peptides could be observed.  
Some of the clear lanes might be explained in several ways. It might be that the 
lanes were not loaded, however it was not likely since the samples were mixed gently 
before loading the gel, so the small sediments would be tested as well. Each gel was 
done more than once so a human error was not likely. Most likely that the peptide did 
not fall out of the gel, the gels were always stopped when the frontier of the run was one 
centimetre from the end of the gel. The bromophenol blue, which runs on the frontier, is 
around 1kDa. 
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5.2.3 2-D gel electrophoresis of digested CI 
Two-dimensional (2-D) gel electrophoresis is the core technology for separating 
complex protein mixtures in most proteome projects. This is due to its power to separate 
thousands of proteins.
38
 The first separation the proteins is by their isoelectric point, 
called isoelectric focusing (IEF). The proteins are separated in a pH gradient that is 
being applied to an IPG strip. The second dimension separation is based on size (mass) 
separation of proteins coated with SDS (negatively charged) which allows their 
migration according to molecular weight. This dimension is performed at a 90 degree 
angle from the first. The proteins will be attracted to the more positive side of the gel 
proportionally to their charge-to-mass ratio. Once this analysis has indicated proteins of 
interest, it is relatively straightforward to directly identify and characterize proteins 
from polyacrylamide gels with mass spectrometry.
118
 
 
Aim:  Compare the separation of digested CI between 1-D and 2-D SDS-PAGE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: 2-D SDS–PAGE of digested CI by CNBr & trypsin 
A sample containing CI digested by CNBr and trypsin was resolved by equilibrium on a 
pH gradient gel electrophoresis (pH 3-10) and 12.5% SDS-PAGE electrophoresis as 
described in protocol 2.2.2.3. Red arrow represents an area with smear and red circle 
represent peptide spots. In the left gel it is possible to see a light smear in the upper left 
corner (red arrow). The gel on the right, apart of the native protein smear (red arrow), 
several other peptides are present on the gel (circle in red). Stains were Coomassie (left 
figure) and silver (right figure). The position of the molecular weight markers (in kDa) 
is shown on the left. 
kDa 
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100- 
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Results: In the 2-D SDS-PAGE (figure 5.44) digested CI with CNBr and then 
with trypsin was evaluated. In the left gel which was stained by Coomassie, it is 
possible to see a light smear in the upper left corner (red arrow). This area might 
represent the native CI although the molecular weight is too high. The low pH 
corresponds to the acidic environment in which the digestion took place. The gel on the 
right was done under the same condition and was stained by silver. In it, apart of the 
native protein smear, this time at the right molecular weight (red arrow), we can observe 
several other peptides on the gel (circle in red). In each circle there are one or more dots 
of different peptides that are separate from each other due to the first dimension. The 
lower two dots around 15kD might be trypsin peptides as seen in figure 5.3. The other 
dots are newly formed peptides of CI. 
 
Conclusions: When we compare the 2-D gel to the 1-D gel (for example figure 
4.3, lane CI + CNBr + trypsin) more details of the different peptides of the digested CI 
can be seen. In the 1-D gel they look like a smear or some light bands. 
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5.2.3 Capillary electrophoresis of digested CI 
Capillary electrophoresis (CE) is a technique capable of high resolution 
separation of macromolecules, such as proteins and peptides, in narrow-bore capillaries 
by electrophoresis. Typical capillary dimensions are 25- 75µm i.d. When the sample is 
loaded into the capillary high voltage is applied and the migrating analytes are recorded 
as they pass the ultraviolet (UV) detector. The separation of the proteins and peptides is 
based on their mobility (speed and direction of movement) which depends on 
differences in the charge-to-mass ratio.  CE has high resolution, it is a fast and simple 
technique, and there is a need for a small volume of sample (less than 10 µl).
93
  
 
Aim: To evaluate cleavage in digested proteins by capillary electrophoresis. 
 
 
 
 
 
 
 
Figure 5.11: Capillary electrophoresis profiles of uncleaved CI 
The CE scan of CI looks like a noise around the zero absorbance unit level. 
 
Results: Figures 5.44-5.43 demonstrates the total UV (215 nm) electrophoretic 
profile of the collagenous peptides obtained following digestion with ROS, CNBr and 
trypsin under different conditions. The Y-axis of the figures represents the absorbance 
response (mAU) and the X-axis represents the time of the run. Differences in the 
profiles can be determined by peaks and valleys changes between the control (the native 
form of the protein) and the digested protein.  
CI 
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Figure 5.44 of a CE scan of CI looks like a noise around the zero absorbance 
unit level. This “negative” scan was due to the large 3D structure of the native CI. The 
native form of the molecule cannot enter the capillary.  
 
 
 
 
 
 
 
Figure 5.12: Capillary electrophoresis profiles of mix modified CI 
The CE profile of mix modified CI present peaks, however the peaks are very narrow 
which mean that not all of them are real. 
 
CE profile of mix modified CI (figure 5.44) present both increased and 
decreased peaks if comparing to native CI, however the peaks are very narrow which 
mean that not all of them are real, some are peptides that blocked the capillary for a 
short time during the scan. Cleavage of CI by ROS still leaves large peptides that it is 
hard to scan in the CE. 
 
 
 
 
 
 
 
 
 
Mix modified CI 
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Figure 5.13: Capillary electrophoresis profiles of CI digested with Argingipain (2 
hours) 
Both figures (a & b) presents different peaks (height and place), it present the different 
small peptide fragments as a result of the digestion. 
 
 
 
 
 
 
 
 
Figure 5.14: Capillary electrophoresis profiles of CI digested with Argingipain (4 
hours) 
The CE profile of mix modified CI present several peaks along the scan. 
 
CI digested with argingipain (2 hours) a 
CI digested  with argingipain (2 hours) 
b 
CI digested with          argingipain (4 hours) 
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CE profile of CI digested with argingipain for 2 hours (figure 5.46 a & b) and 
for 4 hours (figure 5.40) were scanned. All three figures show difference in peaks height 
and place, it present the different small peptide fragments as a result of the digestion. 
The difference between the figure 5.46 a and b both of which are CI digested according 
to the same protocol suggested that the cleavage of the native protein was inconsistent. 
The digestion started each time at different amino acids locations, the cleavage 
continued and/or stops according to the new peptide 3D conformation which exposed or 
hid other potential cleavage sites.  
 
 
 
 
 
 
 
Figure 5.15: Capillary electrophoresis profiles of Argingipain 
Several peaks seen at around 7.5-10 min scan. 
 
CE profile of Argingipain (figure 5.44) partially resemble to the 4 hours 
cleavage of CI by argingipain (figure 5.40) but other peaks seen at around 7.5-10 min 
scan are of cleaved peptide. 
 
 
 
 
 
 
 
Figure 5.16: Capillary electrophoresis profiles of CI digested with CNBr 
There are new wide peaks formed presenting newly formed peptides. 
CI + CNBr 
Argingipain 
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Digestion of CI by CNBr appeared to be very aggressive in CE (figure 5.43), 
there are new peaks formed, equal to new peptides formation. Adding trypsin as another 
step of digestion (figure 5.43) seem to totally digest the cleave protein to small peptides. 
In this case, other scans of repeating of the same protocol ended in a highly cleaved 
scan but not identical (data not shown). Adding mix ROS as a first step before digesting 
with CNBr and trypsin (figure 5.43) totally cleaved the CI. 
 
 
 
 
 
 
 
Figure 5.17: Capillary electrophoresis profiles of CI digested with CNBr and 
trypsin 
Many small peptides are seen along most of the scan. 
 
 
 
 
 
 
 
 
Figure 5.18: Capillary electrophoresis profiles of mix modified CI digested with 
CNBr and trypsin 
A scan of totally cleaved protein presented as a noise along the scan timeline. 
 
 
CI + CNBr + trypsin 
Mix modified CI + argingipain + CNBr 
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Conclusions: With CE it was possible to evaluate high level digestion of native 
proteins. The native form of CI is too big to enter the capillary and therefore it was not 
possible to see it in the CE profile, the same situation most likely happened with ROS-
CI and Argingipain alone. CE is more sensitive than SDS-PAGE and able to present 
low molecular weight peptides. However, it is not possible to determine the molecular 
weight of the newly formed peptides or to isolate them in CE, just to show their 
existence. The cleaved proteins not always show the same CE profile and that is due to 
different site digestion order and natural folding of the native and cleaved proteins. 
When the reading was of a "noise" around the 0mAU units it mean that the 
reading was negative. If newly picks were formed, however the reading was for a very 
short period of time (the pick looked like a line and not as a wave), it meant that it was a 
false reading. A large peptide was stuck in the capillary for a short instant. 
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5.2.3 Western blot evaluation of autoantibodies 
The next objective was to identify the neoepitopes to which sera or saliva from 
AgP patient's binds to after the combined cleavage described above. The rational was to 
identify as small as possible fragments to be used in MS to determine the chemical 
structures of reacting peptides.  Hence, using gradient gels and 2D gels were expected to 
give better separation between the cleaved peptides. The gels containing the cleaved 
proteins were used to perform western blotting (WB) (protocol 2.2.4.3). The 
nitrocellulose membranes were probed with sera from AgP or CP with the aim of 
identifying a specific polypeptide epitope to which sera are responding. Once such a 
peptide was identified, the polypeptide should be extracted from the gel and then 
subjected to MS analysis in order to determine the elemental composition of the 
peptide. 
Native and ROS-CI, digested with or without MMP-1, Argingipain and CNBr as 
target antigen were evaluated. Modified and native proteins were run on different 
denaturing SDS gel and electroblotted onto a nitrocellulose membrane. After blocking 
with 5%MPBS in 0.05% Tween, membranes were incubated with a 1:25 dilution of 
serum samples in 5%MPBS in 0.05% Tween for 2 hours at room temperature, followed 
by incubation with anti-human IgG-HRP reagents. Membranes were washed 
extensively with 0.1% TPBS for different periods of time, to reduce the background, 
before development with enhanced chemiluminescence.  
 
 

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5.2.3.1 Reactivity of AgP sera to CI cleaved by Argingipain, CNBr and Trypsin 
Aim: Evaluation of reactivity of AgP sera to cleaved CI by Argingipain, CNBr and 
Trypsin. 
 
Figure 5.19: Binding of sera to CI 
digested with CNBr, Trypsin and 
Argingipain as determined by 
Western blotting 
 Binding of a pool of six AgP sera 
samples to native CI and CI digested by 
CNBr, Trypsin (Try) and Argingipain 
(Arg). Arg was evaluated as well by 
itself (right lane). Results are shown for 
the pattern of binding to the proteins. 
Apart of bands in the CI lane a smear is 
noticeable along the CI+CNBr+Try lane. 
The position of molecular weight 
markers (in kDd) is shown on the left. 
 
 
 When a pool of six AgP sera samples were evaluated against CI cleaved by 
CNBr, CNBr + Trypsin, CNBr + Trypsin + Argingipain (figure 5.19), none of the 
cleaved CI seem to have autoantibodies against their peptides. Binding to native CI was 
clearly observed (first lane on the left). But in the CI+CNBr+Try there is a smear 
through the lane. The Argingipain lane was clear as well, so no antibodies were found 
against the enzyme. 
  
Conclusions: The lack of clear reactivity may be as a result of a too high level 
of digestion so the small peptides formed were not recognized by the autoantibodies in 
the AgP sera. It might be as well that residues of CNBr changes the sample's Ig so it 
could not react strongly. 
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5.2.44 CIII digestion 
The same set of experiments described for CI was repeated with CIII. 
 
A.   CIII was cleaved with increasing amounts of MMP-1 and it was decided 
that the same MMP-1 concentration should be used with CIII (5µg/ml). With SDS-
PAGE, native CIII showed major electrophoretic band of the native that migrated to the 
region below the 150-kDa protein marker (Figure 5.21-5.25, native CIII lane).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20: 15% SDS–PAGE of digested CIII by ROS and MMP-1 
Each lane represents different ROS-CIII or mix ROS-CIII digested with 5µg/ml of 
MMP-1. The different ROS-CIII that undergo digestion with MMP-1 show different 
molecular weight bands, changes in the molecular weight of bands, disappearance of 
bands and some smear. Stain was done with Coomassie. The position of the molecular 
weight markers (in kDa) is shown on the first lane on the left. 
 
 
 
 
 
 
 
 
5µg/ml of MMP-1 was add to ROS-CI 
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Figure 5.21: 15% SDS–PAGE of digested CIII by ROS and MMP-1 
Each lane represents different ROS-CIII or mix ROS-CIII digested with 5µg/ml of 
MMP-1. The different ROS-CIII that undergo digestion with MMP-1 show different 
molecular weight bands, changes in the molecular weight of bands, disappearance of 
bands and some smear. Stain was done with silver. The position of the molecular weight 
markers (in kDa) is shown on the first lane on the left. 
 
When examining the changes between the digest CIII with MMP-1, with and 
without ROS it is noticeable that there were changes in the band profile. The different 
ROS-CIII that undergone digestion with MMP-1 showed different molecular weight 
bands when compared the native CIII. In between the different ROS modifications the 
biggest difference was with glycation and hypochlorous acid. The changes were in the 
apparent molecular weight of bands displayed on the SDS-PAGE, disappearance of 
bands and some smear.  
 
B.   CIII was cleaved as CI with different cleavage systems such as ROS, 
Argingipain and CNBr. The cleavage was evaluated by CE. 
 
 
 
5µg/ml of MMP-1 was add to ROS-CI 
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Figure 5.22: Capillary electrophoresis profiles of uncleaved CIII 
The CE scan of CIII looks mainly like a noise around the zero absorbance unit level, 
some narrow peaks are seen as well. 
 
 
Figure 5.44 of a CE scan of CIII looks like a noise at zero absorbance. This 
“negative” scan was due to the large 3D structure of the native CIII.  
Imposing CIII to the same digesting protocols carried more or less a similar 
profile in CE scans such as with CI. Examples for such scans are in figures 5.44-5.44. 
 
 
 
 
 
 
 
 
Figure 5.23: Capillary electrophoresis profiles of mix modified CIII 
The CE scan looks like a noise around the zero absorbance unit level. 
 
 
 
 
Exposure of CIII to mix ROS resulted in hardly any new peaks, most likely 
because the new peptides formed were too big to be scanned in CE. 
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Figure 5.24: Capillary electrophoresis profiles of ROS-CIII digested with 
Argingipain 
The CE scan looks like a noise around the zero absorbance unit level. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25: Capillary electrophoresis profiles of ROS-CIII digested with 
Argingipain and CNBr 
The CE scan looks like a noise around the zero absorbance unit level. 
 
 Cleavage of ROS-CIII by Argingipain (figure 5.40) with (figure 5.44) or without 
CNBr resulted in a cleaved protein. In the CE scans there were hardly any picks of 
cleaved peptides. Sometimes there was a narrow pick which is due to a peptide that 
blocked the capillary for a short time. 
 
Conclusions: With SDS-PAGE and CE it was possible to evaluate high level 
digestion of native CIII. The profiles of the cleaved CIII were similar to the profiles of 
cleaved CI as seen in chapter 5.2.3. As before, in chapter 3, it was more difficult to 
present and exhibit the CIII changes in compare to CI.  
WB scans were done as well to native and cleaved CIII, however, the 
membranes had high background and thus reactivity could not be observed. 
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5.3 Summary 
Since one of the aims of the project was to identify the exact neoepitope of the 
immune response by MS there was a need to reduce the cleaved proteins to low 
molecular weight peptides by combining different systems of cleavage. Cleavages of CI 
and CIII by various proteases such as argingipain or by other know systems for protein 
cleavage such as CNBr and trypsin was done and optimised. Monitoring the cleavage of 
the proteins by SDS-PAGE was not enough in order to exhibit low molecular weight 
peptides at low concentrations. Thus, tricine SDS-PAGE, 2D electrophoresis and CE 
were performed. 
Large tricine SDS-PAGE and 2D electrophoresis were able to present low 
molecular peptides more clearly, CE was able to show breakdown of proteins when gels 
were not sensitive enough to present the digestion products and fluorescence scan of 
gels did not added much to the visualisation of peptides on gels when comparing to 
silver stain. 
Cleavage CI by MMP before exposing the proteins to ROS did not change the 
autoreactivity profile. AgP still bind best to native CI and better then CP or G. 
The digested native proteins presented low molecular weight peptides however 
the digestion profile was not reproducible. This was considered to be due to the present 
of aggregates in the protein preparation. 
When a radical approach of digestion is induced, the protein loose most of its 
unique sites and a totally cleaved protein is left. Such totally cleaved protein is not 
suitable to evaluate in order to identify a specific polypeptide epitope to which sera are 
responding to. Therefore, the optimized protocols for identifying polypeptide which 
involve in the autoimmune response are moderate digested proteins which can be 
extracted from the gel and then subjected to MS analysis. 
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Analysis of autoantibody binding to ROS-modified collagens by WB suggests 
that some of the autoantibodies present bound specifically to ROS-modified epitopes. 
The reactivity profile was always negative to CP. However, the reactivity profile to AgP 
was very variable and a different reactivity profile was seen in different samples and 
under different conditions. 
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Chapter 6: Develop of Antibody Fragments Specific to 
Native and ROS Modified CI & CIII 
6.1 Introduction 
Using phage display antibody technology, scFv specific to native and ROS 
modified CI and CIII were developed. 
Antibody phage display is a robust technology whereby small antibody 
fragments are expressed as fusion proteins on the surface of filamentous 
bacteriophage.
150
 The phage display libraries consist of a mixture of filamentous 
bacteriophage. Each bacteriophage displays a different antibody fragment and thus 
specificity. In general, antibodies have been fused to the N-terminus of the minor coat 
protein pIII of the phage, resulting in libraries of huge diversity e.g. billions of phage, 
each displaying different antibody fragments.
150
   
 Typical selection uses target protein immobilised on a plastic surface and 
exposed to a library of antibody-phage fusions; unbound phage are then washed away 
and antigen-binding phage were eluted and amplified.  Since each phage packages the 
DNA encoding the coat protein-antibody fusion, there is a physical linkage between 
phenotype (specific antigen binding) and genotype (antibody gene sequence), enabling 
phage isolated purely on their binding properties to be amplified and characterised.
66
 
Typically a phage pool would be enriched for antigen-specific phage by several rounds 
of selection, with each round followed by amplification in bacteria.  As detailed in the 
following, this simple selection approach was modified in this study to be able to select 
phage binders which are specific to structurally modified CI and CIII. 
A semi-synthetic phage display human single chain library, namely Tomlinson 
library was used to select antibody fragment specific to native and ROS modified CI 
and CIII. The Tomlinson library used in this study is a semi-synthetic scFv library built 
from a single VH (DP-47) and a single VL (DPK9) with diversity at 18 residues selected 
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from the CDR2 and CDR3 regions of both VH and VL. Selection was done using 
immunotubes coated by CI, CIII or ROS modified CI and CIII. In addition as selection 
was done to raise antibody specific to ROS-CI and CIII, a subtraction against native CI 
and CIII was done.  Eluted phage were propagated and used for further rounds of 
subtraction/selection. Phage produced in individual TG-1 bacterial clone from the final 
round of each set of selections were taken forward for monoclonal phage ELISA. At the 
end of the panning E. coli HB2151 were infected and individual bacterial clone 
producing antibody fragments were screened for binding to the target antigens.
10
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6.2 Results  
6.2.1 Selection against target proteins 
6.2.1.1 Selection Set I 
 Aim: Select the phage library against the target proteins (CI, CIII, ROS-CI, 
ROS-CIII). 
Three rounds were done against native CI, native CIII, ROS-modified CI and 
ROS-modified CIII. To avoid multiple selections CI and CIII were modified by mixed 
ROS: glycation, HOCl, OH∙ and ONOO∙ (according to protocols 2.2.1.1 and 2.2.1.2). 
10μg/ml ROS-CI and ROS-CIII were used for coating immunotubes. Two protocols 
were performed at this stage: the first was to use the standard selection protocol without 
subtraction (tubes 1-4) and second with subtraction (tube 5-6) as detailed in table 6.1. 
 
Target protein of 
selection 
Subtraction steps with native CI or native CIII 
Round 1 Round 2 Round 3 
1 Native CI 
no subtraction no subtraction no subtraction 
2 Native CIII 
3 Mix ROS-CI  
4 Mix ROS-CIII  
5 Mix ROS-CI  30min CI on rocker 
1) 30min CI on rocker 
2) 30min CI standing 
1) 30min CI on rocker 
2) 30min CI standing 
6 Mix ROS-CIII  30min CIII on rocker 
1) 30min CIII on rocker 
2) 30min CIII standing 
1) 30min CIII on rocker 
2) 30min CIII standing 
 
Table 6.1: Subtraction steps for selections (set I) 
  
 Increased phage titre was observed after each round of selection has shown in 
figure 6.1, as first indication that selection had worked. 
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Figure 6.1: Growth of infected TG1 by phage after selections (set I) 
After each round of selection, 100µl of the infected TG1 were taken to make a series of 
4-5 100-fold serial dilutions in 2xTY. 100µl of each dilution was plated on the 
appropriate selective TYE plates. 
 
 
 Populations of phage produced at each round of selection were then screened for 
binding by ELISA to the selected antigen, to identify "polyclonal" phage antibodies. 
Briefly, ELISA wells were coated overnight at room temperature with 10µg/ml of 
native CI and mix modified CI as target antigen (depending in which selection), native 
CII as control antigen from the collagen family and BSA as another control protein 
which is abounded in human sera. Binding of phage is detected by a HRP-anti-M13 
conjugate antibody.  
 
 Chapter 6: Develop Antibody Fragment Specific to Native and ROS Modified CI & CIII 
433 
 
 
0
0.5
1
1.5
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
O
ri
g
in
al
 l
ib
ra
ry
B
u
ff
er
 o
n
ly
selection vs CI selection vs modified 
CI
selection vs modified 
CI with subtruction
. .
E
L
IS
A
 U
n
it
s 
O
D
 (
4
5
0
n
m
)
Polyclonal ELISA of Phage Against native and modified CI CI 
modified CI 
BSA
CII
 
0
0.5
1
1.5
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
R
o
u
n
d
 1
R
o
u
n
d
 2
R
o
u
n
d
 3
O
ri
g
in
a
l 
li
b
ra
ry
B
u
ff
e
r 
o
n
ly
selection vs CIII selection vs modified CIII selection vs modified CIII 
with subtruction
. .
E
L
IS
A
 U
n
it
s 
O
D
 (
4
5
0
n
m
)
Polyclonal ELISA of Phage Against native and modified CIII CIII
modified CIII
BSA
CII
 
Figure 6.2: Polyclonal reactivity with native and modified proteins in ELISA 
Polyclonal Phage ELISA showing binding activities of purified populations of phage 
after 1, 2 or 3 rounds of selection on proteins.  Phage were allowed to bind to 96-well 
plates coated with immobilised proteins (CI, CIII, ROS-CI, ROS-CIII, CII, and BSA). 
Unbound phage were washed off and bound phage detected with peroxidase-conjugated 
anti-M13 antibody. Bound antibody was visualised by a colour change reaction on 
addition of TMB+. The reaction was stopped with 1N H2SO4 and the colour change 
quantified by measurement of the absorbance at 450nm. 
 
 
 Figure 6.2  shows the reactivity of the phage with the different target proteins 
increased reactivity to CI, mix modified CI and CII (figure 6.2.a) and an increase in the 
reactivity to immobilised CIII, mix modified CIII and CII (figure 6.2.b). No reactivity is 
seen to BSA. The high reactivity to CII may be due to inadequate subtraction step on 
a 
b 
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CII and/or due to the high structural similarity between the two.
92
 For both target 
proteins however, reactivity of the phage changed mostly between the first and second 
round of selections.  
 After the “polyclonal” evaluation, 92 colonies from infected TG1 from each 
different selection were picked and grown individually for monoclonal phage ELISA. 
 Selection protocol 1 done against native CI without subtraction (figure 6.3.a) 
resulted in a high percent of binders to CII. Six of the colonies (B4, C5, C6, C11 and D5 
and H3) were specific to native CI. 
 
 
 
Figure 6.3.a: Monoclonal phage ELISA of clones from selection on native CI 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, ROS-CI and CII. Non-specific binding 
sites were blocked by incubation with 2% Marvel prior to exposing to phage. Bound 
phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system was 
used to visualise bound peroxidase.  X-axis letters and numbers represent clone location 
on 96-well plate.  Data show monoclonal phage from selection set I.  All phage were 
derived from the Tomlinson library. 
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 Selection protocol 2 against native CIII (figure 6.3.b) resulted with many 
colonies specifically binding to native CIII and stronger than to native CII or mix 
modified CIII.  
 
 
 
Figure 6.3.b: Monoclonal phage ELISA of clones from selection on native CIII 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CIIII, ROS-CIII and CII. Non-specific 
binding sites were blocked by incubation with 2% Marvel prior to exposing to phage. 
Bound phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system 
was used to visualise bound peroxidase.  X-axis letters and numbers represent clone 
location on 96-well plate.  Data show monoclonal phage from selection set I.  All phage 
were derived from the Tomlinson library. 
 
 Selection protocol 3 against mix modified CI, (figure 6.3.c) resulted in binders 
which are more likely to be CII specific. Selection against mix modified CIII protocol 4 
(figure 6.3.d) however resulted in clones that bind better to native CIII.  
 Chapter 6: Develop Antibody Fragment Specific to Native and ROS Modified CI & CIII 
434 
 
 
Figure 6.3.c: Monoclonal phage ELISA of clones from selection on mix modified 
CI 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, ROS-CI and CII. Non-specific binding 
sites were blocked by incubation with 2% Marvel prior to exposing to phage. Bound 
phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system was 
used to visualise bound peroxidase.  X-axis letters and numbers represent clone location 
on 96-well plate.  Data show monoclonal phage from selection set I.  All phage were 
derived from the Tomlinson library. 
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Figure 6.3.d: Monoclonal phage ELISA of clones from selection onmix modified 
CIII  
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CIII, ROS-CIII and CII. Non-specific 
binding sites were blocked by incubation with 2% Marvel prior to exposing to phage. 
Bound phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system 
was used to visualise bound peroxidase.  X-axis letters and numbers represent clone 
location on 96-well plate.  Data show monoclonal phage from selection set I.  All phage 
were derived from the Tomlinson library. 
 
 Adding subtraction while selecting against ROS-CI, protocol 5, resulted in a 
lower reactivity in most of the colonies. Hence, it did not solve the problem of high 
background binding to CII (figure 6.3.e).  
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Figure 6.3.e: Monoclonal phage ELISA of clones from selection on mix modified 
CI with subtraction 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, ROS-CI and CII. Non-specific binding 
sites were blocked by incubation with 2% Marvel prior to exposing to phage. Bound 
phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system was 
used to visualise bound peroxidase.  X-axis letters and numbers represent clone location 
on 96-well plate.  Data show monoclonal phage from selection set I.  All phage were 
derived from the Tomlinson library. 
 
 
 The same subtraction was done in protocol 6 against mix modified CIII, (figure 
6.3.f). But the binders profile was more or less as seen when the selection was done 
without subtraction. 
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Figure 6.3.f: Monoclonal phage ELISA of clones from selection on mix modified 
CIII with subtraction 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CIII, ROS-CIII and CII. Non-specific 
binding sites were blocked by incubation with 2% Marvel prior to exposing to phage. 
Bound phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system 
was used to visualise bound peroxidase.  X-axis letters and numbers represent clone 
location on 96-well plate.  Data show monoclonal phage from selection set I.  All phage 
were derived from the Tomlinson library. 
 
 Conclusions for the next set of selections: The high cross reactivity between 
CI and CII was due to the similarity in their protein structures. CII consist of three α-
chains while CI consists of two α-chains (α1 and α2) and one β chain. The resemblance 
between the α-chains is very high. CII α-chains concentration is higher than CI at the 
same concentration since CII consists from three α-chains and CI only from two.92 CIII 
consists of three α-chains as well and as a result some cross reactivity was also seen. 
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 Since cross reactivity to CII was seen in all the above protocols, the next step 
included a subtraction against CII. The protocol needed to be adjusted so that the 
selected phage would react better against the ROS modified proteins than to the native 
form of the proteins. 
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6.2.1.2 Selection Set II 
 To overcome the cross reactivity against CII the following selections were done 
with additional subtraction step against native CII. Phage were subtracted in 
immunotubes coated with 10g/ml of CII for 30 min on a rocker and then for additional 
30 min standing on the bench, both in room temperature. Another reactivity issue was to 
drive the selection towards ROS-CI or ROS-CIII rather than observing mainly binders 
to the native collagens.  To this end 1μg/ml of the native CI or CIII was added to the 
phage solution in the final step of the selection, before adding to the immunotubes 
coated with the ROS modified target proteins. 
The rest of the subtraction steps are summarized in table 6.2. 
Target protein of 
selection 
Subtraction steps 
Round 1 Round 2 Round 3 
7 Mix ROS- CI 
 
1) 30min CII on rocker 
2) 30min CII standing 
3) 30min CI on rocker 
4) 30min CI standing 
1) 30min CII on rocker 
2) 30min CI on rocker 
1) 30min CII on rocker 
2) 30min CI on rocker 
8 Mix ROS-CIII  
 
1) 30min CII on rocker 
2) 30min CII standing 
3) 30min CIII on rocker 
4) 30min CIII standing 
1) 30min CII on rocker 
2) 30min CIII on rocker  
1) 30min CII on rocker 
2) 30min CIII on rocker  
 
Table 6.2: Subtraction steps for selections (set II) 
 
 Figure 6.4 summarises the phage titres through the selection. After the second 
round of selection there is an increase in the number of colonies, however, after the 
third round of selection their number decrease as a result of the stringent subtraction 
steps (as native CI or CIII was added to the phage before binding to immunotubes). 
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Figure 6.4: Growth of infected TG1 by phage after selections (set I) 
The 2 batches of infected TG1 were pooled and 100 µl were taken from each to make a 
series of 4-5 100-fold serial dilutions in 2xTY. 100 µl of each were then plated on the 
appropriate selective TYE plates. 
 
 After the third round, 184 colonies from each of the selections were picked up 
and grown for monoclonal ELISA. The new adjustments to the selection protocol did 
not resolve the problem of cross-reactivity to CII (figure 6.5.a) and that the reactivity to 
the target proteins was even lower than before. Selection against mix modified CIII 
(figure 6.5.b) resulted in low reactivity to the control antigen (CII) in most colonies but 
reactivity to native CIII was still higher than to mixed modified CIII. 
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Figure 6.5.a: Monoclonal phage ELISA of clones from selection on mix modified 
CI  
 
 
 
Figure 6.5.b: Monoclonal phage ELISA of clones from selection on mix modified 
CIII  
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, ROS-CI and CII (a) or CIII, ROS-CIII 
and CII (b). Non-specific binding sites were blocked by incubation with 2% Marvel 
prior to exposing to phage. Bound phage were detected with peroxidase-conjugated 
anti-M13.  The TMB+ system was used to visualise bound peroxidase.  X-axis letters 
and numbers represent clone location on 96-well plate.  Data show monoclonal phage 
from selection set I.  All phage were derived from the Tomlinson library. 
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 Conclusions: For the next set of selections, the subtraction step against CII 
needed to be more stringent since the reactivity to CII was usually higher than the target 
proteins.  
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6.2.1.3 Selection Set III 
 To overcome the high cross-reactivity to CII, part of the subtraction step was 
performed at 37ºC instead of room temperature. In order to improve the specify of the 
selections more stringent modification with ROS was performed to minimize the 
number of residual native epitopes in the ROS modified CI and CIII.  
 CI was modified for 3 nights instead of one with ribose, HOCl, H2O2 and 
peroxynitrite. No native bands of CI could be observed in the SDS-PAGE gel (figure 
6.6). CI was also modified as well with a mixed ROS for 3 nights. That mix was then 
cleaved further with Argingipain, with and without CNBr and trypsin (as described in 
protocols 2.2.5.2, 2.2.5.4 and 2.2.5.5 respectively).  
  
 
 
 
 
  
 
 
 
 
 
Figure 6.6: SDS–PAGE analysis of CI modifications for selections 
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) analysis of 
chemically modified CI. Samples containing CI were incubated at 37°C with or without 
the various free radical generators. Equal amounts of protein were boiled with loading 
buffer containing β-mercaptoethanol for 5 minutes before loading on the SDS–PAGE. 
Each lane represents different native or modified CI or mix modified CI with or without 
Arg and CNBr. All of the native bands disappeared and some newly formed bands and 
smear is noticeable. Stain was done with Coomassie. The migration position of the 
molecular weight markers (in kDa) is indicated on the left-hand lane of the gels. 
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 Seven different selections were done according to the table below (table 6.3). 
First round of selection was done with subtraction while the second round was done 
without subtraction. In the final round, subtraction was done only against the native CI. 
The rationale behind the differences between the rounds of selection will be discussed 
below. 
Target protein of selection 
Subtraction steps 
Round 1 Round 2 Round 3 
1 Strong mix ROS-CI 
1) 30min CII 
standing in 37°C 
2) 30min CII 
standing in room 
temperature 
3) 30min CI 
standing in 37°C 
4) 30min CI 
standing in room 
temperature 
no subtraction 
1) 30min CI standing in 37°C 
2) 30min CI standing in room 
temperature 2 Strong glycated CI 
3 Strong HOCl CI 
selection was stopped  
4 Strong H2O2 CI 
5 Strong ONOO- CI 
1) 30min CI standing in 37°C 
2) 30min CI standing in room 
temperature 
6 
Strong mix ROS-CI + 
Argingipain  
selection was stopped 
7 
Strong mix ROS-CI + 
Argingipain + CNBr  
 
Table 6.3: Subtraction steps for selections (set III) 
  
 For all of the selections titre was low due to the stringent subtraction, thus, no 
subtraction was done in the second round of selections (figure 6.7). In only three of the 
selections protocols 1, 2 and 5 colonies were observed after second round thus only 
these were taken for further third.  
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Figure 6.7: Growth of infected TG1 by phage after selections (set III) 
The 2 batches of infected TG1 were pooled and 100 µl were taken from each to make a 
series of 4-5 100-fold serial dilutions in 2xTY. 100 µl of each were then plated on the 
appropriate selective TYE plates. 
 
 
 In the final round of selections 1,2 and 5, the titre increased and thus 92 colonies 
from each of the selections were picked up and grown for a monoclonal ELISA. 
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Figure 6.8.a: Monoclonal phage ELISA of clones from selection on glycayed CI 
(protocol 2) 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, glycated-CI and CII. Non-specific 
binding sites were blocked by incubation with 2% Marvel prior to exposing to phage. 
Bound phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system 
was used to visualise bound peroxidase.  X-axis letters and numbers represent clone 
location on 96-well plate.  Data show monoclonal phage from selection set I.  All phage 
were derived from the Tomlinson library. 
 
 
 As shown in figure 6.8.a, when selection against strongly glycated CI was done, 
with subtraction, most of the clones evaluated reacted better to glycated CI and not to 
the native CI. Hence, only two clones (F2 and G2) had a high reactivity to native CII. 
 Selection against CI highly modified by peroxynitrite (figure 6.8.b) was not as 
successful and many clones were cross reactive with CII. Some of them were more 
reactive to native CI (e.g. E10) while the minority (e.g. F5) were slightly more reactive 
to modified CI. 
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Figure 6.8.b: Monoclonal phage ELISA of clones from selection on CI modified by 
peroxynitrite (protocol 5) 
Single TG1 clones were grown in 96-well plate format and phage production induced 
by the addition of helper phage.  Supernatant containing phage was harvested the next 
day and allowed to bind wells coated with CI, peroxynitrite -CI and CII. Non-specific 
binding sites were blocked by incubation with 2% Marvel prior to exposing to phage. 
Bound phage were detected with peroxidase-conjugated anti-M13.  The TMB+ system 
was used to visualise bound peroxidase.  X-axis letters and numbers represent clone 
location on 96-well plate.  Data show monoclonal phage from selection set I.  All phage 
were derived from the Tomlinson library. 
 
 Conclusions for selections: Subtraction was necessary in order to reduce the 
cross reactivity to CII. ”Aggressive” modification of CI which minimises the residual of 
native epitopes was necessary to enable a specific selection against modified CI. 
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6.2.2 Further characterization of lead clones 
 Aim: Evaluate the specifity of the lead clones after selection. 76 colonies that 
reacted specifically to glycated-CI were taken for another screening by ELISA using 
different ROS-CI modification (glycation, HOCl, OH∙ and peroxynitrite) as well as 
native CI, native CII and BSA.  
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Figure 6.9 :Reactivity of selected scFv against immobilised target proteins 
96-well plates were coated overnight with different target proteins (CI, ROS-CI, CII and 
BSA), non-specific binding sites blocked by incubation with 2% Marvel.  Samples of 
scFv 2, 3, 18, 39, 51, 52, 53, 65, 66, 72, 73 and 1D8 were exposed to the coated wells 
for one hour. Bound myc-tagged scFv were detected with mouse anti-myc and 
peroxidase-conjugated anti-mouse. 
 
 Figure 6.9, representative binding profile of the 76 different phage taken for 
further screening. Each clone was screened for binding to CI modified by glycation, 
HOCl, H2O2 and peroxynitrite as well as native CI, native CII and BSA.  
 Binders were grouped into seven different reactivity profiles. Clones 2 and 3, 18 
and 39 (and possibly 72 and 73) represent antibodies that react strongly to CI modified 
by peroxynitrite, HOCl and glycated CI and with low level to CI modified by HOCl but 
 Chapter 6: Develop Antibody Fragment Specific to Native and ROS Modified CI & CIII 
434 
 
at a moderate level to native CII. Clones 53 and 65 had high cross reactivity with CII. 
Clones 51, 52 and 66 were specific to native CII. None of the clones reacted to BSA.  
 
6.2.3 PCR of monoclonal colonies 
 Aim: Now that 76 binders with different binding properties had been identified 
the next step was the analysis of their sequence in order to identify the various unique 
clones according to the sequence variability.  
 Firstly, the integrity of the antibody insert in the vector was screened by 
polymerase chain reaction (PCR) where multiple copies of a target DNA sequence are 
made by enzymatic amplification. In our library two specific oligonucleotide primers 
anneal to the template DNA: fdseq1 or pHEN (3’ oligo) and LMB3 (5’ oligo) flanking 
the VL and VH insert. PCR products were analysed using gel electrophoresis. Because of 
its negative charge, DNA will migrate towards a positive electrode. The agarose gel 
restricts the movement of DNA, so that shorter or more compact molecules will move 
faster through the gel than longer or more relaxed molecules. 
 The PCR of all of the 76 colonies resulted in a strong major band at around the 
1000bp marker which corresponds to the size of the scFv insert (figure 6.10). 
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Figure 6.10: DNA Gel of PCR products of Monoclonal Colonies 
The integrity of the 76 antibody insert in the vector was screened by PCR. Two specific 
oligonucleotide primers were annealed to the template DNA: fdseq1 or pHEN (3’ oligo) 
and LMB3 (5’ oligo) flanking the VL and VH insert. PCR products were analysed using 
gel electrophoresis. An agarose gel loaded with DNA ladder marker (marker lanes) and 
with the 76 colony products of a PCR reaction (lane 1-76). 
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6.2.4 Sequencing 
 Aim: Evaluate the unique sequences of each of the 76 selected clones. 
The bidirectional sequencing were performed with two primers LMB3 (5’ 
CAGGAAACAGCTATGAC 3’) and pHEN (5’ CTATGCGGCCCCATTCA 3’) for 
each clone so both strands could be sequenced.  
 A summary of the sequences for the eight different unique sequences groups is 
presented below (table 6.4). From each group a representative clone was chosen for 
further evaluation of the selected scFv. 
 
Clone CDRH2 CDRH3 CDRL2 CDRL3 
3 SISNSGTNTD YADSVKG NYAS FDY YASY LQS QQ GSASPS T 
18 AISDAGAATY YADSVKG TTSA FDY SASN LQS QQ GYDDPN T 
51 AIANNGDGTD YADSVKG DAYA FDY DASN LQS QQ ASSDPA T 
53 SIDGGGGYTD YADSVKG SYTD FDY TASY LQS QQ SYASPS T 
65 DIGTDGTDTT YADSVKG NYTY FDY SASS LQS QQ YYYSPT T 
66 SINSDGGSTT YADSVKG DYAT FDY GASY LQS QQ SYAAPD T 
73 SIYYAGAGTD YADSVKG SYAN FDY SASY LQS QQ AYAAPD T 
1D8 AISDSGSATG YADSVKG DYAT FDY LHPT LQS QQ NNPPGT T 
 
Table 6.4: A summary of amino acid sequences of selected monoclonal scFv of 
clones isolated from the Tomlinson library 
Variable parts are shown in bold. 
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6.2.5 Analysis of secreted, soluble, monoclonal scFv 
Aim: The next step was to analyse the binding of the lead clones as soluble scFv 
fragments detached from the phage.   
This was done by infecting E. coli strain HB2151 with the eight lead phage 
clones isolated so far.  The TG1 E. coli used prior to this section for phage propagation 
are a ‘suppressor’ strain, that add glutamate residue at the AMBER stop codon encoded 
between the scFv and pIII.  Unlike TG1, HB2151 recognise AMBER stop codons, 
therefore the encoded scFv-pIII fusion is translated only to the end of the myc-tag, and 
the free scFv are secreted into the bacterial supernatant and periplasm. The 
expression is driven by the lacZ promoter, and is therefore induced by IPTG. The 
bacteria are grown at low glucose concentration (0.1%) to ensure that the glucose is 
completely metabolized by the time the IPTG is added.
31
  
 
 After collecting bacterial supernatant from each individual lead clone 
monoclonal ELISA was performed using plated coated with native CI, ROS-CI and 
control CII and BSA. A 96-well plate was coated with 10g/ml of the different proteins 
overnight at 4C and remaining non-specific binding sites blocked by incubation with 
2% Marvel.  ScFv-phages were allowed to bind for one hour and bound myc-tagged 
scFv detected with 9E10 (mouse anti-myc) and peroxidase-conjugated anti-mouse 
antibodies. 
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Figure 6.11: Reactivity of selected scFv against target proteins 
96-well plates were coated overnight with different target proteins (CI, ROS-CI, CII and 
BSA), non-specific binding sites blocked by incubation with 2% Marvel.  Samples of 
scFv 3, 18, 51, 53, 65, 66, 73 and 1D8 were exposed to the coated wells for one hour. 
Bound myc-tagged scFv was detected with mouse anti-myc and peroxidase-conjugated 
anti-mouse. 
 
  
 None of the lead scFv candidate bound to BSA (figure 6.11). Clones 3, 18, 53, 
65 and 73 scFvs were specific to ROS-CI. Clones 53, 65 and 73 had lower reactivity to 
CI modified by HOCl and sometimes more reactivity to CI modified by OH
.
. Clones 51 
and 66 were specific to native CII while clone 1D8 was specific to native CI with low 
reactivity to all of the modifications of CI. 
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6.2.6 Large scale production of scFv 
 Aim: Produce a large amount of the specific scFv and evaluate their specifity. 
Antibody fragments from the E. coli periplasm or supernatant can be purified 
using a range of different columns, the choice of which depends on the type of antibody 
fragment and the tag attached to it. Using the Tomlinson library there were two 
alternative options for purification. The first was to use a nickel column as there is a 
histidine tag. The polyhistidine binds strongly to the nickel so the suspension can be 
passed through a column containing immobilized nickel ions, which binds the 
polyhistidine tag. Alternatively, scFv can be purified by protein A as library was built 
from DP47 which is a VH3 family that is known to bind to protein A.
2
  
One litre cultures of each of the six lead clones were induced with IPTG and 
incubated overnight, shaking, at 30C.  Periplasmic proteins were extracted and scFv 
purified by Protein-A-Sepharose Affinity Chromatography (protocols 2.2.8). Purified 
proteins yield were monitored by an O.D 280 (table 6.5) and visualised by 12% SDS-
PAGE (figure 6.12) followed by WB analysis (figures 6.13). 
Table 6.5: A summary of the scFv protein yield is in the table below (table 6.5) 
calculated (1O.D = 800g/ml).  
 
Table 6.5: A summary of the scFv protein yield 
Bacterial cultures (10ml) were induced with IPTG and incubated at 30C overnight, 
before separation of the supernatant by centrifugation and extraction of periplasmic 
proteins from the bacterial pellet. O.D levels measured and calculated (1O.D = 
800g/ml). 
 3 18 53 65 73 1D8 
Protein A column Fraction I 0.089 0.348 0.298 0.048 0.144 0.713 
Protein A column Fraction II 0.566 1.256 0.891 0.944 0.338 1.314 
Protein A column Fraction III 0.540 0.518 0.472 0.807 0.381 0.598 
Protein A column Fraction IV 0.640 0.287 0.225 0.448 0.524 0.472 
After Dialysis 0.640 0.98 0.814 0.846 0.180 0.68 
Protein yield g/ml 512 784 651 676 144 544 
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The next step was to visualise the scFv by a 12% SDS-PAGE (figure 6.12), the 
lower yield of clone 73 is seen also in the SDS-PAGE. 
 
 
Figure 6.12: 12% SDS-PAGE analysis of purified, soluble scFv 
5g of each soluble scFv (except clone 73) were combined with an equal volume of 
reducing sample buffer and loaded into the wells of a 12% acrylamide gel.  After 
separation by electrophoresis, protein bands were visualised by staining with Coomassie 
Blue. 
 
 One major band could be seen in each of the six lanes loaded with soluble scFv 
product (Fig 6.12) protein migrating at approximately 27kDa and appeared by 
Coomassie staining to have a high degree of purity which corresponds to the scFv size 
(25-30kDa). Other minor bands observed at lower molecular weight has previously 
been observed with many other Tomlinson-derived clones, and most likely represents a 
degradation product (A. Nissim, personal communication). 
 The purity of the scFvs was then tested by WB. Tomlinson library-derived scFv 
contain both myc and His tags, which can both be used for probing the scFvs.  
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Figure 6.13: Western blot analysis of the purified scFv using anti-His antibodies 
for probing scFv 
5 µg of purified proteins were loaded into a 4-20% SDS-PAGE followed by Western 
blotting and detection with an anti-4xHis monoclonal antibodyand visualised using 
Enzyme Chemiluminescence followed by autoradiography. 
 
 Strong band at approximately 27kDa, which corresponds to the molecular mass 
of scFv, confirmed the purity of the scFv. Once again week band of small protein 
degraded scFv could also be observed. Lower yield of clone 73 is also confirmed as 
reflected by weaker band at 27K. 
 Analysis of the scFv binding activity of the purified scFv to confirm specificity 
was then performed by ELISA (figure 6.14). Reactivity was analyzed against native and 
ROS CI, CII and CIII, and against native BSA, CIV, CVI and CIX. Clones 3, 18, 53, 65 
and 73 scFvs were once more specific to ROS-CI with differences in their reactivity 
profile. 1D8 was specific to native CI. None of the scFvs tested bound to control 
collagens such as CIV, CVI, CIX or BSA. 
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Figure 6.14: Binding profile of lead scFvs 
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96-well plates were coated overnight with different target proteins as written in the x-
axis and remaining non-specific binding sites blocked by incubation with 2% Marvel.  
Samples of scFv 3, 18, 53, 65, 73 and 1D8 were diluted 1:50, 1:150, 1:450 in 4% 
Marvel and exposed to the coated wells for one hour. Bound myc-tagged scFv was 
detected with 9E10 (mouse anti-myc) and peroxidase-conjugated anti-mouse. 
 
 Reactivity profile of each scFv was then analysed by WB. Purified scFvs were 
diluted 1:100 and used to bind to native and ROS modified collagen in WB.  
 
 
Figure 6.15: WB of native and modified CI and CII developed with scFv 
Detection of native and modified CI and CII by monoclonal scFv fragments. Wells were 
loaded with the different target proteins, a 4-20% SDS-PAGE was used, followed by 
Western blotting. The WB was probed with scFv 3, 18, 53, 65 and 73 and detection was 
done with an anti-4xHis monoclonal antibodyand visualised using Enzyme 
Chemiluminescence followed by autoradiography. At the top and bottom of the figure 
the different proteins and modifications are marked. The marker sizes are written on the 
left (in kDa). 
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  Figure 6.15 summarise the binding profile of the five different scFv in WB. All 
of the scFv bound to modified CI (3,18,53,65 and 73). Clone 3 and 18 bind strongly to 
CI modified by HOCl, including high aggregates at the origin of the lane and until the 
area below 100kDa. The same clones bind to glycated-CI and some weak bands were 
observed at the other CI modification. Clone 3 bound stronger also to native CI. All had 
some background reactivity to native CII and very weak background to glycated CII and 
CII modified by peroxynitrite. ScFv 53 and 73 seems to bind better to CI modified by 
peroxynitrite. The reactivity of clone 53 to native CI was moderate and it hardly reacted 
to native CII and even less to modified CII. ScFv 65 seems more specific to HOCl 
modified CI. There was no detected reactivity to native CI, native CII or modify CII.  
 To conclude, a panel of lead scFv were raised with variety of specificity.  
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6.3 Summary 
 Generation of ROS-CI specific scFv was done by selection using phage display 
semi-synthetic scFv library.  Three different selection methods were used in an attempt 
to isolate specific scFv from the Tomlinson phage libraries, including different 
incubations during the selections, using target proteins at several modifications levels, 
with and without subtraction.  
 The reactivity of the polyclonal phage populations increased mainly in the 
second round of selection and kept its specificity at the third and last round.  
Monoclonal analysis of the enriched phage populations resulted in the identification of 
six unique clones which were specific for different ROS-CI. After sequencing, the 
number of different unique clone reduced to five: 3, 18, 53, 65 and 73.  
 To evaluate the scFv, a large scale production of soluble antibodies from this 
five clones and a control scFv against native CI (1D8) was done. From each of the six 
clones, adequate amounts with an adequate concentration of scFv were produced. The 
expression of the scFv was evaluated by a SDS-PAGE and WB. In both systems 
different scFvs showed different binding profile to CI and ROS-CI but were negative in 
most cases to the control antigens. 
 Unfortunately, due to the lack of biopsies, these experiments to evaluate the 
scFv could not be pursued further.  It would have been particularly interesting to scan 
AgP, CP and G patients’ biopsies to prove the localisation of the ROS-CI epitope in the 
inflamed tissue, and to prove the specificity of the scFv produced in the detection of 
AgP form of the periodontal disease. Ethical approval to perform this study is being 
discussed for further ongoing future study. 
The antibody fragments developed might be a good candidate for targeting 
therapy to the periodontium area since they are specific to the post-translationally 
modified-CI present only in the damaged periodontium, especially as CI is a major 
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component of many structures of the body. It might be used for evaluating the disease 
state or to subclassify the AgP patients differently. It might also assist in predicting the 
prognosis of the disease or monitor the therapy of it, particularly when autoimmunity 
becomes a part of it. The anti-ROS-CI scFv candidates need to be further characterised 
by scanning of AgP, CP and G patients’ biopsies to demonstrate the localization of the 
ROS-CI epitopes in the inflamed tissue in a longitudinal study as well as to prove the 
specificity of the scFv to damaged periodontal tissue. In the long term, to the scFv could 
be further developed at first for diagnostic purposes.  
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Chapter 7: Discussion 
 Periodontitis is one of the two highly prevalent oral diseases, and affects over 
20% of people in most adult human populations. Although the primary etiologic factor 
of periodontitis is the bacterial plaque biofilm,
 51 ,  52
 the factors that may determine the 
presence and rate of progression of the disease are complex and not fully understood. 
The potential involvement of autoimmunity in the pathogenesis of periodontitis has 
been considered intermittently for many years. Autoantibodies against a wide range of 
self-antigens, such as CI, host DNA, laminin, fibronectin and desmosin, have been 
described previously.
5,6,7,47
 However, these reports are  inconsistent, some describing 
high levels of autoantibodies to CI,
40,139
 while others report low levels of anti-CI.
61
 
Recently, it has been suggested that autoimmune responses may be increased 
particularly in patients with AgP. De-Gennaro and co-workers
32
 showed increased 
autoantibodies to fibronectin and laminin, but not to CI, in patients with AgP. In 
addition, Koutouzis and co-workers,
83
 in a small pilot study, have shown increased 
tissue autoreactivity and anti-CI antibody titres specifically in patients with localized 
AgP. 
The exact aetiology of autoimmune reactivity in periodontitis is not known, but 
may be linked to the inflammatory process resulting from the primary activity of 
periodontal microbial pathogens such as Porphyromonas gingivalis and 
Aggregatibacter actinomycetemcomitans.  Within the inflamed lesion, there is a high 
influx of immune cells that consume increased amounts of oxygen, thus leading to 
overproduction of ROS.
146
 These include superoxide radical, hydroxyl radical, nitric 
oxide radical, peroxynitrite, and non-radical derivatives of oxygen, such as hydrogen 
peroxide and hypochlorous acid.
24
 In addition, advanced glycation end-products 
produced by sequential oxidative reactions
26
 are known to be present in inflamed 
tissues.
12
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The major protein components of the periodontal tissue are CI and CIII and thus 
are the major proteins that are susceptible to ROS attack. Furthermore, cleavage of 
extracellular proteins by matrix metalloproteases
103
 or citrullination by peptidylarginine 
deiminase (PAD)
143
 also contributes to formation of post-translationally modified 
proteins. These two enzymatic post-translational modifications are of particular interest 
in periodontitis, since P. gingivalis produces both Argingipain
72
 and peptidylarginine 
deiminase (PAD).
94
  
Post-translational modification of CI, CIII by ROS results in the formation of 
altered self-protein, neoepitopes to which the body has little or no tolerance for and thus 
initiation the pathogenesis of autoimmune diseases.  The interactions of proteins with 
components of the immune system may be profoundly affected by post-translational 
modifications.
28
 T-cell responses to post-translational modified antigens tend to be 
specific for the modified form of self-antigen and do not recognize the unmodified 
form. In contrast, B-cell responses to post-translationally modified self-antigens tend to 
be more diverse in that antibodies recognize, so both the modified and the native self-
antigen are recognized. This reaction suggests that the post-translational modification of 
a particular self-antigen promotes epitopes spreading, known to occur in virtually all 
autoimmune diseases, such as diabetes,
 114
 lupus,
100
 and multiple sclerosis.
86
 
The aim of the present study was to test the hypothesis that periodontal disease 
pathogenesis is affected by autoimmunity processes as characterized by responses to 
native and post-translationally modified extracellular matrix proteins. Hence, the 
objective was to test the involvement of reactive oxidants present in the inflamed tissue 
in formation of neoepitopes and thus breaching immune tolerance. 
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7.1 Modifications of collagens  
The hypothesis of this study was that periodontal tissue inflammation results in 
high influx of immune cells, mainly polymorphonuclear leukocytes (PMN) that 
consume increased amounts of oxygen thus leading to overproduction of ROSs.
 
The 
ROS can modify structurally and metabolically functional macromolecules in the 
process of balancing their unpaired electronic state.
12,112,131 
The ability of ROS to modify CI, the major component of the periodontal 
extracellular matrix tissue and CIII, which is the major building block of the blood 
vessels populating the tissue, was a key concept to show that there are autoantibodies 
against post-translationally modified CI and CIII as well as to the native form of the 
proteins. Optimization of the in vitro post-translational modification of CI, CIII and 
Albumin as a control protein by different ROS (HOCl, OH
.
, ONOO
.
 and glycation), 
present in the inflamed periodontium was done. In order to decide on the optimised 
protocol, confirmation of the modification was done by SDS-PAGE and 3D 
fluorescence analysis. 
Monitoring ROS modification of CI and CIII by SDS-PAGE was done by 
staining by Coomassie and silver, which are the most common staining methods. 
Coomassie is a colloidal stain and is the least sensitive stain with a detection limit of 
0.1-1ng of protein per spot,
46
 it binds non-specifically to proteins but not to the gel, 
thereby allowing visualization of the proteins as blue bands within the translucent 
matrix of the gel.
43
 Coomassie is however cheap, easy to use and compatible with the 
majority of protein analysis equipment, such as MS.
46
 Silver staining is the most 
sensitive stain, allows detection of proteins resolved by gel electrophoresis at 
concentration nearly 100-fold lower than those detected by Coomassie staining.
46
 The 
identification of proteins by silver staining is based on the differential reduction of 
silver ions that are bound to the side chains of amino acids.
132 
Silver staining is 
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temperature dependent and involves precise timing when stopping development.  
Because of this it is less reproducible then Coomassie.
43
 Both methods are not ideal but 
do complement each other so modified proteins could be evaluated.  
Coomassie stain was usually enough to determine that the native form changed, 
but was not always able to show the newly formed low molecular weight peptides. 
Silver stain was able to present lower molecular weight peptides and at a lower 
concentration. In both staining systems fragmentation and aggregation were observed in 
addition to the disappearance of the native proteins bands. 
In some cases SDS-PAGE was not sufficient to resolve the occurrence of the 
modifications and the structural changes of the proteins or that the native form of the 
protein have changed (e.g. ROS-CIII, 3.1.1.3). This was address by studying the 
fluorescent profile of the native versus modified collagen. Protein structure-function 
studies have benefited greatly from the use of fluorescence techniques. Light in the 
ultraviolet light range is absorbed by three aromatic amino acids: phenylalanine, 
tyrosine and tryptophan.
125
 Tryptophan is an indole amino acid which is the most 
popular amino acid used in protein studies using fluorescence.
96
  Therefore studies on 
these tryptophan residues are easy to conduct, and since the nature of fluorescence of 
the tryptophan residue differs in accordance with the surrounding intra-molecular 
environment, it is possible to predict the possible molecular structure neighbouring it.
125
 
As a result it is possible to look at peptide orientation, structure and dynamics.      
Based on the previous work done by the group, it was possible to monitor 
modification of CII by ROS by determining the fluoresce of ROS-CII versus native 
CII.
108
 Therefore, fluorescent profile was used to monitor ROS modifications of CI, CIII 
and BSA. 3D fluorescence analysis was done and it showed that the fluorescent profile 
was changed as a reflection of structure changes of the ROS modified CI and CIII in 
comparison to the native molecules. Indeed, increase in the scattering which was 
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associated with aggregation and changes in the fluorescence spectra which were due to 
chemical modification of the aromatic and other amino acids were observed, 
particularly with glycated proteins and proteins modified by peroxynitrite.  
 Using these two complementary approaches ROS modifications of CI, CIII and 
BSA were optimised. 
 
7.2 Reactivity of clinical samples 
 Once the ROS modification was established the next step was to show that 
patients with periodontal disease have autoimmune responses to native and post-
translationally modified CI and CIII which are the two major components of the 
periodontal attachment structures. CI and CIII were tested in serum from three different 
groups of patients with periodontal and gingival diseases. CP and AgP are the two main 
forms of periodontitis and the definition of them is based on a combination of clinical 
signs and symptoms.
8,9
 AgP occurs in patients who are otherwise clinically healthy. 
Common features include rapid attachment loss and bone destruction and familial 
aggregation. CP results in a chronic inflammation within the supporting tissues of the 
teeth, progressive attachment and bone loss. It is prevalent in adults, but can occur at 
any age. The third group was gingivitis which is an inflammatory process limited to the 
soft tissue, the gingiva, and characterized clinically by gingival redness, oedema, 
bleeding and does not result in clinical attachment loss.
48
 
 Binding to both native and ROS modified CI and CIII was observed only in the 
AgP samples, whilst no binding was observed in either CP or G serum samples (p < 
0.01). Out of 25 AgP samples tested 19 showed a positive reaction and only 6 were 
negative to CI. In contrast, only 2 samples with CP and 1 with G reacted against CI. 
Similarly, only samples from AgP responded to CIII but not CP and G samples. CII, 
which is a known auto-antigen in rheumatoid arthritis,
108
 as well as BSA were used as 
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control antigens, both of which did not show any reactivity with periodontal patients’ 
samples. The fact that no reactivity was seen against CII, which is the major component 
of articular cartilage and a known autoantigen in rheumatoid arthritis suggest that the 
autoreactivity towards CI and CIII in the AgP samples is diseased tissue specific, 
especially as sera from patients with RA showed statistically significant autoantibody 
titres to CII, but not to CI or CIII. 
The samples evaluated were chosen arbitrarily at first for the pilot experiments 
or when there was a high reactive sera patient and the same patient had also saliva 
sample, its samples were chosen as well. The rationale behind  was that a highly 
reactive patient will be reactive in both sera and saliva. It might be that sometimes 
during the optimization of the protocol, not the best sample was used. However, after 
the protocol was optimized all the samples were scanned and nice distribution of the 
results were seen.  
No statistically difference was observed between the smokers and the non-
smokers groups of AgP, CP and G tested. Most of the AgP samples were reactive, 
including the few smokers. None of the CP and G samples were reactive, included 
several smokers. It is possible that being a smoker did not influence the results even 
though the number of smokers in each group was limited. A bigger cohort of smokers is 
needed to validate these results. 
The blood samples used were of fresh whole blood which was centrifuged and 
the plasma was aliquot and stored at -80°C until further analysis. Some of the samples 
were frozed and defrozed for many times, however they were still reactive. It might be 
that some of the reactivity was lost with this repetitive use of the sample, but since the 
deviation between the AgP, CP and G group was so astonishing it is possible to believe 
that all the samples were still holding a substantial amount of Ig to scan. 
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 A summary of our data showed that: 
1. The demonstration that collagen autoantibody production is specific to the 
diseased tissue as no reactivity was observed to CII, which is the major 
component of the articular cartilage. 
2. The auto-reactivity is seen specifically in patients with generalized aggressive 
periodontitis. 
3. The demonstration of statistically significant autoantibody production to ROS-
modified collagens. 
 
The novelty of the current findings is mainly the demonstration that periodontitis 
is a heterogeneous disease and that only AgP features autoimmune disease 
characterization. Indeed, the suggestion that autoantibody production may be seen 
specifically in patients with AgP is supported by two recent studies, although their 
findings differ to the data presented here in both clinical detail and types of auto-
antibodies described.
32,83 
De-Gennaro and co–workers32 showed increased autoantibodies to fibronectin 
and laminin, but not to CI, in patients with AgP. In addition Koutouzis and co 
workers,
83
 in a small pilot study, have shown increased tissue autoreactivity and anti-CI 
antibody titres specifically in patients with localized AgP.
 
 
In some respects the homogeneity of the responses seen in AgP was surprising, 
given that AgP may be considered a clinical syndrome with different aetiological factors 
playing a distinct role in different patients, such as different genetic and microbial 
factors.
9,56,77,116 
The results are also striking in the sense that although inflammation was 
evident in AgP, CP, and G only AgP had autoreactivity. So the reactivity was not 
simply auto-inflammatory response. The AgP diseases consist of several forms of 
disease clinically indistinguishable from other forms of periodontitis, and several forms 
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of disease with a uniquely localized clinical presentation with significant destruction at 
a very early age.
3,22
 Epidemiological surveys have shown that the prevalence of 
aggressive periodontitis varies among ethnic groups, regions and countries and may 
range from 0.1% to 15%.
3
 In contrast our data showed that the AgP group tested 
presented a homogenous positive response to native and ROS-modified CI and CIII, 
while the CP group tested did not respond as a homogenous group. 
Patients with AgP are reported to have a “hyper-inflammatory” phenotype6 and 
the present data raises the question of whether the production of autoantibodies may be 
a primary pathogenic event in this condition, or whether the production of 
autoantibodies is secondary to other inflammatory events. To address this, the 
concentration of salivary IL-1α, reflecting the ongoing inflammation, in the 3 patient 
groups was tested.  It was tested during the study by Tonnie K Mulli (a PhD student of 
Prof. Francis Hughes, Kings College London with whom we have collaborated). These 
assays were carried out on a larger group of individuals than those available for serum 
collection, including samples where serum was not available for analysis. The results 
indicated that there were no statistically significant differences in salivary 
concentrations of IL-1α among the different groups. However, there was a 60% 
decrease in mean concentrations in AgP patients 10 weeks following a standardized 
course of nonsurgical periodontal therapy according to their previously described 
clinical protocol.
68
 It was notable that there were no statistically significant differences 
among patient groups in salivary IL-1α concentration, all of which were similarly 
elevated and which decreased post-initial periodontal treatment, confirming once more 
that IL-1α expression is associated with inflammation.  
Exclusion criteria for the samples used were patients with a history of 
periodontal treatment or antimicrobial therapy within the previous 6 months, affected by 
any systemic condition likely to affect the periodontal tissues (including pregnancy), or 
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were taking any medication which might have the same effects.
9
 In light of this 
selection it was not possible to evaluate or to analyze the result in respect of systemic 
diseases. Periodontitis is connected or claimed to be related to many systemic 
conditions, such as diabetic or cardiac conditions. Though all of the patient claimed to 
be healthy, it might be that some of them had an latent health condition that they were 
not aware of. As mentioned before the homogeneity of our data of the AgP group is 
surprising. Taking into account other systemic diseases will be interesting and might 
imply on a missing link between periodontitis and other diseases. 
Since in most cases, the AgP sera samples reacted better to the native form of CI 
and CIII, Western blot was used to identify the exact molecular pattern to which serum 
from AgP bind to CI and CIII. In WB, autoantibody binding to ROS-modified CI was 
seen in sera from AgP patients. Usually a smear at a lower molecular weight then the 
native bands, mainly between 50 to 150 kDa was detected by autoantibodies from sera 
of patients with AgP after ROS modification. Autoantibodies against native CI were 
seen as well in AgP samples. There was however a difference in the bands patterns 
detected by different AgP patients. None of the CP sera tested showed autoantibodies in 
WB to either native or ROS-CI. This homogeneity once more is surprising, however a 
bigger cohort of fresh samples should be evaluated to confirm this. 
Interestingly, in the ELISA format most of the AgP samples bound better to 
native CI and CIII than to ROS-CI and ROS-CIII. In the WB a weak reaction was seen 
to bands of native CI while a stronger one was seen to different ROS-CI. The 
differences seen between the ELISA and WB can be attributed to the fact that proteins 
in SDS gels are under strong denaturing conditions, and therefore the binding seen in 
the WB would be to denatured epitopes. Thus autoantibodies in AgP do not bind to 
denatured CI and CIII but could bind to denatured epitopes of ROS-CI and ROS-CIII. 
Hence, by WB the binding profile epitopes could be determined for the tested samples, 
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especially to observe binding to high molecular mass aggregates, which were not 
necessarily immobilized on plastic. 
 In order to address the possibility that auto-reactivity to additional aberrant post-
translational modification of self-proteins is present in periodontitis, measurements of 
the reactivity against citrullinated peptides were done. Citrulline is a non-coded amino 
acid generated by post-translational modification of arginine residues by PAD. The 
presence of antibodies directed toward citrullinated proteins in the serum of patients 
with RA has been described in detail. Anti-CCP can be detected in up to 80% of RA 
patients with 98% specificity.
153
 It was reasoned that citrullination might also be 
involved in breaching of tolerance in periodontitis, due to similar inflammatory 
processes in RA and periodontitis and also due to the fact that P. gingivalis is the only 
bacterium that is known to express PAD.
148 
Analysis of the data demonstrated that out 
of 25 AgP serum samples, 2 had high anti-CCP autoreactivity, and another 4 samples 
had a borderline titer. No reactivity was detected in either C or G samples. Therefore, 
the breach of tolerance in AgP patients may also result from aberrant enzymatic activity.  
The presence of autoantibodies against citrullinated peptides and the fact that 
citrullinated fillagrin is highly specific for RA
106
 may suggest some mechanisms on the 
link between AgP and RA. Patients with longstanding active RA have a significantly 
increased incidence of periodontitis when compared with healthy subjects and patients 
with periodontitis have a higher prevalence of RA than patients without 
periodontitis.
44,95
 Periodontitis associates bacterial DNA, such as P. Gingivalis, and 
high antibody titers against these bacteria were found in both the serum and the synovial 
fluid of RA patients different stages of the disease.
98
 Another association can be found 
through IL-17 which stimulates the generation and mobilization of neutrophils. It plays 
an important role in the defence of extracellular bacteria and plays an important role in 
the pathogenesis of RA.
140
 On the other hand, IL-17 can be found in periodontal lesions 
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and potentially plays a role in the etiopathogenesis of periodontal disease. P. gingivalis 
antigen which can be found in both diseases stimulates T cells to express IL-17.
140
 
 Another possible enzymatic post-translational modification in periodontitis is 
cleavage by MMP. Fullmer and Gibson
41
 showed that the inflamed gingival connective 
tissues are capable of producing MMPs. MMPs are responsible for remodelling and 
degradation of matrix components. MMPs degrade interstitial and basement membrane 
collagens, fibronectin, elastin, laminin, and the proteoglycan core protein. Collagenase, 
a type of MMP, is found in higher concentrations in inflamed gingival specimens than 
in clinically healthy gingivae. The increased presence of these MMP enzymes in 
diseased over healthy sites and decrease after periodontal treatment suggest that MMPs 
are involved in periodontal tissue breakdown.
104
 They are the only known mammalian 
enzymes capable of degrading the triple helix of collagens, initiating extracellular 
matrix degradation during inflammation, tissue breakdown, remodelling, tissue repair or 
wound healing.  
 In this study, the reactivity to MMP modified CI was tested in several sera 
samples. In ELISA, mix ROS modified CI that were digested by MMP-1 and native CI 
digested by MMP-1 showed high reactivity in the AgP comparing to CP and G. 
However, untreated native CI was at least as reactive as the modified in each group. In 
WB CI digested by MMP-1 showed strong reactivity to aggregates that did not enter the 
gel, and some reactivity to low molecular peptides at around 20 and 37 kDa. Native CI 
was reactive as well in the AgP sample tested. CP sample did not react to either native 
or digested CI by MMP-1. Once more differences in the reactivity of peptides in ELISA 
comparing to WB due to the strong denaturing conditions in SDS gels were observed. 
Nevertheless, since only a small group was tested, a larger cohort needs to be evaluated 
in the future as this may be the source for other newly formed neoepitopes. 
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 Overall the results suggest that autoantibody presence is observed specifically in 
patients with AgP and suggest a potentially very significant mechanism in the 
pathogenesis of this condition. In addition, the observation has potential utility for the 
diagnostic testing of patients with AgP. In view of the importance of this observation, 
and its variance from other reported studies, further investigation in an independent 
patient cohort is needed.  
   
7.3 Towards the identification of the neoepitope(s) 
WB was done to the cleaved proteins in an attempt to identify the fragment to 
which sera from AgP patients binds to. To achieve that, enzymatic cleavage of CI and 
CIII was done, hoping to identify the exact neoepitope(s) of the immune response by 
MS. For such analysis the proteins needed to be reduced to low molecular weight 
polypeptides.  
Cleavages of CI and CIII, ROS-CI and ROS-CIII was done by proteases known 
to be present in the inflamed periodontal tissue such as Argingipain
123
 and MMP-1, as 
small fragments were not observed by this cleavage a combination with CNBr and 
trypsin
110 
was included to obtain small fragments.
 
 Argingipain is a cysteine proteinase 
produced by P. gingivalis and is a diseased relevant protease.
123
 MMP-1 are proteases 
that participate in the normal turnover of periodontal tissues and are increase in levels 
during periodontal diseases in the localised diseased tissue, in saliva and in crevicular 
fluids (GCF).
70,71
 CNBr is widely used to fragment proteins and peptides, it hydrolyzes 
peptide bonds at the C-terminus of methionine residues and Trypsin is one of the most 
common used proteases which cleaves proteins mainly at the C-terminus of the amino 
acids lysine or arginine.
142 
 
The cleavage of the proteins was monitored by SDS-PAGE at first, however, 
when low molecular peptides were observed analysis was done by 2D SDS-PAGE, 
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tricine SDS-PAGE and CE. Large tricine SDS-PAGE and 2D electrophoresis were able 
to present low molecular peptides clearly and individually so that they can be evaluated 
further. With CE the large peptides were not able to enter the capillary, as a result a 
reading of a "noise" around the 0mAU units it means that the reading was negative. The 
same reading was seen as well when proteins were totally cleaved. Only at several 
occasions, such as CI digested by Argingipain, newly picks were formed. CE was able 
to show breakdown of proteins when gels were not sensitive enough to present the 
digestion products, but had its limitation when the proteins were too big or totally 
cleaved.  
Once conditions to observe small fragments were achieved, the same was done 
to ROS modified CI and CIII. The different ROS-CI and ROS-CIII that underwent 
digestion with MMP-1 show different molecular weight bands than the native CI and 
CIII treated only with ROS, meaning that a different cleavage profile was achieved. 
However, the newly formed peptides where of too high molecular weight for analysing 
in MS so they were further digested. When CNBr and trypsin were added, they seemed 
to improve the digestion to lower molecular weight peptides. With the trypsin there 
were strong trypsin background bands, to overcome this issue, 2-D gels were done and 
enabled a high separation between the enzymes and the protein peptides.  
During the experiment it looked as if the order of the digesting agents exposure 
to CI or CIII resulted in a different cleavage pattern, exhibited as different bands on 
SDS-PAGE. As a result a vast variety of peptides had revolved from the digestion 
process.  
While evaluating the different cleavage systems it was noticed that when CI was 
drastically modified by ROS (high concentration and long incubation) the proteins were 
totally degraded to very small peptides. As a result, no reactive bands were seen in WB 
of highly cleaved proteins with AgP sera, they lost most of their unique sites which the 
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autoantibodies recognized. Such totally cleaved protein was not suitable to evaluate in 
order to identify a specific polypeptide epitope to which sera was responding to. 
Therefore, it was decided that the optimized protocols for identifying polypeptide which 
involve in the autoimmune response are moderate digested proteins which can be 
extracted from the gel and then subjected to MS analysis. 
  After optimizing the cleavage with the different enzymes in combination with 
ROS modifications, a WB was done with AgP samples, which previously showed the 
presence or autoantibodies in ELISA and with CP sample as control which were not 
reactive in ELISA. Analysis by WB suggests potential peptide candidates. Nevertheless, 
different AgP samples showed a different profile of reactivity, a variety of bands were 
seen in WB at high and low molecular weight.  
 The reactivity profile to AgP was very variable and a different reactivity profile 
was seen in different samples and under different conditions. As a result of this 
inconsistency, the epitopes were not taken for analysis in MS. A larger cohort would 
need to be screened to verify a consensus peptide neoepitope that can be developed for 
further diagnostic applications.  
 
7.4 Development of Antibody Fragment Specific to Native and ROS Modified 
CI 
 Periodontitis progression may be either continuous or cyclical. The site of the 
disease, during individual’s life, may not change in attachment level which is one of the 
clinical consequences of the disease. Other sites may demonstrate initiation of 
attachment lost at different times during life. These diseased sites may present slowly 
progressive loss of attachment until the tooth is lost or the condition is treated.
81,137
 
These features make screening and diagnostic tools desirable in the management of the 
disease. Although many potential markers exist, no ‘gold standard’ diagnostic for active 
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disease is available. Inflammation due to periodontitis results in attachment loss and 
thus clinicians have a limited ability to predict disease progression using any tests.
8
 
Moreover, in screening tests it is not yet possible to predict the evolution of 
periodontitis. Once such tests are available, the clinician will most likely need other 
treatments regimes other than root planning or antibiotics. In future tests may become 
an important part of the clinical treatment, screening and patient monitoring. 
 With phage libraries, given almost any substance, it is possible to produce 
monoclonal antibodies that specifically bind to that substance. The antibodies can serve 
as therapeutic and diagnostic applications.
10
 In the current study, assuming that ROS-
modified CI is present in the inflamed periodontium and using a phage display human 
antibody library, human scFvs that binds specifically to ROS modified CI was 
identified. 
 Antibodies were developed by screening of phage display human scFv library, 
Tomlinson library. Three different selection methods were used in an attempt to isolate 
scFv from the Tomlinson phage library: partially ROS modified proteins and stringently 
ROS modified proteins by exposure to high levels of ROS, with and without 
subtraction. Most of the selections, apart of the highly subtracted, led to an increase in 
the reactivity of the polyclonal phage populations mainly in the second round of 
selection and kept its specificity at the third and last round.  
 At the first selections, when no subtraction was done to CII, high reactivity to 
CII was observed. The similarity between the α-chains of CI and CII is very high.82 
When moderate ROS modified proteins (CI or CIII) were used for selections, with or 
without subtraction against CII, the selected phage were not specific only to ROS-CI or 
ROS CIII but rather reacted better to the native form of the proteins. In order to improve 
the specificity of the selections, a more stringent modification with ROS was performed 
to minimize the number of residual native epitopes in the ROS modified CI and CIII. 
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Since the initial analysis of the final selection showed more specific phage to ROS-CI 
and not to ROS-CIII, and since CI is the main and specific protein in the periodontium, 
the focus of the analysis of the phage was diverted only to phage specific to ROS-CI.  
 Once the selection was optimised, the monoclonal analysis of the enriched 
phage populations resulted in the identification of six unique clones which were specific 
for ROS-CI. After sequencing, the number of different unique clones reduced to five 
since two of them possessed the same sequence.  
 To evaluate the scFv, a large scale production of soluble antibodies from these 
five clones and a control scFv against native CI was done. From each of the six clones, 
adequate amounts with an adequate concentration of scFv were produced. The reactivity 
of the scFv was evaluated by ELISA and WB. In both systems different scFvs showed 
different binding profile to CI and ROS-CI but were negative in most cases to the 
control antigens. With ELISA, all of the five lead scFvs were specific to ROS-CI, each 
showed different specificity to different ROS modified CI. None of the scFvs tested 
bound to control collagens such as CIV, CVI, CIX or BSA. The control clone was 
specific to native CI with low reactivity to all of the modifications of CI. With WB, all 
of the scFv bounded to modified CI. Clone 3 and 18 bound specifically to CI modified 
by HOCl and to glycated CI. ScFv 53 and 73 bound better to CI modified by 
peroxynitrite and scFv 65 was more specific to HOCl modified CI. All had some 
background reactivity to native CII and very weak background to glycated CII and CII 
modified by peroxynitrite.  
  With WB the tested proteins underwent strong denaturing conditions in SDS 
gels. In addition, some protein oxidation could occur during gel electrophoresis. As a 
result the binding of the five selected scFv to native CI and at a lower level to native CII 
in WB was probably binding to denatured epitopes of native CI.  
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 Future work with the scFv should include a scan of AgP, CP and G patients’ 
biopsies to demonstrate the localisation of the ROS-CI epitopes in the inflamed tissue in 
a longitudinal study, and to prove the specificity of the scFv produced in the detection 
of AgP form of the periodontal disease.  
   
7.5 Summary 
 The present findings support the possibility that chemical modification of self 
antigens, in AgP is the cause of formation of neoepitopes. The oxidative modification of 
CI, possibly in combination with proteolysis, results in formation of CI neoepitopes, 
which may breach immune tolerance. This is subsequently followed by reactivity of 
antibodies against modified self protein to the unmodified self antigen, in a process 
which is characterized as epitope spreading.
37
  
 This study has found that autoimmune reactions to native and post-
translationally modified self antigens may play a role specifically in the pathogenesis of 
AgP. Thus contribute to the vicious circle of evolving of neoepitopes to which the 
immune system is not tolerant to, resulting in stimulation of the immune response 
against self antigens. It is possible that a similar reactivity to native CI and ROS-CI was 
found as the disease was already advance and to address this issue properly a large 
longitudinal prospective study will need to be perform to accurately address the 
possibility that the autoreactivity indeed started by reacting against ROS-CI and then to 
native CI.  
  A major finding of the study described here is the demonstration that AgP has 
evidence of an autoimmune component of pathogenicity. AgP and CP have some 
distinct clinical features, and AgP is reported to be associated with a hyperinflammatory 
macrophage phenotype and in some cases defective neutrophil responses, the findings 
here suggest the ability to stratify it from the other periodontal conditions with a high 
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degree of consistency. This specificity for AgP is unexpected and merits further studies 
on an independent cohort of new patient samples to verify.  
The new cohorts should be examined for a long period of time, this in order to 
evaluate the development of the periodontal disease and the evolving of the 
autoimmunity in it. A prospective study need to be done, with pre and post conventional 
acceptable treatment, with subdividing the AgP group to other known diseases that 
influence periodontitis or consider to have autoimmunity (such as cardiac conditions, 
diabetic, etc.).  
By using a phage display selection process such as the one described in this 
work, scFvs specific to ROS-CI was developed. This, in one hand, can be developed to 
a diagnostic tool and on the other hand can be developed for therapeutic applications 
such as helping to anchor therapy to the diseased periodontal tissue.  In the current 
study, the samples available were however limited and further study will be pending 
upon obtaining Helsinki approvals to using biopsies and hence to join forces with big 
centres, that have access to large cohort that can facilitate longitudinal prospective study 
to confirm the results of this study and to further investigate in order to identify a 
common neoepitope in AgP. By doing that, an important insights into the character of 
the disease can be gained and help significantly in the development of therapeutic 
strategies and potential drugs. 
The antibody fragments developed might be a good candidate for targeting 
therapy to the periodontium area since they are specific to the post-translationally 
modified-CI present only in the damaged periodontium, especially as CI is a major 
component of many structures of the body.  
 
Chapter 7: Discussion 
443 
 
7.6 Future Work 
Further validation of the results using a larger cohort of blood samples, would 
strengthen the findings reported here in particular to address the homogeneous response 
in AgP. Parallel analyses of saliva from the same patients would be advantageous. The 
anti-ROS-CI scFv candidates need to be further characterised by scanning of AgP, CP 
and G patients’ biopsies to demonstrate the localisation of the ROS-CI epitopes in the 
inflamed tissue in a longitudinal study as well as to prove the specificity of the scFv to 
damaged periodontal tissue. In the long term, to the scFv could be further developed for 
diagnostic purposes.  
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AbSTRACT
The aim of this study was to investigate the 
involvement of autoimmune reactions to native 
and post-translationally modified extracellular 
matrix components in the pathogenesis of peri-
odontitis. Sera from individuals with aggressive 
periodontitis (AgP, n = 25), chronic periodontitis 
(CP, n = 14), and gingivitis (G, n = 18) were tested 
for the presence of autoantibodies against: (a) 
native collagen type I (CI) and collagen type III 
(CIII); (b) CI and CIII post-translationally modi-
fied by reactive oxygen species (ROS) of the type 
present during inflammation; and (c) citrullinated 
filaggrin-derived peptides (CCP). Autoantibodies 
to native and ROS-modified CI and CIII as well as 
autoantibodies to CCP were observed exclusively 
in patients with AgP and not in those with CP or G. 
In conclusion, autoimmune reactions to native and 
post-translationally modified self-antigens may 
play a role specifically in the pathogenesis of AgP.
KEY WORDS: collagen type I, collagen type III, 
ROS, periodontitis.
InTRODuCTIOn
A lthough the primary etiologic factor of periodontitis is the bacterial plaque biofilm, the factors that may determine the presence and rate of 
progression of the disease are complex and not fully understood. The potential 
involvement of autoimmunity in the pathogenesis of periodontitis has been 
considered intermittently for many years. Autoantibodies against a wide range 
of self-antigens, such as collagen type I (CI), host DNA, laminin, fibronec-
tin, and desmosin, have been described previously (Anusaksathien and Dolby, 
1991; Anusaksathien et al., 1992a,b; Govze and Herzberg, 1993). However, 
many of these reports have been inconsistent, some describing high levels of 
autoantibodies to CI (Ftis et al., 1986; Sugawara et al., 1992), while others 
report low levels of anti-CI (Hirsch et al., 1988). Recently, it has been sug-
gested that autoimmune responses may be increased particularly in patients 
with AgP. De-Gennaro and co-workers (De-Gennaro et al., 2006) showed 
increased autoantibodies to fibronectin and laminin, but not to CI, in patients 
with AgP. In addition, Koutouzis and co-workers (Koutouzis et al., 2009), in 
a small pilot study, have shown increased tissue autoreactivity and anti-CI 
antibody titers specifically in patients with localized AgP.
The exact etiology of autoimmune reactivity in periodontitis is not known, 
but may be linked to the inflammatory process resulting from Porphyromonas 
gingivalis infection. Within the inflamed lesion, there is a high influx of 
immune cells that consume increased amounts of oxygen, thus leading to over-
production of reactive oxygen species (ROS) (Waddington et al., 2000). These 
include superoxide radical (O2•−), hydroxyl radical (OH•), nitric oxide radical 
(NO•), peroxynitrate (ONOO–), and non-radical derivatives of oxygen, such as 
hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) (Cheeseman and 
Slater, 1993). In addition, advanced glycation end-products (AGE) produced by 
sequential oxidative reactions (Cho et al., 2007) are known to be present in 
inflamed tissues (Bailey et al., 1995). The major protein components of the 
periodontal tissue are CI and CIII and thus are the major proteins that are sus-
ceptible to ROS attack. Post-translational modification of CI, CIII by ROS 
results in the formation of altered self-protein that may initiate an autoimmune 
response. Furthermore, breach of tolerance may also be initiated by enzymatic 
post-translational modification—for example, cleavage of extracellular proteins 
by matrix metalloproteases (Murphy and Nagase, 2008) or citrullination by 
peptidylarginine deiminase (PAD) (van Venrooij and Zendman, 2008). These 
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two enzymatic post-translational modifications are of particular 
interest in periodontitis, since P. gingivalis produces both RgP-
argingipain (Inomata et al., 2009) and peptidylarginine deiminase 
(PAD) (McGraw et al., 1999).
The aim of the present study was to test the hypothesis that 
patients with periodontal disease show autoimmune responses 
to native and post-translationally modified extracellular matrix 
proteins.
MATERIAlS & METHODS
Chemical Modification of CI and CIII
Calf skin CI and CIII from human placenta (Sigma, Dorset, UK) 
(1 mg/mL) in 0.1 M acetic acid pH 6 was modified as previously 
described (Nissim et al., 2005). Briefly, CI and CIII were incu-
bated overnight at 37°C with 1 mM sodium hypochlorite 
(HOCl), 1 mM hydroxyl radical (OH-), 2 mM peroxynitrite 
(ONOO−), or 4 M ribose. Bovine serum albumin (BSA; Sigma, 
Dorset, UK) and bovine Collagen type II (CII) were also modi-
fied as above and were used as control antigens. Modification 
was monitored by 7.5% SDS-PAGE followed by staining with 
Coomassie (Sigma, Dorset, UK) as well as by fluorescence 
spectra with a Hitachi F-4500 spectrofluorometer (Tokyo, 
Japan). The full protocol is described in Appendix I.
Patient Samples
Serum and stimulated saliva samples from AgP, CP, and G were 
collected from new patients attending the Periodontal Consultant 
Clinic, Institute of Dentistry, Barts & The London School of 
Medicine & Dentistry, according to clinical diagnostic criteria 
described in the Table, and as previously described (Hughes 
et al., 2006). Clinical diagnosis of Generalized AgP was per-
formed according to World Workshop in Periodontology criteria 
(Armitage, 1999) as previously described (Hughes et al., 2006). 
Approval was granted by the City and East London Health 
Authority Local Research Ethics Committee (05/Q0601/80 & 
P/00/021). In addition, control sera from patients with rheuma-
toid arthritis (RA) (n = 12) from a previous study (Nissim et al., 
2005) and with unknown periodontal disease status were tested. 
All participants provided written informed consent.
Enzyme-linked Immunosorbent Assays (ElISA)
Autoantibodies to native and ROS-modified collagen were 
tested by ELISA as described previously (Nissim et al., 2005), 
with serum samples diluted 1:100 in 2% powdered milk 
(Marvel™) (Boots, London, UK) in PBS, followed by incuba-
tion with anti-human IgG-horseradish peroxidase (HRP) (Sigma, 
Dorset, UK). ELISA for anti-citrullinated filaggrin-derived pep-
tides (CCP) and IL-1β was done with the Anti-CCP test kit (Axis-
Shield Diagnostics Limited, Dundee, UK) and DuoSet ELISA 
Development kit (R&D Systems, Abingdon, UK), respectively, 
and according to the manufacturer’s instructions. Full details of 
the ELISA protocols are provided in Appendix I.
Statistical Analysis
Analyses of data were performed with Prism software 
(GraphPad, San Diego, CA, USA). Differences in levels of auto-
antibodies were tested by one-way ANOVA and Bonferroni post 
hoc corrections. To ensure equal variances between groups, we 
carried out a natural log transformation of the data prior to 
analysis. P values shown throughout represent adjusted values 
for pair-wise comparisons. To determine diagnostic discrimina-
tion between AgP and CP, we set a cut-off point of 0.1 OD units 
post hoc to construct a contingency table of positive autoantibodies 
against clinical diagnosis (AgP or CP) and tested it by Fisher’s 
Exact Test.
RESulTS
SDS-PAGE Analysis and 3-D Fluorescence Profile Study 
of ROS-modified CI and CIII
On SDS-PAGE, native CI showed two major electrophoretic bands 
that migrated to the region below the 150-kDa protein marker, cor-
responding to the constituent α1 and α2 chains of CI. A higher-
molecular-weight band above the 225-kDa protein marker 
corresponded to the β chain of CI (Fig. 1A, lane 1). Glycation by 
ribose caused a shift in the CI α- and β-chain bands to a position of 
slightly higher molecular weight, as well as loss of intact CI. 
Hypochlorous acid, hydroxyl radical, and peroxynitrite treatments 
resulted in marked loss of most of the intact CI polypeptide, 
Table. Clinical Data of the Three Patient Groups with Periodontal Disease
N Age (yrs; mean ± SD, range) Males
Sites with 
PD < 5 mm
Plaque Score 
(mean ± SD) Current Smoker
Gingivitis 18 38.3 ± 11.5 24 – 60 8 (43%) 0 64 ± 45% 2 (11%)
Chronic PD 14 52.3 ± 10.06 43 – 62 7 (50%) 21 ± 18.4 70.1 ± 28.1% 3 (21%)
Aggressive PD 25 32.6 ± 4.8 22 - 39 12 (48%) 27 ± 15.4 49 ± 20% 5 (20%)
Twenty-five aggressive periodontitis (AgP), 14 chronic periodontitis (CP), and 18 gingivitis (G) patients were tested. AgP samples were from patients 
under the age of 40, having a minimum of 6 teeth with pockets deeper than 5 mm and a clinical diagnosis of Generalized AgP according to World 
Workshop in Periodontology criteria (Armitage, 2000). Patients with CP were over the age of 40, with a minimum of 2 teeth affected by pockets 
deeper than 5 mm. Gingivitis patients exhibited gingival bleeding and no sites deeper than 5 mm pocket depth. AgP samples were taken from a 
subset of patients from a previously reported study (Hughes et al., 2006). CP and G samples were collected separately.
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together with fragmentation presented as a light smear. The 3-D 
fluorescence profile study demonstrated major changes in the fluo-
rescence profile of glycated CI in comparison with native CI (Fig. 
1B). Minor changes were observed for peroxynitrate-treated CI, but 
not to HOCl and OH• modification (Appendix Fig. 1).
Native CIII showed one major band that migrated to the region 
below the 150-kDa protein marker, corresponding to the constitu-
ent α-chain of CIII (Fig. 1C). The effect of modification on the 
SDS-PAGE profile was not as extensive as that seen for CI. The 
3-D profile showed major changes observed for both glycated and 
peroxynitrate-treated CIII (Fig. 1D, Appendix Fig. 1).
Antibody binding to Modified CI and CIII 
in Patients with AgP, CP, G, and RA
Binding to both native and ROS-modified CI and CIII was 
observed only in the AgP samples, while no binding was observed 
in either CP or G serum samples (AgP vs. CP or G, p < 0.01) 
(Figs. 2a-2d). Although there was a trend to greater binding to 
native collagens compared with ROS-modified collagens, there 
was no significant difference in the binding of AgP sera samples 
to native CI or CIII vs. ROS-CI and ROS-CIII (Bonferroni
corrected pairwise comparisons, p > 0.05). In addition, no sig-
nificant binding was seen to the control antigens CII and BSA 
(Figs. 2e, 2f). Control sera from patients with RA showed no 
significant binding to either CI or CIII (Figs. 2c, 2d), but bound 
strongly to ROS-CII (Fig. 2e) as previously described (Nissim 
et al., 2005). In AgP, autoantibody titers to native collagen sig-
nificantly correlated with autoantibody titers to ROS-modified 
collagen, although the correlation coefficients were relatively 
modest (R2 values of 0.44, 0.83, 0.55, and 0.63 for Ribose, 
HOCL, OH•, and OONO-, respectively) (Appendix Fig. 2).
To test the specificity of the binding of autoantibodies to 
native CI in AgP, we established a cut-off point of 0.1 OD 
ELISA units post hoc, based on the data. Based on this cut-off 
point, detection of autoantibodies in AgP compared with CP had 
an Odds Ratio of 20.6 (95% CI 3.6-118), with sensitivity of 0.87 
and specificity of 0.76 (Appendix Fig. 3).
binding to Citrullinated Filaggrin-derived Peptides
Although anti-CCP is used for the diagnosis of rheumatoid 
arthritis, P. gingivalis is the only bacterium known to express a 
PAD enzyme (Wegner et al., 2010), suggesting that periodontitis 
Figure 1. SDS-PAGE analysis and 3-D fluorescence spectra of chemically modified collagen type I (CI) and collagen type III (CIII). Samples 
containing CI and CIII were incubated overnight at 37°C with or without the various free-radical generators. Panels A and C are 7.5% SDS-PAGE 
analysis under reducing conditions. The position of the molecular-weight markers (in kDa) is shown on the left. (A) Lane 1 shows native CI with 
two major electrophoretic bands that migrated to the region below the 150-kDa marker, corresponding to the constituent α1 and α2 chains of CI. 
A higher-molecular-weight band above the 225-kDa protein marker corresponds to the β chain of CI. Glycation by ribose caused a shift in the CI 
α- and β-chain bands to a position of slightly higher molecular weight, as well as loss of intact CI (lane 2). Hypochlorous acid, hydroxyl radical, 
and peroxynitrite treatments (lanes 3-5) resulted in marked loss of most of the intact CI polypeptide, together with fragmentation presented as a 
light smear. (b) The observed 3-D fluorescence spectra of CI demonstrated major changes in the fluorescence profile of glycated CI in comparison 
with native CI, but minor changes for peroxynitrate-treated CI. (C) SDS-PAGE analysis of CIII. (Lane 1) Native CIII with a major band that migrated 
to the region below the 150-kDa protein marker, corresponding to the constituent α-chain of CIII. While the effect of modification on the SDS-PAGE 
profile is not as significant (lanes 2-5), the 3-D profile showed dramatic change after treatment with ROS, with major changes observed for both 
glycated and peroxynitrate-treated CIII (D).
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could be associated with the production of citrullinated proteins. 
Out of 25 AgP serum samples, 2 had high anti-CCP autoreactiv-
ity, and another 4 samples had a borderline titer (Fig. 3). No 
reactivity was detected in either C or G samples.
Salivary Il-1α Concentrations
The concentrations of salivary IL-1α in the 3 patient groups 
tested were: G, 2.5 ± 1.5 ng/mL; CP, 2.7 ± 1.1 ng/mL; and 
AgP, 2.6 ± 1.2 ng/mL. There were no significant differences in 
salivary concentrations of IL-1α among the different groups 
(Appendix Fig. 4a). However, there was a 60% decrease in 
mean concentrations in AgP patients 10 wks following a 
standardized course of non-
surgical periodontal therapy 
(Appendix Fig. 4b) according 
to our previously described 
clinical protocol (Hughes et al., 
2006).
DISCuSSIOn
In the present pilot study, we 
tested the immune response in 
serum from three different 
groups of patients with peri-
odontal diseases to two major 
components of the periodontal 
attachment structures, CI and 
CIII. In addition, we exposed CI 
and CIII in vitro to ROS that are 
involved in acute and chronic 
inflammation (Nissim et al., 
2005). Although IL-1α levels 
were similar in all three groups, 
reflecting the ongoing inflam-
mation, binding to both native 
and ROS-modified CI and CIII 
was observed only in the AgP 
samples, while no binding was 
observed in either CP or G 
serum samples (p < 0.01). Out 
of 25 AgP samples tested, 19 
showed a positive reaction, and 
only 6 were negative to CI. In 
contrast, only 2 samples with 
CP and 1 with G reacted against 
CI. Similarly, only samples 
from AgP, but not CP and G 
samples, responded to CIII. As 
control target proteins we used 
CII, which is a known autoanti-
gen in rheumatoid arthritis, as 
well as BSA, both of which did 
not show any reactivity with 
periodontal patients’ samples. 
The fact that no reactivity was 
seen against collagen type II, which is the major component of 
articular cartilage and a known autoantigen in rheumatoid arthri-
tis, suggests that the autoreactivity toward CI and CIII in the AgP 
samples is diseased-tissue-specific. Hence, sera from patients 
with RA showed significant autoantibody titers to CII, but not to 
CI or CIII.
Analysis of autoantibody binding to ROS-modified colla-
gens by Western blots suggests that some of the autoantibodies 
present bound specifically to ROS-modified epitopes (not 
shown). However, we did not see increased reactivity to ROS-
modified CI or CIII. This is very different from our previous 
observation in RA samples, where reactivity to ROS-CII was 
higher than that to native CII (Nissim et al., 2005). Our findings 
Figure 2. Binding of serum samples to native and reactive oxygen species-modified CI and CIII. Serum 
samples from patients with aggressive periodontitis (AP, n = 25), chronic periodontitis (CP, n = 14), 
gingivitis (G, n = 18), and rheumatoid arthritis (RA, n = 12) were tested. AgP samples bound to both CI 
and CIII whether native or ROS-modified (a and b, respectively). Binding to CI and CIII was significantly 
higher in AgP in comparison with CP and G (*p < 0.01, c and d). In addition, control sera from patients 
with RA showed no significant binding to either CI or CIII, but bound strongly to CII in comparison with 
AgP, CP, and G (*p < 0.001, e). No significant binding was seen to BSA (f).
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appear particularly novel in three important respects: first, the 
demonstration that collagen autoantibody production is specific 
to the diseased tissue, since no reactivity was observed to CII, 
which is the major component of the articular cartilage; second, 
the autoreactivity was seen specifically in patients with general-
ized aggressive periodontitis; and third, the demonstration of 
autoantibody production to ROS-modified collagens. Our obser-
vation is supported by two recent studies, although their find-
ings differ from the data presented here in both clinical detail 
and types of autoantibodies described (De-Gennaro et al., 2006; 
Koutouzis et al., 2009). Overall, this may possibly explain the 
previous inconsistent results (e.g., Ftis et al., 1986; Hirsch et al., 
1988; Sugawara et al., 1992).
To address the possibility of additional aberrant post-transla-
tional modification of self-proteins, we measured the reactivity 
against citrullinated peptides. Citrulline is a non-standard amino 
acid generated by post-translational modification of arginine resi-
dues by peptidylarginine deiminase (PAD). The presence of anti-
bodies directed toward citrullinated proteins in the serum of 
patients with RA has been described in detail. Anti-CCP can be 
detected in up to 80% of RA patients with 98% specificity 
(Zendman et al., 2004). We reasoned that citrullination might also 
be involved in breaching of tolerance in periodontitis, due to simi-
lar inflammatory processes in RA and periodontitis and also due to 
the fact that P. gingivalis is the only bacteria that is known to 
express PAD (Wegner et al., 2010). Analysis of our data demon-
strated that only sera from AgP patients have autoreactivity against 
citrullinated peptide, while no reactivity was demonstrated in 
either C or G samples. Therefore, the breach of tolerance in AgP 
patients may also result from aberrant enzymatic activity.
Patients with AgP are reported to have a “hyper-inflamma-
tory” phenotype (Armitage, 1999), and analysis of our data raises 
the question of whether the production of autoantibodies may be 
a primary pathogenic event in this condition, or whether the pro-
duction of autoantibodies is secondary to other inflammatory 
events. However, it was notable that there were no significant 
differences among patient groups in salivary IL-1α concentra-
tions, all of which were similarly elevated and which decreased 
post-initial periodontal treatment, confirming once more that 
IL-1α expression is associated with inflammation. In some 
respects, the homogeneity of the responses seen in AgP was sur-
prising, given that AgP may be considered a clinical syndrome 
with different etiological factors playing a distinct role in differ-
ent patients, such as different genetic and microbial factors 
(Armitage, 2000; Parkhill et al., 2000; Kamma et al., 2004; 
Haubek et al., 2008). The finding that the presence of autoanti-
bodies may have specific utility as a diagnostic marker of AgP, 
based on a level of ELISA units set post hoc with this dataset, 
would benefit from further study with an independent dataset.
Overall, the results suggest that autoantibody production is 
seen specifically in patients with AgP and suggest a potentially 
very significant mechanism in the pathogenesis of this condi-
tion. In addition, the observation has potential utility for the 
diagnostic testing of patients with AgP. In view of the impor-
tance of this observation, and its variance from other reported 
studies, further investigation in an independent patient cohort is 
a high priority.
Figure 3. Binding to citrullinated filaggrin-derived peptides (CCP) in 
ELISA. The peptide is generated by post-translational modification 
(citrullination) of protein-bound arginine by peptidylarginine deiminase 
(PAD). P. gingivalis express a PAD, an enzyme that has been reported 
to be significantly associated with RA. We observed binding to CCP 
only in AgP serum samples; 2 had high anti-CCP autoreactivity, and 
another 4 samples had a borderline titer. No reactivity was detected 
in either CP or G samples.
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